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Figure 1 The endocrine system
Figure 2 Pituitary gland
General introduction
The classical endocrine system comprises a number of endocrine glands (Figure 1). Endocrine 
glands produce hormones – signalling molecules that are transported by the circulatory 
system to target distant organs to regulate physiology and behaviour. Hormones have 
diverse chemical structures; steroids and amino acid/protein derivates (amines, peptides and 
proteins).  Normally, the secretion of hormones by endocrine glands is carefully regulated 
to meet the physiological needs. However, sometimes, abnormal hormonal secretion or 
enlargement of an endocrine gland occurs due to benign or even malignant growth. In this 
thesis consequences of abnormal hormonal secretion and/or neoplasia in three of these 
glands -the pituitary gland, the adrenal glands and the thyroid gland- are discussed. 
The pituitary gland
The pituitary gland (Figure 2) is about the size of a pea and weighs around 0.5g in humans. 
It is situated at the base of the brain [1]. The anterior pituitary arises from an invagination 
of the oral ectoderm forming Rathke’s pouch. Endocrine cells of the anterior pituitary are 
controlled by regulatory hormones released by hypothalamic cells into capillaries leading to 
venous blood vessels, which in turn lead to a second capillary bed in the anterior pituitary. 
This network constitutes the hypothalamo-pituitary portal system. After diffusing out of 
the second capillary bed, the hypothalamic releasing hormones then influence the function 
of anterior pituitary endocrine cells, stimulating or inhibiting the release of their hormones 
[2]. The anterior pituitary synthesizes and secretes multiple hormones with specific actions 
on their target tissues: prolactin, growth hormone (GH), adrenocorticotropic hormone 
(ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid 
stimulating hormone (TSH). The peripheral hormones of the target glands have feedback 
control on the pituitary in order to balance hormonal production. Two of these hormonal 
axes are disturbed in two of the diseases that are subject of this thesis: the somatotropic 
axis (acromegaly) and the hypothalamic-pituitary-adrenal (HPA) axis (Cushing’s syndrome 
(CS) or Cushing’s disease (CD) in case of pituitary origin). The somatotroph cells account for 
almost 50% of the total anterior pituitary cell population [3]. GH is mainly secreted under 
hypothalamic control of growth hormone releasing hormone (GHRH) and its secretion is 
suppressed by somatostatin. GH induces the production of insulin like growth factor type 1 
(IGF-1) in the liver. IGF-1 induces proliferation and inhibition of apoptosis in nearly all cell 
types of the body. ACTH producing cells account for 20% of the total anterior pituitary cell 
population. Its production is stimulated by hypothalamic corticotropin releasing hormone 
(CRH) secretion. ACTH stimulates the adrenal glands to produce cortisol. The major 
function of the HPA-axis is to mediate the neuroendocrine stress response and maintain 
metabolic homeostasis. 
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1The adrenal glandsThe adrenal glands are located on top of the kidneys (Figure 3) [1]. They produce a variety 
of hormones, e.g. adrenalin, aldosterone and, of special interest in this thesis, cortisol. 
Cortisol is mainly produced by the zona fasciculata of the adrenal cortex. The adrenal cortex 
is the outermost layer of the adrenal gland. The effects of cortisol are widespread. Major 
actions of the hormone are that it stimulates gluconeogenesis, glycogen deposition, protein 
catabolism, fat deposition, sodium retention, potassium loss, free water clearance and uric 
acid production. Cortisol also recruits neutrophils from the bone marrow and has inhibitory 
effects on protein synthesis, host response to infection, lymphocyte transformation, 
delayed hypersensitivity, circulating lymphocytes and circulating eosinophils [4].   
The thyroid gland
The thyroid gland consists of two connected lobes. It is found ventral in the neck below the 
laryngeal prominence (Figure 4) [1]. It secretes thyroid hormones that influence metabolic 
rate, protein synthesis, and have a wide range of other effects, including on development. 
The thyroid hormones (triiodothyronine and thyroxine,T3 and T4) are synthesized from 
iodine and tyrosine. The thyroid also produces calcitonin, which plays a role in calcium 
homeostasis [5]. Hormonal output from the thyroid is regulated by thyroid stimulating 
hormone (TSH) secreted from the anterior pituitary, which itself is regulated by thyrotropin 
releasing hormone (TRH) produced by the hypothalamus [2]. In the thyroid gland, nodules, 
either benign or malignant (thyroid carcinoma) can develop, the latter being of special 
interest in this thesis. 
Cushing’s syndrome
Cushing’s syndrome was first described by Harvey Cushing in 1932 [6]. Cushing’s syndrome 
is a combination of signs and symptoms caused by prolonged exposure to cortisol. These 
may include reddish purple striae, plethora, a “buffalo hump”, proximal muscle weakness, 
osteoporosis and a fragile skin that heals poorly (Figure 5) [7]. Patients with Cushing’s 
syndrome frequently have comorbid features caused by cortisol excess, such as abdominal 
obesity, hypertension and diabetes, that are also common in the general population. 
Women may experience more hair growth and irregular menstruation. Frequent symptoms 
are also changes in mood, and a chronic fatigue [8]. Cushing’s syndrome is caused either 
by excessive cortisol-like medication (iatrogenic), or by endogenous causes like mostly 
benign but sometimes malignant adrenal tumors that produce excess cortisol or by an 
adrenocorticotropic hormone (ACTH) producing pituitary adenoma or ectopic tumor 
that results in the excessive production of cortisol by the adrenal glands. Some of these 
tumors are associated with inherited disorders such as multiple endocrine neoplasia type 
1 or Carney complex. About two to three people per million are affected each year by 
Figure 3 Adrenal gland (www.hormone.org, the endocrine society)
Figure 4 Thyroid gland (www.hormone.org, the endocrine society)
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The earliest reports on Cushing’s syndrome reported a median survival of 4.6 years, and 
in 1952 a 5-year survival of only 50%. Most deaths were caused by vascular or infectious 
complications [6, 15]. In modern times, the standard mortality ratio after successful 
normalization of cortisol was similar of that of an age-matched population during 1-20 
years of follow up in one study [16]. However, whether the standardized mortality ratio is 
similar to the general population remains debatable [16-19]. Successful treatment reverses, 
but may not normalize all features of Cushing’s syndrome. Multiple studies have already 
shown that for example bone mineral density, cognitive function, cardiovascular morbidity 
and hypertension improve after treatment but do not normalize in all patients [20-23]. 
Excess weight and hypertension may persist in 25% of patients [19, 22-32]. The persistent 
hypertension has been attributed to microvessel remodeling, abdominal obesity and insulin 
resistance [23, 33]. Similarly, glucose and lipid metabolism improves but does not fully 
normalize to levels of BMI matched controls several years after remission [19, 24, 27, 31, 
33]. In addition, quality of life improves after treatment but remains below that of normal 
subjects [34, 35]. The persistence of central obesity may play a role in these findings 
[22, 27, 31, 33, 36]. Evaluating and treating the long-term adverse effects of Cushing’s 
endogenous Cushing’s syndrome. It most commonly affects people who are 20 to 50 years 
of age [9]. Women are affected three times more often than men. 
For the initial testing of patients suspected of having Cushing’s syndrome it is recommended 
to use one or more of the following tests: urine free cortisol (at least two measurements), 
late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression 
test or the low-dose dexamethasone suppression test (2mg/d for 48 hours) [8]. These four 
tests have acceptable diagnostic accuracy when the suggested cutoff points are used [10]. 
After the diagnosis has been established biochemically, imaging studies and/or sampling 
studies are required to localize the cause.
The goal of treatment of patients with Cushing’s syndrome is to eliminate its primary cause 
and to eliminate its associated signs, symptoms, and comorbidities and to improve quality 
of life. The recommended first-line treatment option is resection of the primary lesion(s) 
by means of unilateral adrenalectomy, resection of ectopic ACTH-secreting tumors or 
transsphenoidal selective adenomectomy, unless surgery is not possible or unlikely to 
significantly reduce cortisol excess [8]. Additional treatments are recommended in patients 
with persistent hypercortisolism after surgery. There are multiple second-line treatment 
options: repeat transsphenoidal surgery, radiotherapy, medical therapy or bilateral 
adrenalectomy. Repeat transsphenoidal surgery is particularly recommended in patients 
with evidence of incomplete resection or a pituitary lesion on imaging. Radiotherapy is 
a possible therapy in patients who have failed transsphenoidal selective adenomectomy 
or have recurrent Cushing’s disease. Medical treatment with steroidogenesis inhibitors 
(ketoconazole, metyrapone) is recommended as a second-line treatment after 
transsphenoidal selective adenomectomy in patients with Cushing’s disease, as primary 
treatment of ectopic ACTH secretion in patients with occult or metastatic disease and 
as adjunctive treatment to reduce cortisol levels in adrenocortical carcinoma (mitotane). 
Pituitary directed medical treatments (cabergoline, pasireotide) are suggested in patients 
with Cushing’s disease who are not surgical candidates or who have persistent disease after 
transsphenoidal selective adenomectomy. These treatments are not effective in adrenal 
causes of Cushing’s syndrome, and their role in the treatment of ectopic ACTH production 
remains to be determined. Glucocorticoid antagonists (mifepristone) are another option in 
patients who are not surgical candidates or who have persistent disease after transsphenoidal 
selective adenomectomy. Furthermore, targeted therapies (octreotide) nowadays can be 
used to treat ectopic ACTH production [11]. In a number of recent reports, tyrosine kinase 
inhibitors (vandetanib, sorafenib) have shown to rapidly and fully control hypercortisolism 
caused by ACTH secretion from medullary thyroid carcinomas [12-14]. The lack of tumor 
reduction in these reports suggests a direct antisecretory effect of these medications. 
Figure 5 Cushing’s syndrome (www.hormone.org, the endocrine society)
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1therapy [46, 47]. When acromegaly persists after surgery, medical therapy is recommended. SRLs or pegvisomant, a human GH receptor antagonist, are the initial adjuvant medical 
therapy of choice [38]. In mild cases, a dopamine agonist, usually cabergoline, can be used 
[38]. In patients with inadequate response to these medications, they can be combined 
[38]. The final therapeutical option is radiotherapy/stereotactic radiotherapy which is 
recommended in patients with residual tumor mass after surgery and if medical therapy is 
unavailable, unsuccessful, or not tolerated [39, 40, 48]. 
The mortality rate of patients with acromegaly appears to be increased. Death is primarily 
from cardiovascular disease, a risk that may be reduced by strict biochemical control of the 
disease [49].  The prognosis of acromegaly is generally favorable when the disease is under 
strict biochemical control [40, 49]. Therefore, long-term psychosocial effects of the 
disease, such as persistent facial deformities, become more important as will be pointed out 
in this thesis.   
Figure 6 Acromegaly (www.hormone.org, the endocrine society)
syndrome may therefore be important to reduce morbidity, improve quality of life, and 
reduce long-term excess mortality. Furthermore, investigating the effects of chronic 
hypercortisolism on body tissues and physiology is crucial in order to tailor follow up and 
treatment of comorbidities. For these reasons, this thesis focuses on a number of long-term 
physical consequences of Cushing’s syndrome. 
Acromegaly
The first medical description of acromegaly goes back to 1772 when Nicolas Saucerotte 
reported “Accroissement singulier en grosseur des os d’un homme âgé de 39 ans” (The 
unique growth in size of the bones of a 39-year-old man) [37]. The term is from Greek 
ἄκρον akron meaning “extremity” and μέγα mega meaning “large” and was first coined 
by French neurologist Pierre Marie in 1886.  Acromegaly is a condition that results from 
excessive growth hormone (GH)- and subsequently insulin like growth factor type 1 (IGF-
1) production after the growth plates have closed. The initial symptom is typically acral 
enlargement. There may also be enlargement of the forehead, jaw, and nose leading to clear 
physical disfigurement (Figure 6). Other symptoms may include joint pain, thicker skin, 
deepening of the voice, headaches, and visual disturbances. Complications of the disease 
may include type 2 diabetes, sleep apnea, debilitating arthritis, carpal tunnel syndrome, 
hyperhidrosis and hypertension [38]. Acromegaly is typically caused by a GH producing 
pituitary adenoma [39]. Rarely acromegaly is caused by ectopic hormone production by 
tumors in other parts of the body. If excessive GH production occurs during childhood 
it results in gigantism which is beyond the scope of this thesis. Acromegaly affects about 
60 per 1000,000 people [40]. It is most commonly diagnosed in middle aged men and 
women, both genders being equally affected. 
The diagnosis of acromegaly is made by measuring increased age-normalized serum IGF-
1 levels [41]. In patients with elevated or equivocal serum IGF-1 levels, confirmation of 
the diagnosis is recommended by finding lack of suppression of GH to <1µg/L following 
documented hyperglycemia during an oral glucose load [38]. Following biochemical 
diagnosis, magnetic resonance imaging is recommended to visualize tumor size and 
appearance as well as parasellar extent [42]. Performance of formal visual field testing is 
mandatory when the tumor is found to abut the optic chiasm [38]. 
Transsphenoidal surgery is the primary therapy in most patients [43]. For patients with 
severe pharyngeal thickness and sleep apnea, or high-output heart failure, preoperative 
medical therapy with somatostatin receptor ligands (SRLs) like octreotide long-acting 
release, lanreotide depot/autogel or pasireotide is advised to reduce surgical risk from 
severe comorbidities [44, 45]. In patients with parasellar disease, which makes total surgical 
resection unlikely, surgical debulking is advised to improve subsequent response to medical 
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1the tumor in whom no other treatments are available [62]. After treatment, follow-up is performed using thyroglobulin measurements (after TSH stimulation). This is a sensitive 
marker of the presence of (malignant) thyroid cells in the body.
The prognosis of thyroid carcinoma is generally favorable which results in a rising 
prevalence of thyroid carcinoma worldwide. The 5-year survival reaches 84% nowadays 
in the Netherlands (www.cijfersoverkanker.nl). This strengthens the importance of the 
consequences of the disease on the long-term. A recent literature review showed that health 
related quality of life remains impaired after differentiated thyroid carcinoma treatment 
especially concerning fatigue, sleeplessness, role functioning and mental health [63]. There 
are also indications that mental and physical quality of life is impaired after surgery in these 
patients [63]. There might also be a negative influence on quality of life of long-term TSH 
suppressive therapy with levothyroxine [63]. A number of factors influencing this health-
related quality of life (HRQoL) are the main topic of a number of chapters in this thesis.
The aftermath of cure
For many diseases of the endocrine system there is treatment available. In the diseases that 
are the subject of this thesis -acromegaly, Cushing’s syndrome and thyroid carcinoma- 
the main symptoms can often be controlled, tumors can be removed and hormonal levels 
can be normalized. This is what we are often call “cure”.  Although the primary disease is 
biochemically cured, patients often remain dependent on long-term hormonal substitution 
therapy. Furthermore, it becomes more and more clear that these diseases have long-term 
physical consequences, even after biochemical cure [17, 22, 33, 36, 64-67]. In addition, as 
survival is nowadays excellent in these patients, HRQoL becomes increasingly important [34, 
63, 68-73]. It therefore seems that there exists an aftermath of cure, influenced and caused 
by different factors, which deserves the attention of all physicians who treat these patients. 
This is why this thesis focuses on the long-term quality of life and physical consequences of 
patients treated for acromegaly, Cushing’s syndrome and thyroid carcinoma. 
Thyroid carcinoma
Thyroid carcinoma is a cancer originating from follicular or parafollicular thyroid cells. 
Follicular cells give rise to the well-differentiated cancers papillary thyroid carcinoma and 
follicular thyroid carcinoma (80-85% of all thyroid carcinoma patients) and to anaplastic 
thyroid carcinoma. In the latter case, tumor cells are poorly differentiated (beyond the 
scope of this thesis). The second cell type, the C-cell or parafollicular cell, produces the 
hormone calcitonin and is the cell of origin for medullary thyroid carcinoma [50]. Most 
often the first symptom of thyroid cancer is a nodule in the thyroid region of the neck [51]. 
However, many adults have small nodules in their thyroids (3-8% of European adults, http://
oncoline.nl/schildkliercarcinoom), but typically less than 5% of these nodules are found to 
be malignant. Sometimes the first sign is an enlarged lymph node. Later symptoms that can 
be present are discomfort in the anterior region of the neck and changes in voice due to an 
involvement of the recurrent laryngeal nerve. Thyroid cancer is usually found in a euthyroid 
patient. The yearly incidence of thyroid carcinoma in the Netherlands is 2/100.000/year in 
males and 4.5/100.000/year in females (http://oncoline.nl/schildkliercarcinoom). 
When thyroid carcinoma is suspected in a thyroid nodule based on clinical and ultrasound 
findings, ultrasound guided fine needle aspiration cytology (FNAC) is the diagnostic 
method of choice [52-54]. The aspirated material is then described by the pathologist using 
the Bethesda-system, which is a valid method for reporting thyroid cytopathology [55, 56]. 
Based on the Bethesda classification a decision is made on whether or not to perform 
surgery as an additional diagnostic modality (Bethesda 3/4) or as a treatment (Bethesda 
5/6). Depending on the size and subtype of the tumor, a hemi- or total thyroidectomy is 
performed, followed by radioactive iodine treatment in order to treat any residual disease and 
lymph node metastases. Clinically significant lymph node metastases are surgically removed 
by means of selective neck dissections. Removal of all lymph nodes in a certain neck region 
reduces the chance of locoregional recurrent disease when compared to only removing 
macroscopic metastases (node picking) [57, 58]. Distant metastases can be surgically 
resected or treated by radioactive iodine or radiotherapy when resection is not possible. 
In case of progressive radioactive iodine refractory differentiated thyroid carcinoma, with 
high tumor volume and/or symptoms, treatment with a tyrosine kinase inhibitor (such as 
sorafenib or lenvatinib) can lead to partial response or disease stabilization [59, 60]. Thyroid 
surgery can have a number of complications of which damage of the laryngeal recurrent 
nerve and hypoparathyroidism are the most important. After surgery and radioactive iodine 
treatment, TSH suppressive therapy is advised using thyroid hormone depending on risk 
classification. Suppression of TSH levels has  been reported to have a positive effect on 
disease specific survival but this has been debated [61]. External beam radiation therapy 
is only recommended in selected patients with macroscopically incomplete resection of 
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1with clinical, demographical and psychological variables measured by means of the hospital anxiety and depression scale, the illness cognition questionnaire and an ad-hoc 
questionnaire in order to gain a broader view of the emotional and psychological factors 
influencing distress in differentiated thyroid carcinoma survivors. The DT in combination 
with a problem list is a tool validated and currently recommended for screening for distress 
experienced by oncologic patients [83-85]. This questionnaire is a good starting point for 
further discussion in a clinical interview and can be completed in just a few minutes, which 
makes it easy to implement in daily practice. A meta-analysis has shown the DT to be as 
accurate as the hospital anxiety and depression scale but superior to it with respect to 
efficiency [86]. Although widely used in other types of cancer, it was never used in patients 
with differentiated thyroid carcinoma before. 
An important factor that could contribute to distress is the fact that surgical treatment of 
head and neck malignancy, especially when involving neck dissections, is well known to be 
associated with shoulder complaints, with its subsequent impact on QoL [87, 88]. Shoulder 
complaints are frequently reported in the outpatient clinic after surgical treatment for 
thyroid carcinoma. In a recent survey on psychosocial/informational needs in patients 
with thyroid carcinoma, almost 30% of participants complained of numbness of the neck 
region and/or restricted shoulder/neck movement more than 1 year after treatment [89]. In 
other types of cancer, there has been a recent emphasis on quality of life related to spinal 
accessory nerve damage and shoulder complaints after neck dissection [90, 91].  The few 
studies on this topic in this disease population were not specifically designed to investigate 
shoulder complaints in patients with thyroid carcinoma [89]. 
In chapter 3 we therefore investigated the prevalence of self-reported long-term shoulder 
complaints and the associations of shoulder complaints with QoL in a historical cohort of 
patients who had surgery for thyroid carcinoma compared to a healthy control group using 
the “disabilities of the arm, shoulder and hand questionnaire” (DASH) and the European 
Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-C30 
(EORTC QLQ-C30). The DASH questionnaire was developed to measure the patients’ 
perception of the ability to perform different activities and roles and to monitor symptoms 
associated with any condition in the upper limb and was never used in thyroid carcinoma 
patients before [92]. In addition, our aim was to identify possible clinical and demographic 
correlates of shoulder complaints and to evaluate associations between shoulder complaints 
and QoL. 
Health related quality of life after treatment of acromegaly
Psychological changes, including changes in personality due to impaired self-esteem, 
body image distortion, disturbed interpersonal relationships, social withdrawal, anxiety and 
Outline
Part 1 Long-term health related quality of life after treatment of thyroid 
carcinoma and acromegaly
Health related quality of life
The concept of HRQoL and its determinants has evolved since the 1980s to encompass 
those aspects of overall quality of life that can be clearly shown to affect health—either 
physical or mental [74]. On the individual level HRQoL includes physical and mental health 
perceptions (e.g., energy level and mood) and their correlates—including health risks and 
conditions, functional status, social support, and socioeconomic status.    On the basis of 
a synthesis of the scientific literature and advice from its public health partners, the US 
center for disease control and prevention (CDC) has defined HRQoL as “an individuals or 
groups perceived physical and mental health over time”. HRQoL questions have become 
an important component of public health surveillance and are generally considered valid 
indicators of unmet needs and intervention outcomes. Self-assessed health status is also 
a more powerful predictor of mortality and morbidity than many objective measures of 
health [75, 76]. HRQoL measures make it possible to demonstrate scientifically the impact 
of health on quality of life. 
Health related quality of life after treatment of thyroid carcinoma
Patients in remission of thyroid carcinoma for many years still report impaired HRQoL [63, 
68]. Patients with differentiated thyroid carcinoma report impaired HRQoL in relation 
with initial surgery and hypothyroidism preceding treatment with radioactive iodine [63, 
77]. One factor that negatively influences QoL in other cancer populations is distress 
which is defined as an unpleasant experience of emotional, psychological, social or spiritual 
nature, that interferes with the ability to cope with cancer treatment, which extends along 
a continuum from common normal feelings of vulnerability, sadness and fear, to disabling 
problems such as true depression, anxiety, panic and feeling isolated or in a spiritual crisis 
[78]. Distress is also associated with longer recovery time and worse treatment adherence 
in cancer patients [79]. Distress is frequently not noticed by physicians and systematic 
screening may be necessary [80-82]. The level of distress and problems experienced 
by thyroid carcinoma survivors and its relation to QoL had never been investigated in 
differentiated thyroid carcinoma patients. 
In chapter 2 we therefore investigated the level of distress and problems experienced 
by survivors of differentiated, non-medullary, thyroid carcinoma, using the distress 
thermometer (DT) and problem list and whether this correlates with clinical and 
demographical variables. In addition we investigated whether reported distress correlated 
2322
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1the differences between patients in the severity of the adverse metabolic and vascular profile after cure of Cushing’s syndrome could be explained by differences in glucocorticoid 
sensitivity due to GR polymorphisms.
In chapter 5 we measured the presence of GR polymorphisms (BclI (rs41423247), N363S 
(rs56149945), ER22/23EK (rs6189/rs6190), and 9β (rs6198)) and investigated their 
associations with metabolic and vascular alterations in patients in long-term remission of 
Cushing’s syndrome.  
Successful treatment is associated with significant decreases of cardiovascular risk and 
mortality [109]. Only a limited number of studies have investigated vascular health in 
patients in remission of Cushing’s syndrome. However, cardiovascular disease is the main 
cause of mortality in patients with active Cushing’s syndrome[110].  Previous studies in 
patients in remission of Cushing’s syndrome reported contradictory results using different 
kinds of surrogate markers of vascular health [22, 33, 66, 67, 111-113]. Moreover, these 
reports used only single markers of vascular function and had small sample sizes. 
In chapter 6 we investigated micro- and macrovascular health in a large group of patients in 
long-term remission of Cushing’s syndrome with adequately treated comorbidity if present, 
in comparison with a matched healthy control group. We measured serum biomarkers 
associated with endothelial dysfunction, performed gold standard measurements of 
endothelial function and investigated the presence of overt atherosclerosis.
Previous studies in Cushing’s syndrome in long-term remission have demonstrated that 
centripetal fat distribution, physical disability and tiredness are frequent self-reported 
problems [36, 72, 73]. It is suggested that the persistence of these symptoms impairs 
physical performance in the context of employment and daily life [73]. When physical 
capacity decreases, for example due to Cushing’s syndrome, workload of daily physical 
activities demands a relatively higher percentage of one’s physical capacity, resulting in the 
earlier onset of experiencing fatigue [114]. No previous study has examined physical fitness 
in patients in long-term remission of CS. Furthermore, no previous study has examined the 
relation between physical fitness and daily physical activity levels in these patients nor was 
investigated whether any long standing direct effects of hypercortisolism on the muscles is 
present in these patients.
In chapter 7 we investigated physical fitness, as measured by the gold standard approach of 
peak oxygen uptake (VO2 peak) during a maximal exercise test, in patients in long-term (> 4 
years) remission of CS and in an age-, gender-, body mass index (BMI)-, smoking-, physical 
activity level- and ethnicity matched control group. Furthermore, we explored the relation 
depression are present in acromegaly patients [69, 93]. In patients in biochemical remission 
of acromegaly, multiple factors have been found to negatively influence quality of life, 
e.g. prolonged postoperative use of somatostatin analogues [94], radiotherapy treatment 
[95, 96], persisting joint complaints [97], presence of osteoarthritis [98] and presence 
of GH deficiency after treatment [99]. It was recently shown by our group that facial 
appearance in patients in remission of acromegaly does not fully return to normal after 
biochemical cure [100]. It has been suggested that changes in appearance can lead to 
self-consciousness about appearance, leading towards self-esteem disintegration, social 
withdrawal, body image distortion and an impaired quality of life [69]. Despite the fact 
that the appearance subscale was the most affected subscale in patients in remission of 
acromegaly in studies that used the AcroQoL questionnaire [70, 101-103], it had never 
been investigated whether these changes in appearance negatively influence QoL and 
consequently cause psychosocial dysfunctioning and distress.
In chapter 4 we investigated the psychological distress and dysfunction related to self-
consciousness about appearance and its effect on QoL in patients in long-term remission 
of acromegaly compared to a gender-, age- and body mass index matched control group. In 
addition, we aimed to identify the anatomical sources of self-consciousness.  In order to do 
so, patients and controls completed the modified Derriford appearance scale (DAS59) and 
research and development 36 (RAND-36) questionnaires, and the acromegaly quality of 
life questionnaire (AcroQoL). The Derriford appearance scale is developed for research in 
plastic surgery and oncology. It has good validity and reliability and has been recommended 
for the assessment of feelings about appearance [104, 105]. However, it has never been 
used in patients with acromegaly before.
Part 2 Long-term physical sequelae of Cushing’s syndrome
Long-term physical consequences of previous hypercortisolism in patients in remission of 
Cushing’s syndrome have become a focus of research in the last years. We [36] and others 
[33, 64] have shown that many adverse metabolic and body compositional changes might 
persist after treatment, even after long-term remission. Although these adverse metabolic 
characteristics are common in these patients, their incidence and severity vary among 
patients. This variation seems not to be explained by differences in cortisol excess or disease 
duration alone. Therefore, a variable sensitivity to glucocorticoids, due to glucocorticoid 
receptor (GR) polymorphisms, may play a role in modulating the effect of cortisol excess. 
The functional role of GR polymorphisms has been extensively studied in the general 
healthy population. However, only a small number of studies have been performed on the 
functional role of GR polymorphisms in active Cushing’s syndrome and Cushing’s syndrome 
in remission [106-108]. At the start of our project no information was available on whether 
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Introduction
Differentiated non-medullary thyroid carcinoma (DTC) is associated with a favorable 
prognosis with long-term survival rates that reach 80-95% [1]. Since most patients with 
DTC become in remission after treatment, the number of disease-free survivors is high. 
Quality of life (QoL) is an important issue in the care for long-term survivors of DTC [2]. 
Patients with DTC report impaired QoL in relation with initial surgery and hypothyroidism 
preceding treatment with radioactive iodine (RAI) [3, 4]. Moreover, several studies have 
shown that even patients being in remission of DTC for many years report impaired QoL 
compared to healthy controls [4, 5]. 
One factor that has negative effects on QoL is the level of distress. There is increasing 
evidence that cancer patients, including long-term survivors, are at increased risk of 
distress compared to healthy population controls [6-13], with distress defined as “an 
unpleasant experience of emotional, psychological, social or spiritual nature, that interferes 
with the ability to cope with cancer treatment, which extends along a continuum from 
common normal feelings of vulnerability, sadness and fear, to disabling problems such as 
true depression, anxiety, panic and feeling isolated or in a spiritual crisis” [10]. Distress has 
also been shown to negatively influence recovery time and treatment adherence in cancer 
patients [14]. Distress is often not noticed by medical professionals unless it is explicitly 
assessed [15, 16]. For these reasons it is nowadays often recommended that all oncologic 
patients should be systematically screened for distress [9, 17]. In order to meet the need 
for screening tools that can be used efficiently in an outpatient clinic setting, several short-
tools have been developed for detection of distress. However the majority of these have not 
been robustly validated in cancer settings [18].
The distress thermometer (DT) in combination with a problem list (PL) is a tool validated 
and currently recommended for screening for distress experienced by oncologic patients 
[19-21]. In contrast to other well-known QoL questionnaires, such as the hospital anxiety 
and depression scale (HADS), the self-reported problems on the PL are a starting point 
for further discussion in the clinical interview. In addition, the DT can be completed in 
just a few minutes, which makes it easy to implement in everyday outpatient practice. In 
this respect, a recent meta-analysis found DT to be as accurate as HADS as a short-tool 
to screen for distress in cancer settings but superior to it with respect to efficiency [22]. 
Although widely used in other types of cancer, the use of DT has never been evaluated in 
patients with DTC. 
Abstract
Context: Cancer patients are at increased risk for distress. The Distress Thermometer (DT) 
and problem list (PL) are short-tools validated and recommended for distress screening in 
cancer patients.
Objective: To investigate the level of distress and problems experienced by survivors of 
differentiated non-medullary thyroid carcinoma (DTC), using the DT and PL and whether 
this correlates with clinical and demographical variables. 
Participants, design and setting: All 205 DTC patients, under follow-up at the outpatient 
clinic of our university hospital, were asked to fill in the DT and PL, hospital anxiety 
and depression scale (HADS), illness cognition questionnaire (ICQ) and an ad hoc 
questionnaire. Receiver Operator Characteristic analysis (ROC) was used to establish the 
optimal DT cut-off score according to HADS. Correlations of questionnaires scores with 
data on diagnosis, treatment and follow-up collected from medical records were analyzed.
Results: Of the 159 respondents, 145 agreed to participate (118 in remission, median 
follow-up 7,2 years (range 3 months-41 years)). Of these, 34.3% rated their distress score 
≥5, indicating clinically relevant distress according to ROC analysis. Patients reported 
physical (86%) over emotional problems (76%) as sources of distress. DT scores correlated 
with HADS scores and ICQ subscales. No significant correlations were found between DT 
scores and clinical or demographical characteristics except for employment status. 
Conclusion: Prevalence of distress is high among patients with DTC even after long-
term remission and cannot be predicted by clinical and demographical characteristics. DT 
and PL are useful screening instruments for distress in DTC patients and could easily be 
incorporated into daily practice. 
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have validated the DT against the HADS and established proper cut-off scores with receiver 
operating characteristics (ROC) curve analysis [6, 11-13]. In the current study a ROC 
analysis was performed in order to establish the cut-off score for the DT using a HADS 
cutoff score ≥15 as the gold standard for detecting cases of severe emotional distress. This 
cut-off is similar to that used in a validation study performed in a cohort of patients with 
several other malignancies and having the same cultural background as our cohort [7, 24].
We used the previously validated [7]  Dutch version of the DT and problem list (PL) which 
is currently recommended for use in the clinical practice in the Netherlands. The Dutch 
version is adapted from the original NCCN version of the DT and PL based on evaluations by 
the Comprehensive Cancer Center the Netherlands (CCCN) focus groups. In comparison 
to the original 35 items of the original NCCN version, 15 items were added on the PL in 
the Dutch version (added items are depicted in italics in Table 2). The items sadness, worry 
and loss of interest in usual activities were removed from the NCCN problem list, yielding 
a total of 47 items. The items are grouped in categories: physical problems (25), emotional 
problems (10), practical problems (7), social problems (3) and spiritual issues and religion 
(2). Respondents were instructed to indicate whether the items listed had been a problem 
in the past week by selecting from a fixed yes/no response [25].  In addition respondents 
were asked to indicate whether they would like to be referred to a professional for additional 
support [11]. 
Hospital anxiety and depression scale (HADS)
The HADS is a measure of anxiety and depression for patients with physical illness. It 
contains 14 items. Each item is scored between 0-3. Half of the items assess anxiety and 
the other half depression. For the anxiety and depression subscales scores 0-7 indicate 
normal values, 8-10 mild disorder, 11-14 moderate disorder and 15-21 severe disorder [26]. 
The 2 subscales can be combined into a single scale, and scores ≥15 on this scale were used 
to indicate severe emotional distress [7, 24].  The HADS is widely used in oncology and has 
good reliability and validity [27]. The Dutch version of the HADS was used, which has been 
validated in several subgroups of Dutch patients [28].
Illness cognition questionnaire (ICQ)
The ICQ was used to measure helplessness, acceptance and perceived disease benefits. This 
is an 18-item questionnaire that contains three six-item scales, each with a scoring range 
of 6-24. Each item is answered on a four point scale to the extent to which one agrees with 
the item [29].  The ICQ was used because illness cognitions are related to psychological 
distress as theorized in Leventhal’s Self-Regulatory Model (SRM) [30] and confirmed by 
several studies [31-33]. 
Previous data suggest that patients with DTC perceive their illness as severe on a subjective, 
emotional basis unrelated to disease severity [23]. Therefore, the aim of this study was 
to evaluate the level of distress and problems experienced in a cohort of DTC subjects 
presenting for follow-up at the outpatient clinic of our tertiary referral academic hospital, 
using the DT and PL as short screening tools. In addition we investigated whether reported 
distress correlates with clinical, demographical and psychological variables measured by 
means of the HADS, illness cognition questionnaire (ICQ) and an ad hoc questionnaire in 
order to gain a broader view of the emotional and psychological factors influencing distress 
in DTC survivors. 
Methods
Patients
All patients (>18 years old) who were treated for DTC and are under follow-up at the 
Department of Endocrinology of the Radboud University Nijmegen Medical Centre 
were invited to participate in the present study. The research has been approved by the 
Ethics Committee of the Radboud University Nijmegen Medical Centre. The patients 
were requested to fill in a questionnaire package sent by mail. Non-responders received a 
reminder letter four weeks later. Clinical variables were collected from medical charts and 
included information on diagnosis, treatment and follow-up. Primary treatment consisted 
of total thyroidectomy in all but two cases of papillary (PTC) microcarcinoma and one 
case of minimally invasive follicular thyroid carcinoma (FTC), and modified radical neck 
dissections in patients with confirmed nodal metastases. This was followed in the majority 
of patients by ablation with RAI (I131) of residual thyroid tissue 4-6 weeks after surgery. 
Initial cure was defined as undetectable thyroglobulin (Tg) in absence of anti-Tg antibodies 
and no evidence of loco-regional disease or distant metastases on whole body iodine scans 
(WBS) and/or neck ultrasonographic examinations at six months after RAI ablation. Tumor 
recurrence was defined as evidence of loco-regional disease or distant metastases more 
than six months after successful primary therapy. Current disease status was defined as 
cured (in remission) in case of undetectable Tg in the absence of anti-Tg antibodies and no 
evidence of loco-regional disease or distant metastases at last follow-up visit. Persistent 
disease was defined as either detectable Tg or evidence of loco-regional disease or distant 
metastases.  
Questionnaires
Distress thermometer and problem list (DT and PL)
The DT is a modified visual analogue scale ranging from 0 (no distress) to 10 (extreme 
distress) resembling a thermometer [13]. Most of the validation studies in cancer patients 
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Table 1. Patient characteristics and relation to distress thermometer (DT) score.
Correlation to DT score
% Spearman’s-rho p-value
Gender (n): male/ female 38/ 107 0.145 0.090
Age: mean (SD) (years) 51.7 (13.8) -0.054 0.531
Age at diagnosis: mean (SD) (years) 40.1 (13.1) -0.059 0.497
Duration since diagnosis: median (range) (years)
<1 year: n (%)
1-5 year: n (%)
5-10 year: n (%)
>10 year: n (%)
8.8 (0-41)
8 (5.5)
29 (20.0)
44 (30.3)
64 (44.1)
0.081 0.349
Follow up since last treatment: median (range) (years) 7.2 (0-41) 0.036 0.676
Histopathological subtype: (n)
Papillary
Folliculary
Mixed
106
36
3
73.1
24.8
2.1
-0.123
0.127
0.000
0.151
0.138
0.994
TNM classification* stage: (n)
I
II
III
IV
Unknown
68
22
11
33
11
46.9
15.2
7.6
22.7
7.6
-0.094 0.292
Surgical treatment: (n)
Hemithyroidectomy
Total thyroidectomy 
Lymph node dissection
Unknown
3
140
50
2
2.8
96.6
34.5
1.4
-0.128
0.052
-0.133
0.140
0.550
0.125
RAI treatment:
Number of treatments: 
0
1
2
>2
Unknown
Cumulative dose of I-131:
0 mCi
<100 mCi
100-200 mCi
>200 mCi
Unknown
12
76
37
19
1
12
6
70
55
2
8.3
52.4
25.5
13.1
0.7
8.3
4.1
48.3
37.9
1.4
0.067
0.055
0.437
0.525
Complications of surgery: (n)
Hypoparathyroidism (permanent)
Recurrent laryngeal nerve paralysis
No complications
Disease status: (n)
Remission
Active disease
43
8
95
118
27
29.7
5.5
65.5
81.4
19.7
0.134
0.023
-0.141
0.054
0.118
0.786
0.101
0.533
Mean TSH at last follow-up: (IU/L) (SD) 0.4 (1.1) 0.061 0.486
*UICC TNM Classification of malignant tumors, 6th edition [43]
Demographic variables
Demographic information on age, gender, marital status, level of education, religion, age 
at diagnosis and employment status was collected by means of an ad-hoc questionnaire. 
Statistical analysis
Spearman correlations were performed between the demographic characteristics, 
questionnaire scores and clinical characteristics. Significance was defined as p<0.05. ROC 
analysis was performed to examine the ability of the DT to detect distressed patients, and 
a HADS cutoff score ≥15 was set as the gold standard for detecting cases of clinically 
significant emotional distress [7, 24]. Positive (PPV) and negative (NPV) predictive values 
were calculated for every DT score. All statistical analyses were also performed separately 
for the subgroup of patients currently being in remission of the disease according to the last 
follow-up data.  All statistical analyses were performed using SPSS 16.0. 
Results 
Patient characteristics
Two hundred and five patients were eligible for this study. Of these, 159 patients responded 
(response rate 77.6%). Fourteen patients refused to participate because they had other 
interests or were unable to answer the questions because of language problems. A total of 
145 patients (73.8% female, mean age (SD; range) 51.7 (13.8; 19-83) years) were enrolled 
in the study.  Mean age at diagnosis was 40.1 (SD; range) (13.1; 9-79) years. Median follow-
up time (range) since the last treatment was 7.2 years (3 months - 41 years). Regarding 
current disease status, most patients (118, 81.4%) were in remission and under follow-up, 
18 (12.4%) patients had only detectable stable low Tg level without macroscopic evidence 
of disease and 9 (6.2%) patients had persistent disease detectable on imaging. Serum TSH 
levels at last follow-up appointment had a mean (SD) value of 0.42 IU/L (1.12). Clinical 
characteristics are depicted in Table 1. Participants and non-participants did not differ with 
respect to patient characteristics (p-values >0.2 for all items). 
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(100%) reported at least one item of concern on the PL. Of the patients with a DT score 
<5, 69 (76.7%) reported at least one item of concern on the PL.
There was a strong significant correlation between DT scores and the total number of 
reported problems on the PL (r = 0.827; p < 0.001). Significant correlations were also 
found between DT scores and the number of reported problems in each specific category. 
Table 2 shows the frequency distribution for endorsement of the PL and their correlation 
with the DT score. 
Table 2. Problem list (PL) items and correlation to distress thermometer (DT) score (*n represents the 
number of patients reporting a specific problem in the total group and in the active disease group).
Correlation of total 
group PL score to total 
group DT score
Problem list Mean score 
(SD)
n* 
(Total / active disease)
% 
(Total / active disease)
Spearman’s-
rho
p-value
Overall number of problems 9.5 (8.3) 0.827 <0.001
Practical problems
Child care
Housing
House holding
Transportation
Work/school
Financial
Insurance
0.9 (1.3)
13 / 2
8 / 1
41 / 6
9 / 1
35 / 9
18 / 4
8 / 1
9.0 / 7.4
5.5 / 3.7
28.3 / 22.2
6.2 / 3.7
24.1 / 33.3
12.4 / 14.8
5.5 / 3.7
0.715 <0.001
Social problems
Dealing with partner
Dealing with children
Dealing with friends/relative
0.4 (0.8)
27 / 3
20 / 4
18 / 3
18.6 / 11.1
13.8 / 14.8
12.4 / 11.1
0.468 <0.001
Emotional problems
Grip on emotions
Memory
Confidence
Fears
Sadness
Nervousness
Loneliness
Concentration
Feeling of guilt
Loss of control
2.5 (2.8)
47 / 4
47 / 11
35 / 4
31 / 4
40 / 7
58 / 9
20 / 2
51 / 8
21 / 2
24 / 6
32.4 / 14.8
32.4 / 40.7
24.1 / 14.8
21.4 / 14.8
27.6 / 25.9
40.0 / 33.3
13.8 / 7.4
35.2 / 29.6
14.5 / 7.4
16.6 / 22.2
0.652 <0.001
Spiritual-religious problems
Meaning of life
Faith in god/religion
0.2 (0.5)
16 / 1
13 / 5
11.0 / 3.7
9.0 / 18.5
0.233 0.006
Demographic characteristics 
Two of the participants (1.4%) had less than 8 years of education, 42 (29.2%) 8-12 years, 
38 (26.4%) 12-16 years, 44 (30.6%) 16-21 years and 18 (12.5%) had a university degree. 
One participant omitted to fill in the highest education level.  One hundred and twenty 
five (86.2%) participants were married or engaged in a relationship and 20 (13.8%) had 
no relationship, were divorced or a widow/widower. Eighty-two (56.6%) participants had 
full- or part time employment, 34 (23.6%) were unemployed, 26 (18.1%) were retired and 
3 (2.1%) were students. 
Distress thermometer scores and problems
One hundred and thirty seven patients rated their distress level on the DT and showed a 
mean score (SD) of 3.33 (2.70) with a 0-10 range. Of these, 47 participants (34.3%) rated 
their distress score ≥5, indicating clinically relevant distress as depicted later in the ROC 
analysis. 60 participants (43.8%) rated their distress score >3 which is the NCCN distress 
management guideline cut-off [34].  Eight patients failed to score their distress on the DT 
because they forgot. Mean DT (SD) scores in the 110 patients being in remission and the 
27 patients having persistent disease were 3.40 (2.72) and 3.04 (2.62) respectively and 
the percentages of patients reporting DT scores > 5 in these groups were 36.4% and 25.9%. 
There were no significant correlations between DT scores and the clinical characteristics 
regarding age at diagnosis, severity of the disease, disease status, treatments received 
or complications (Table 1). In addition there was no correlation between the duration of 
(disease-free) follow-up or the TSH levels and DT scores. DT scores and level of education 
did not correlate significantly (r = -0.146, p = 0.089) in the total group. When analyzing 
the subgroup of patients being in remission of the disease, we found a slight but significant 
correlation between the DT score and the level of education (r = -0.212, p = 0.027). DT 
scores did not correlate significantly to having a partner (r = -0.072, p = 0.402). There 
was a slight but significant correlation between the DT scores and the employment status 
(r = -0.251, p = 0.003), the participants having a full- or part time employment reporting 
significantly less distress. 
One hundred and forty five respondents completed the PL (Table 2). The most frequently 
reported problems were fatigue (62.1%), lack of physical fitness (46.9%), sleep problems 
(41.4%), muscle strength (40.0%) and nervousness (40.0%), weight changes (31.7%) and 
paresthesia (31.7%). The physical problems category was the most frequently reported 
category with 86.1% of the patients reporting at least one item. Emotional problems were 
reported by 76.0%, practical problems by 61.5%, social problems by 48.6% and problems 
regarding spiritual issues or religion by 39.4% of the patients. In total, 124 patients (89.9%) 
reported at least one item of concern on the PL. Of the patients reporting DT ≥5, 47 
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Table 3. Hospital anxiety and depression scale (HADS) and illness cognition questionnaire (ICQ) scores 
and correlation to distress thermometer (DT) scores (*n represents the number of patients with a score 
above the mentioned threshold). 
Correlation to DT score
Spearman’s-rho p-value
HADS
Total
≥15 n* (%)
Mean score = 9.2
SD = 7.7
32 (22.1%)
0.611 <0.001
Anxiety
≥8 (n* (%))
Mean score = 5.4
SD = 4.3
 36 (24.8%)
0.547 <0.001
Depression
≥8 (n* (%))
Mean score = 3.8
SD = 3.9
 28 (19.3%)
0.602 <0.001
ICQ
Helplessness Mean score = 9.0
SD = 3.6
0.662 <0.001
Acceptance Mean score = 19.0
SD = 4.2
-0.544 <0.001
Disease benefits Mean score = 16.1
SD = 4.5
-0.092 0.285
Cut-off scores and predictive values
The ROC curve predicting elevated distress according to the HADS showed an area 
under the curve of 0.82 (standard error 0.043; 95% confidence interval, 0.739-0.906; P 
<0.001) (Fig. 1). Table 4 lists the sensitivity and specificity values for all DT scores, including 
frequencies. The cut-off score of 5 correctly identified 77% of HADS cases (sensitivity) 
and 77% of HADS non-cases (specificity). 
Physical problems
Appearance
Changes in urination
Constipation
Diarrhea
Eating
Feeling swollen
Fever
Mouth sores
Nausea
Nose dry/congested
Pain
Sexuality
Skin dry/itchy
Sleep
Breathing
Vertigo
Speech
Taste
Weight changes
Paresthesia in hands/feet
Washing/dressing
Getting around
Fatigue
Physical fitness
Muscle strength
5.3 (4.5)
22 / 5
12 / 3
23 / 2
12 / 3
23 / 5
35 / 8
1 / 0
18 / 8
16 / 3
38 / 4
35 / 5
25 / 4
42 / 5
60 / 9
17 / 2
28 / 4
17 / 3
14 / 5
46 / 11
46 / 14
3 / 1
26 / 5
90 / 15
68 / 8
58 / 5
15.2 / 18.5
8.3 / 11.1
15.9 / 7.4
8.3 / 11.1
15.9 / 18.5
24.1 / 29.6 
0.7 / 0.0
12.4 / 29.6
11.0 / 11.1
26.2 / 14.8
24.1 / 18.5
17.2 / 11.1
29.0 / 18.5
41.4 / 33.3
11.7 / 7.4
19.3 / 14.8
11.7 / 11.1
9.7 / 18.5
31.7 / 40.7
31.7 / 51.9
2.1 / 3.7
17.9 / 18.5
62.1 / 55.6
46.9 / 29.6
40.0 / 18.5
0.782 <0.001
HADS and ICQ
All participants completed the HADS questionnaire. The mean (SD) total score on the 
HADS was 9.25 (7.79), mean (SD) scores for anxiety and depression subscales were 
5.40 (4.37) and 3.85 (3.93) respectively.  Mean score on the HADS, number of patients 
reaching the subscale score >8 (threshold for mild, moderate and severe disorder) and their 
correlations with DT scores are depicted in Table 3. Thirty-two (22.1%) of the patients had 
scores > 15 (threshold for severe disorder).
The mean (SD) scores on helplessness, acceptance and disease benefits domains of the 
ICQ were 9.03 (3.66), 19.08 (4.28) and 16.13 (4.52) respectively. There was a significant 
correlation between DT score and helplessness and acceptance domains (Table 3).  One 
participant failed to fully complete the ICQ.    
Table 2. Continued
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Wish for referral
Nineteen patients (13.1%) expressed their wish to discuss with another professional for 
additional support. Thirty-seven patients (25.5%) answered this question with ‘maybe’. Of 
the patients reporting a DT score ≥5, 19.1% wished to be referred for additional support 
and 34.0% were considering it (and answered ‘maybe’). There was a significant correlation 
between the DT score and the wish for referral for additional support (r = 0.193, p = 0.025). 
‘Maybe’ willing to be referred for additional support significantly correlated with DT score 
as well (r = 0.230, p = 0.007).  Four respondents omitted to report whether they wished 
to be referred. 
Discussion
Cancer patients experience high levels of distress [6, 10, 20]. Relying on the subjective 
estimates of distress levels by medical professionals is often inaccurate and misleading [15, 
16]. The DT combined with a PL is a tool developed initially by National Comprehensive 
Cancer Network (NCCN) [34] for screening for distress in patients with breast tumors. 
It has been validated for use in several types of cancer and in populations with different 
ethnic backgrounds, including a series of Dutch patients [6, 7, 11, 13, 35]. This easy-to-use 
instrument helps identify treatable problems and specific issues that may cause distress, 
allowing physicians to tackle these issues more targeted. In addition, patients are explicitly 
requested whether they wish to be referred for additional specialized help. This potentially 
improves communication between patients and healthcare providers as well as patient care 
and satisfaction and may help to use limited consultation time more effectively [8].  This is 
the first study evaluating the level of distress using the DT and PL in DTC patients. 
The main finding of the present study is that the patients with DTC report experiencing 
significant levels of distress even years after being cured, with 34.3% of the patients 
reporting distress scores ≥5 on the DT, which may count for significant distress and possibly 
requires intervention. Surprisingly, this percentage is comparable to the 28.6-50% reported 
in series [19, 36-39] with similar response rates, including patients with other types of 
cancer such as lung-, breast cancer and leukemia, having a more aggressive course and being 
associated with more physical burden than patients with DTC, the majority of whom were in 
long-term remission.  However, these studies differ with respect to type of cancer, patient 
characteristics, cultural background, type of treatment, duration of follow-up and DT cut-
off level [4-6] used to define distress, and therefore cannot be compared appropriately. In 
DTC patients, although on the long-term QoL approaches that of the healthy population, 
previous studies indicate that most long-term survivors report specific persistent problems 
such as the negative effects of thyroid hormone withdrawal for radioiodine follow up 
Table 4. Frequencies, sensitivity, specificity, positive predictive values (PPV), and negative predictive values 
(NPV) of distress thermometer (DT) scores (*n represents the number of patients with the respective score 
in the total group and in the group of patients with active disease).
DT score n* (cum.%)
Total group
n*(cum.%) 
Active disease
Sensitivity Specificity PPV NPV
0 26 (19.1)  6 (22.2) 1.00 0.00 0.22 0.00
1 18 (32.4)  5 (40.7) 0.97 0.24 0.26 0.96
2 17 (44.9)      1 (44.4) 0.97 0.41 0.32 0.98
3 15 (55.9)      4 (59.3) 0.90 0.55 0.36 0.95
4 13 (65.4)  4 (74.1) 0.80 0.66 0.40 0.92
5 12 (74.3) 0 (74.1) 0.77 0.77 0.49 0.92
6 12 (83.1)   3 (85.2) 0.60 0.84 0.51 0.88
7 13 (92.6)   3 (96.3) 0.50 0.92 0.65 0.87
8 7 (97.8) 1 (100.0) 0.20 0.96 0.60 0.81
9 2 (99.3) 0 (100.0) 0.07 0.99 0.67 0.77
10   1(100.0) 0 (100.0) 0.04 1.00 1.00 0.79
Figure 1. Receiver operating characteristics (ROC) curve of distress thermometer (DT) scores versus 
hospital anxiety and depression scale (HADS) cut-off scores.
AUC 0.82, SD 0.043, 95%CI 0.739-0.906, P < 0,001
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The high DT score alone does not automatically imply that the patient should be referred 
for additional support, despite the clear correlation between DT score and the wish to 
be referred. Many problems that can be important sources of distress can be resolved 
by discussing them with nurses or physicians, others may require consultation of other 
professionals such as dieticians, physical therapists or social workers. The PL that 
accompanies the DT is a very useful starting point when discussing with patients about 
their specific problems. Previous data suggest that acknowledging and discussing problems 
alone may already yield clinical benefits and improve patient satisfaction [19]. In addition, 
the wish for intervention for individual patients must be taken into account, and therefore 
some patients can explicitly refuse further referral or just ‘maybe’ consider it.  In this 
series, although majority of patients did not express a wish to be referred for additional 
support, 13.1% of them addressed wishes for referral and 25.5% ‘maybe’ considered it. These 
percentages are lower compared with other forms of cancer such as lung cancer where 
approximately 22% expressed wishes for referral [20]. Nevertheless, considering that this 
series consisted mainly of long-term disease-free patients, these numbers are relevant and 
the needs of these patients should be addressed in a multidisciplinary fashion.
Distress scores correlated with HADS anxiety, depression and total scores. This is in 
accordance with previous data in other types of cancer [42].  Cut-off score of 5 resulted 
in optimal sensitivity and specificity relative to the HADS. The sensitivity of the DT in the 
current study was comparable to the results of a recent meta-analysis (77% vs. 78.3% in the 
meta-analysis), whereas specificity was higher (77% vs. 66.5% in the meta-analysis) [22]. In 
addition, NPV in the current study (92%) was higher compared to the meta-analysis (84%) 
[22], confirming that the DT is excellent for ruling out clinically elevated distress in this 
patient category, but given its low PPV of 49% it is less useful as diagnostic tool. Therefore 
a DT score ≥ 5 is only a starting point for further diagnostic evaluation by a physician or 
specialized nurse, if necessary followed by further intervention. 
This study has a number of limitations. The cross sectional retrospective nature of this study 
does not allow evaluation of the course of distress in time. Some periods during treatment 
or follow-up might be associated with higher levels of distress, such as the period short 
after establishing the diagnosis and the period of invasive treatment (surgery, RAI). Also 
patients with persistent disease might experience more distress than long-term disease-
free survivors. This series includes only few patients with persistent disease, as expected 
given the good prognosis of the disease, and lacks the statistical power required to analyze 
these correlations. In addition this study was not designed to investigate the clinical benefit 
of screening these patients.  
procedures, the fear and uncertainty related to a cancer diagnosis, feelings of diagnosis 
being dismissed as not seriously or ‘having a benign cancer’, confrontation with daily 
use of thyroid hormone medication and the fluctuating thyroid hormone levels [4]. The 
nature and intensity of these problems can change during the oncologic trajectory and 
become sources of distress. As the duration of follow-up increases for instance, the thyroid 
hormone withdrawal is not required anymore and the thyroid hormone levels become stable 
and remain within the normal range in the majority of patients. On the other hand other 
problems such as concerns about fertility can become more relevant after longer follow-
up. Therefore, identifying patients who may experience distress and may benefit from 
additional help and addressing the specific problems should be important objectives in the 
ongoing care of these long-term DTC survivors. When considering the range of DT scores 
and the nature of reported problems we conclude that the DT is a useful screening tool for 
this particular population. 
In consistence with findings in other types of cancer [19], no significant correlations were 
found between level of distress and either clinical or demographic characteristics, with the 
exception of employment status. The role of employment status in patients with chronic 
conditions and in oncologic patients is not clear and data in the literature are lacking. It has 
been suggested that unemployment influences distress levels in patients with cardiovascular 
disease [40]. Although not completely comparable with DTC survivors, this might support 
the need for reintegration strategies for patients in the work process after they have been 
cured. This is particularly important for patients with DTC who are often very young at time 
of diagnosis. Some specific problems reported by patients in this study slightly correlated 
with clinical characteristics, such as paresthesia in patients with hypoparathyroidism or 
mouth sores and impaired speech in patients receiving a higher cumulative dose of RAI (data 
not shown). These problems are very specific for thyroid carcinoma patients and should be 
recognized and addressed by the physicians. The majority of reported problems however 
did not correlate with clinical characteristics. Altogether these results demonstrate that 
distress is a profound individual reaction which cannot be predicted by objective clinical 
data and emphasize the need for routine specific screening for distress. 
Consistent with previous findings, patients cited physical problems over emotional problems 
as sources of distress [41]. Nevertheless, the correlation of DT scores with those of HADS 
and ICQ helplessness domain suggest that physical problems may lead to an increased 
psychological burden for these patients. In addition, the negative correlation with scores of 
the ICQ acceptance domain suggests that the increasing burden render the patients less 
likely to accept these problems. 
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Introduction
Surgical treatment of head and neck malignancy, especially when involving neck dissections, 
is well known to be associated with shoulder complaints [1, 2]. After radical neck dissection, 
shoulder dysfunction has even been shown to be the most important source of long-term 
morbidity of the patient with symptoms consisting of shoulder pain, limitation in shoulder 
mobility and winging of the scapula [3]. This has led to a trend towards more conservative 
management of the neck. Nevertheless, shoulder complaints are still frequently reported 
after surgical treatment for thyroid carcinoma. 
In a recent multinational patient/survivors initiated survey on the psychosocial/informational 
needs of patients with thyroid carcinoma/survivors 28.9% of the participants complained 
of numbness in the neck region and 26.8% reported restricted shoulder/neck movements 
more than 1 year after treatment [4]. However this study was not specifically designed 
to investigate shoulder complaints in these patients. Investigation of shoulder function is 
important because, due to the excellent prognosis of thyroid carcinoma with survival rates 
exceeding 90%, recovery of functional abilities, which are strongly related to  distress in 
these patients, is essential to improve the quality of life (QoL) [5]. The relation between 
shoulder complaints and neck dissections is of special interest as, over the last decades, there 
has been a major emphasis on QoL related to (temporary) spinal accessory nerve (SAN) 
damage and “shoulder syndrome” after radical neck dissection in head and neck malignancies 
[6, 7]. However as the majority of patients with thyroid carcinoma do not require extensive 
neck dissection, the shoulder complaints in these patients are thought to be limited and 
the majority of patients do not routinely receive information on this topic. Therefore, the 
purpose of this study was to assess the prevalence of self-reported long-term shoulder 
complaints in a historical cohort of patients who had surgery for thyroid carcinoma 
compared to a healthy control group.   Exploratory aims were to identify possible clinical 
or demographic correlates of shoulder complaints, and to evaluate associations between 
shoulder complaints and QoL.
Patients and methods
Design
A cross-sectional analysis was performed in a historical cohort of adults (18-80 years old) 
surgically treated for thyroid carcinoma in the past (either in our hospital or in another 
hospital) and who were currently under routine follow-up at our tertiary referral center. 
Primary treatment consisted of total thyroidectomy (and neck dissection in patients with 
preoperative clinically and/or radiologically confirmed nodal metastasis) followed in the 
Abstract
Background: Shoulder complaints are frequently reported  after surgical treatment for 
thyroid carcinoma. However, no specific literature on this topic is available for these 
patients and hence, its impact on quality of life (QoL) is unknown and there are no known 
predictors of shoulder complaints in this specific patient population. Therefore the purpose 
of this study was to assess the prevalence of shoulder-related complaints and its relation 
to QoL and clinical characteristics after thyroid carcinoma surgery by means of a cross-
sectional case control study in a tertiary referral center.
Methods: The prevalence of shoulder complaints and its relation to clinical characteristics 
and QOL after thyroid carcinoma surgery (n=109) was compared to a healthy control group 
(n=81). Main outcome measures are prevalence of self-reported shoulder complaints, results 
of the Disabilities of the Arm, Shoulder and Hand questionnaire (DASH) and the European 
Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-C30 
(EORTC-QLQ-C30).
Results: Patients with thyroid carcinoma, on average 10.2 years after thyroid surgery, 
reported a 58.7% prevalence of shoulder-related complaints, which was significantly more 
than the 13.6% reported by healthy controls (p<0.01). Patients with thyroid carcinoma 
scored worse than healthy controls on most of the different subscales of the DASH and 
EORTC-QLQ-C30. Bivariate association analysis identified level V neck dissection as 
being associated with the prevalence of shoulder complaints and DASH score, and spinal 
accessory nerve damage and employment status as being associated with DASH score. 
Prevalence of shoulder complaints and DASH scores were significantly correlated to several 
EORTC-QLQ-C30 scores. Only 11.9% of patients with thyroid carcinoma retrospectively 
reported having received preoperative information on possible shoulder complaints and 
only 34.9% of patients with thyroid carcinoma retrospectively reported having received 
additional care for their shoulder complaints.
Conclusions: Shoulder complaints represent an underestimated problem and are reported 
by many patients who had surgery for thyroid carcinoma. Information provision to the 
patient should be improved, shoulder complaints should be registered and additional care 
should be provided after thyroid carcinoma surgery to improve QoL.
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were included. All items refer to the situation in the last week. The responses are scored 
on a 5-point Likert scale, ranging from no difficulty to unable, from none to extreme, from 
no impact to high impact. The raw score is transformed to a 0-100 score. A score of 0 
reflects no disability, and 100 indicates maximal disability. In this study, a Dutch language 
version was used which has shown excellent internal consistency in literature (Cronbach’s 
α = 0.95) [12] and an even better internal consistency for the total questionnaire and 
different subscales in the current study sample (total questionnaire Cronbach’s α = 0.98, 
work module Cronbach’s alpha = 0.97 and sports/performing arts Cronbach’s alpha = 0.98)
European Organization for Research and Treatment of Cancer, Quality of Life 
Questionnaire-C30
The European Organization for Research and Treatment of Cancer, Quality of Life 
Questionnaire-C30 (EORTC QLQ-C30) (version 3.0) is a 30-item questionnaire 
assessing functional health, symptom experience and quality of life (QoL) of cancer 
patients, in general. It consists of 5 scales on physical-, role-, cognitive-, emotional- and 
social functioning, a global health status scale (GHS), 3 symptom scales on fatigue, nausea 
and vomiting and pain, and 6 single items assessing dyspnea, insomnia, loss of appetite, 
constipation, diarrhea and financial impact. All items refer to the situation in the last week. 
Each item is scored on response scale ranging from 1 (not at all) to 4 (very much), with the 
exception of the GHS, which is scored on a modified linear analogue scale ranging from 1 
(very poor) to 7 (excellent). All scales and single items are transformed to a 0-100 scale. 
A higher score on the functional scales and GHS indicates better functioning and QoL, 
whereas higher scores on the symptom scales indicate more complaints.
Demographical characteristics
Demographic information on age, gender, relationship status, educational level and 
employment status was collected by means of an ad-hoc questionnaire. 
Information provision on shoulder complaints and additional care consumption 
An ad-hoc questionnaire consisting of 4 items was used to gather information on whether or 
not patients had shoulder complaints (yes/no), recalled receiving information preoperatively 
on the possibility of postoperative shoulder complaints (yes/no) and the amount of extra 
care/therapy that was received because of shoulder complaints (yes/no) and the time it 
took after surgery (in months) before extra therapy was started. 
Statistical analysis
Statistical analysis was performed using SPSS version 20.0 (SPSS Inc, Chicago, Illinois). 
Differences in demographical and clinical characteristics and questionnaire scores between 
the subgroups of participants were analyzed using independent samples t-test or χ2 test 
majority of patients by ablation with radioactive iodine (I131) of residual thyroid tissue 4 
to 6 weeks after surgery. Patients who had completed treatment as well as those who were 
still receiving active treatment were included. No minimal time since completion of last 
treatment was required in order to participate. Subjects were invited to participate in this 
study by receiving an information letter and questionnaire package by mail.  Participating 
patients were kindly asked to provide their own healthy control subject of the same gender 
and the same age. The advantage of using acquaintance controls is that they are more likely 
to be similar to the patients in regard to baseline characteristics such as age, relationship 
status, social status, education level and community of residence. Patients who could not 
find a suitable acquaintance control were still included in the analysis. Non-responders 
received a reminder call 4 weeks later. Subjects with any intercurrent illness or disease such 
as trauma, inflammatory conditions or cerebrovascular accidents, that could cause shoulder 
complaints, were excluded. The presence of exclusion criteria in both the patients and the 
controls was checked using an ad-hoc questionnaire. 
This study has been approved by the institutional Ethics Committee and all patients 
provided written informed consent before participation.
Clinical characteristics
Clinical variables were collected from medical charts and included information on 
histopathological tumor subtype, tumor stage, time since treatment, radioactive iodine 
treatment including frequency and cumulative dose, neck dissection type, surgical dissection 
of the SAN and sternocleidomastoid muscles (SCM) as reported by the surgeon, present 
disease status, age at diagnosis, thyroid stimulating hormone (TSH) level in the period 
around completing the questionnaires (<6 months) and comorbidities. Comorbidities at the 
time of study participation were evaluated using the American Society of Anesthesiologists 
(ASA) classification [8]. Current disease status was defined as cured (remission) in case 
of undetectable Tg in the absence of anti-Tg antibodies and no evidence of loco-regional 
disease or distant metastases at last follow-up visit. Persistent- or recurrent disease was 
defined as either detectable Tg or evidence of loco-regional disease or distant metastases. 
Questionnaires
Disabilities of the Arm, Shoulder and Hand questionnaire
The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire was developed to 
measure the patients’ perception of the ability to perform different activities and roles and 
to monitor symptoms associated with any condition in the upper limb [9]. The questionnaire 
has been validated with a variety of upper limb disorders [10, 11]. The 30-items questionnaire 
includes 21 physical function items, 6 symptom items, and 3 social or role function items. 
In this study, optional modules on work (4 items) and sports/performing arts (4 items) 
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EORTC-QLQ-C30
The scaled EORTC-QLQ-C30 scores are depicted in Table 2. Patients with thyroid 
carcinoma scored significantly worse, compared to healthy controls, on all subscales 
(P<0.05) except for the symptom subscales of nausea and vomiting and constipation. 
Table 1. Demographic and clinical variables
Variable Patients with thyroid 
carcinoma (n=109)
Healthy controls 
(n=81)
P- value
Gender 
Male: n (%)
Female: n (%)
 30 (27.5)
 79 (72.5)
22 (27.2)
59 (72.8)
0.57
Age: mean (SD) (years)  53.3 (13.3) 51.3 (12.7) 0.31
Age at diagnosis: mean (SD) (years)
≤45: n (%)
>45: n (%)
40.8 (13.3)
62 (56.9)
47 (43.1)
N/A N/A
Follow up time since last treatment: median (range) (months)
≤12: n (%)
>12: n (%)
97.3 (0.5-565.1)
15 (13.8)
94 (86.2)
N/A N/A
Histopathological subtype: n (%)
   Papillary
   Folliculary
   Medullary
   Mixed
75 (68.8)
21 (19.3)
3 (2.8)
7 (6.4)
N/A N/A
TNM stage*: n (%)
   I
   II
   III
   IV
68 (62.4)
10 (9.2)
15 (13.8)
16 (14.7)
N/A N/A
Surgical treatment: n (%)
   Hemithyroidectomy
   Total thyroidectomy
   Neck dissection1
4 (3.7)
105 (96.3)
51 (46.8)
N/A N/A
RAI frequency: mean (SD) 1.55 (1.11) N/A N/A
RAI cumulative dose: mean (SD)
   None
   ≤100 mCi: n (%)
   100-200 mCi: n (%)
   >200 mCi: n (%)
9 (8.3)
9 (8.3)
51 (46.8)
40 (36.7)
N/A N/A
Neck dissection level: n (%)
   None
   VI
   II-IV
   V
58 (53.2)
31 (28.4)
43 (39.4)
29 (26.6)
N/A N/A
Additional structures damaged in surgery: n (%)
None reported
Sternocleidomastoid muscle
Spinal accessory nerve
103 (94.5)
4 (3.7)
3 (2.8)
N/A N/A
in case of categorical variables. Cohen’s d effect size of differences between patients and 
controls on questionnaire scores was calculated.  Within the thyroid carcinoma group, 
bivariate associations between clinical and demographical variables and prevalence of 
shoulder complaints and total DASH scores were tested using Mann-Whitney-U test or 
Kruskal-Wallis ANOVA. For the bivariate associations between two categorically coded 
characteristics χ2-test or Fisher’s exact test was used as appropriate. To reveal possible 
predictors of prevalence of shoulder complaints and total DASH scores, multiple linear/
logistic regression analysis was performed as appropriate. Variables with a p ≤0.25 in the 
bivariate analysis were included in multiple linear/logistic regression analysis as appropriate. 
On an exploratory basis, correlations between prevalence of shoulder complaints, DASH 
scores and EORTC-QLQ30 subscale scores in the patients with thyroid carcinoma were 
examined using Spearman’s rank correlation testing in order to examine  the relation 
between shoulder complaints, DASH scores and the diverse aspects of QoL. Statistical 
significance was defined as a p<0.05.  
Results
Subject characteristics
One hundred and ninety-three patients were invited for this study. Of these, 112 patients 
responded (response rate 58%). Two patients refused to participate because of recent 
traumatic injury to the arm/shoulder. One patient was excluded because of a recent 
cerebrovascular infarction. Twenty-eight patients were not able to find their own control 
subject.  A total of 109 patients with thyroid carcinoma [72.5% female, mean age (SD) 53.3 
(13.3) years] with a median (range) follow-up time since last treatment of 97.3 (0.5-565.1) 
months and 81 healthy controls [72.8% female, mean age (SD) 51.3 (12.7) years] were enrolled 
in the study. Clinical- and demographical characteristics of all subjects are depicted in 
Table 1. Participating and non-participating patients with thyroid carcinoma did not differ 
with respect to clinical characteristics (P-value >0.2 for all items).
DASH
The scaled DASH scores are depicted in Table 2. Patients with thyroid carcinoma had 
significantly worse full scale DASH scores compared to healthy controls (P<0.01). 
Furthermore, the patients with thyroid carcinoma scored worse on the optional modules on 
work and sports/performing arts compared to healthy controls (P<0.05).
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complaints (P=0.03) and higher total DASH score (P=0.02). Reported SAN damage 
during surgery was significantly associated with higher total DASH score (P=0.03) and 
being unemployed was significantly associated with higher total DASH score (P=0.01). 
The remaining clinical and demographical variables were not significantly associated with 
shoulder complaints or DASH scores. 
Results of the multiple logistic/linear regression analysis are reported in table 5. TNM 
stage turned out to be significantly associated with prevalence of shoulder complaints 
(P<0.05) and total DASH score (P<0.05) with lower TNM stage predicting more shoulder 
complaints and worse total DASH score. Furthermore, reported SAN damage during 
surgery was significantly associated with total DASH score (P<0.05). Employment status 
was significantly associated with total DASH score (P<0.01).
Table 2. Questionnaire scores and between group differences
Variable Patients with 
thyroid carcinoma 
(n=109)
Healthy controls (n=81) P-value Cohen’s d
DASH
DASH Total: mean (SD) 21.5 (20.1)  7.2 (13.4) <0.01 0.84
DASH work: mean (SD) 16.9 (17.8) 6.6 (13.5) <0.01 0.65
DASH sports/arts: mean (SD) 24.8 (18.9) 6.0 (11.3) <0.01 1.21
EORTC-QLQ-C30
Physical functioning: mean (SD) 82.1 (17.5) 95.0 (7.6) <0.01 -0.96
Role functioning: mean (SD) 77.1 (27.1) 91.6 (17.5) <0.05 -0.64
Emotional functioning: mean (SD) 82.4 (19.9) 89.5 (13.7) <0.01 -0.42
Cognitive functioning: mean (SD) 79.8 (25.2) 93.2 (16.0) <0.01 -0.63
Social functioning: mean (SD) 82.7 (23.6) 96.5 (12.3) <0.01 -0.73
GHS: mean (SD) 73.4 (20.7) 84.6 (15.4) <0.01 -0.61
Fatigue: mean (SD) 29.0 (27.1) 12.5 (13.7) <0.01 0.77
Nausea and vomiting: mean (SD) 2.4 (7.5) 1.0 (4.0) 0.11 N/A
Pain: mean (SD) 18.5 (20.0) 11.9 (19.8) <0.05 0.33
Dyspnea: mean (SD) 16.2 (23.4) 6.6 (15.3) <0.01 0.49
Insomnia: mean (SD) 27.5 (30.7) 12.8 (22.1) <0.01 0.55
Loss of appetite: mean (SD) 5.8 (15.6) 0.8 (5.2) <0.01 0.43
Constipation: mean (SD) 8.9 (20.1) 4.9 (15.0) 0.13 N/A
Diarrhea: mean (SD) 6.4 (16.7) 1.6 (7.3) <0.01 0.37
Financial impact: mean (SD) 9.8 (21.4) 2.0 (9.6) <0.05 0.47
DASH, Disabilities of the Arm, Shoulder and Hand questionnaire; GHS, Global Health Score; N/A, not 
applicable; EORTC-QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire-Core-30-questions.
Note1: p-values were derived from independent samples t-test. Cohen’s d values depict effect sizes ( d=0.2, 
small effect; d=0.5, medium effect; d=0.8, large effect)
Note2: higher scores indicate worse functioning on the DASH, and higher scores indicate better functioning 
on the EORTC-QLQ-C30 functioning scales but worse status on the symptom scales.
ASA classification: n (%)
   I
   II
   III
   IV
0 (0.0)
100 (91.7)
7 (6.4)
2 (1.8)
65 (80.2)
13 (16.0)
3 (3.7)
0 (0.0)
<0.01
Disease status: n (%)
   Remission
   Active disease
Biochemical active disease
Anatomical active disease
85 (78.0)
24 (22.0)
17 (15.6)
7 (6.4)
N/A N/A
TSH around the time of participation: n (%)
<0.01 mE/l (suppressed)
0.01-0.40 mE/l 
0.40-4.00 mE/l (normal range)
>4.00 mE/l
26 (23.9)
42 (38.5)
39 (35.8)
2 (1.8)
N/A N/A
Relationship status: n (%)
   Married/cohabiting
   Divorced
   Widow(er)
   Single
94 (86.2)
5 (4.6)
3 (2.8)
7 (6.4)
58 (71.6)
8 (9.9)
6 (7.4)
9 (11.1)
0.66
Education level: n (%)
   Primary school
   Secondary education
   Higher secondary education
   University
5 (4.6)
21 (19.3)
45 (41.3)
38 (34.9)
1 (1.2)
8 (9.9)
36 (44.4)
36 (44.4)
0.30
Employment status: n (%)
   Employed
   Unemployed
56 (51.4)
53 (48.6)
56 (69.1)
25 (30.9)
<0.05
TNM, Tumor Node Metastasis; RAI, Radioactive Iodine ; ND, Neck Dissection; ASA, American society of 
Anesthesiologists; N/A, not applicable; TSH, thyroid stimulating hormone
* Union for International Cancer Control Classification of malignant tumors, 6th edition [27 ]
Note1: Not all neck dissections were performed synchronously with the thyroidectomy.
Note2: p-values were derived from independent samples t-test or χ2-test as appropriate.
Prevalence of shoulder complaints, information supply and additional care 
consumption 
Significantly more patients with thyroid carcinoma (58.7%) reported having shoulder 
complaints compared to the healthy controls (13.6%) (P<0.01). Only 11.9% of the patients 
with thyroid carcinoma recalled receiving pre-operative information about possible 
postoperative shoulder complaints. Of the patients with thyroid carcinomas, 34.9% 
received additional care for their shoulder complaints. All data about prevalence of shoulder 
complaints, information supply and additional care consumption are provided in Table 3.
Bivariate associations and regression analysis
Bivariate associations in the patients with thyroid carcinoma between subject 
characteristics, prevalence of shoulder complaints and DASH scores are depicted in 
Table 4. Level V ND was significantly associated with higher prevalence of shoulder 
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Table 4. Bivariate associations between demographic and clinical variables and DASH scores and shoulder 
complaints for patients with thyroid carcinoma only
Variable DASH total score 
(mean (SD))
Shoulder complaints 
(n (%))
Gender: 
Male
Female
P-value
19.6 (17.9)
22.2 (20.9)
0.58
16 (53.3)
48 (60.8)
0.48
Age: (years)
≤45
>45
P-value
20.8 (18.3)
22.4 (22.4)
0.84
38 (61.3)
26 (55.3)
0.53
TNM stage: 
   I
   II
   III
   IV
P-value
21.4 (19.3)
32.8 (15.6)
14.7 (21.4)
20.6 (23.0)
0.08
43 (63.2)
7 (70.0)
4 (26.7)
9 (56.3)
0.23
RAI cumulative dose:
   None
   ≤100 mCi
   100-200 mCi
   >200 mCi
   P-value
12.1 (16.4)
22.6 (24.2)
23.5 (20.5)
20.7 (19.4)
0.56
6 (66.7)
6 (66.7)
30 (58.8)
22 (55.0)
0.88
Neck dissection:
   Yes
   No
P-value
22.4 (20.1)
20.7 (20.2)
0.58
34 (66.7)
30 (51.7)
0.11
Neck dissection level II-IV:
   Yes
   No
P-value
24.2 (20.5)
19.7 (19.7)
0.22
30 (69.8)
34 (51.5)
0.06
Neck dissection level V:
   Yes
   No
P-value
28.2 (20.5)
19.1 (19.5)
0.02*
22 (75.9)
42 (52.5)
0.03*
Neck dissection level VI:
   Yes
   No
P-value
18.8 (17.9)
22.6 (20.9)
0.54
19 (61.3)
45 (57.7)
0.73
SCM damaged during surgery:
   Yes
   No
P-value
27.1 (29.0)
21.3 (19.8)
0.60
3 (75.0)
61 (58.1)
0.64
SAN damaged during surgery:
   Yes
   No
P-value
48.9 (19.6)
20.7 (19.6)
0.03*
3 (100.0)
61 (57.5)
0.27
Table 3. Patient’s retrospective reports about shoulder complaints and the information and care they 
received
Variable Patients with 
thyroid carcinoma 
(n=109)
Healthy controls 
(n=81)
P-value
Shoulder complaints: n (%)
   Yes
   No
64 (58.7)
45 (41.3)
11 (13.6)
70 (86.4)
<0.01
Received preoperative information on possible postoperative 
shoulder complaints: n (%)
   Yes
   No
13 (11.9)
96 (88.1)
N/A N/A
Received additional care for shoulder complaints: n (%)
   Yes
   No
38 (34.9)
71 (65.1)
N/A N/A
Time it took before additional care was provided after 
surgery: mean (SD)
   Directly: n (%)
   1-3 months: n (%)
   3-12 months: n (%)
   >12 months: n (%) 
1 (0.9)
15 (13.8)
12 (11.0)
10 (9.2)
N/A N/A
N/A, not applicable.
Note: p-values were derived from independent samples t-test or χ2-test as appropriate.
Correlations between prevalence of shoulder complaints, DASH scores and 
EORTC-QLQ-C30 scores in patients with thyroid carcinoma 
The prevalence of shoulder complaints was positively correlated with total DASH score 
( r = 0.617, P<0.01) and DASH work (r = 0.568, P<0.01) and sports/performing arts module 
scores (r = 0.670, P<0.01). Furthermore, prevalence of shoulder complaints and total 
DASH score were negatively correlated with all EORTC-QLQ-C30 functional- (physical-, 
role-, cognitive-, emotional- and social functioning) and GHS subscale scores and positively 
correlated with all symptom subscale (fatigue and pain) and single item (dyspnea, insomnia, 
constipation and financial impact)  scores except for nausea and vomiting, loss of appetite, 
and diarrhea (data shown in Table 6). 
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Table 5. Multiple logistic/linear regression analyses for patients with thyroid carcinoma only
Variable DASH total score
β (P-value)
Shoulder complaints 
OR (95%-CI) (P-value)
TNM stage(I/ II vs. III/IV) -.239 (0.013*) .31 (0.12-0.81) (0.017*)
Neck dissection level II-IV (Yes vs.No) -.015 (0.913) 1.90 (0.53-6.74) (0.323)
Neck dissection level V (Yes vs.No) .190 (0.155) 1.96 (0.47-8.12) (0.355)
SAN damaged during surgery (Yes vs.No) .198 (0.031*) 0.00 (0.00) (0.99)
ASA classification (II vs.III/IV) .101 (0.251) N/A
Education level (Primary school/ Secondary education vs.Higher 
secondary education/University)
-.179 (0.054) N/A
Employment status (Employed vs.Unemployed) .281 (0.004*) N/A
DASH, Disabilities of the Arm, Shoulder and Hand Questionnaire; 95% CI, 95% confidence interval; SAN, 
spinal accessory nerve; ASA, American Society of Anesthesiologists.
Note1: Neck dissection (yes/no) was deleted from the regression analysis because of multicollinearity with 
the predictors “Neck dissection level II-IV” and “Neck dissection level V”.
Note2: R2 for the multiple linear regression =.25 
Note3: R2 for the multiple logistic regression =.15 (Nagelkerke)
N/A, Not applicable; β, standardized beta; OR, odds ratio.
* p <0.05
Table 6. Correlations between prevalence of shoulder complaints, DASH scores and EORTC-QLQ-C30 
scores in patients with thyroid carcinoma
EORTC-QLQ-C30 subscales DASH total score Shoulder complaints
r P-value r P-value
Physical functioning -.741 <0.01 -.404 <0.01
Role functioning -.784 <0.01 -.517 <0.01
Emotional functioning -.377 <0.01 -.203 0.03
Cognitive functioning -.362 <0.01 -.242 0.01
Social functioning -.495 <0.01 -.273 <0.01
GHS -.551 <0.01 -.306 <0.01
Fatigue .564 <0.01 .263 0.01
Nausea and vomiting .181 0.06 .114 0.24
Pain .793 <0.01 .566 <0.01
Dyspnea .327 <0.01 .263 <0.01
Insomnia .529 <0.01 .349 <0.01
Loss of appetite .135 0.16 .126 0.19
Constipation .201 0.04 .216 0.02
Diarrhea .059 0.54 .012 0.90
Financial impact .303 <0.01 .210 0.03
GHS, Global Health Score; DASH, Disabilities of the Arm, Shoulder and Hand Questionnaire; EORTC-
QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-
Core-30-questions.
Note: p-values were derived from Spearman’s rank correlation testing. r = Spearman’s-rho.  
Follow up since last treatment: (months)
   ≤12
   >12
P-value
19.3 (16.0)
21.8 (20.7)
0.89
10 (66.7)
54 (57.4)
0.30
ASA classification: 
   II
   III
   IV
P-value
20.9 (19.8)
22.0 (22.1)
50.4 (13.6)
0.17
57 (57.0)
5 (71.4)
2 (100.0)
0.37
Disease status: 
   Remission
   Active disease
P-value
22.4 (20.7)
18.2 (17.6)
0.40
48 (56.5)
16 (66.7)
0.37
Relationship status: 
   Married/cohabiting
   Single
P-value
21.0 (20.2)
24.3 (20.0)
0.46
56 (59.6)
8 (53.3)
0.65
Education level: 
   Primary school
   Secondary education
   Higher secondary education
   University
P-value
29.3 (22.9)
31.9 (22.5)
17.2 (17.6)
19.7 (19.6)
0.07
3 (60.0)
14 (66.7)
26 (57.8)
21 (55.3)
0.86
Employment status: 
   Employed
   Unemployed
P-value
16.1 (16.6)
27.2 (22.0)
0.01*
30 (53.6)
34 (64.2)
0.26
TNM, Tumor Node Metastasis; RAI, Radioactive Iodine; ND, Neck Dissection; ASA, American 
Society of Anesthesiologists; DASH, Disabilities of the Arm, Shoulder and Hand Questionnaire; SCM, 
sternocleidomastoid; SAN, spinal accessory nerve.
Note: p-values were derived from Mann-Whitney-U test or Kruskal-Wallis ANOVA as appropriate.  For 
the bivariate associations between two categorically coded characteristics χ2-test or Fisher’s exact test was 
used as appropriate .
Table 4. Continued
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reported SAN damage, traction, devascularisation or transsection of the fine branches may 
contribute to a temporary or a persistent shoulder discomfort. 
Part of the shoulder complaints in patients with thyroid carcinoma might be attributable 
to the cutaneous sensory distribution of the four major cervical roots. Especially patients 
undergoing more limited procedures might experience more radicular pain and abnormal 
motor activity in this cervical distribution as these nerves are irritated but not sacrificed. 
Furthermore, SCM preservation will also add to the postoperative discomfort, as the 
muscle usually retains its sensory capacity. In addition, some authors consider these nerves 
to provide a contribution to upper trapezius muscle motor innervations [18]. 
In this study, the shoulder complaints in patients with thyroid carcinoma might also be 
related to adhesive capsulitis of the glenohumeral joint, associated with non-use of the 
upper limb during the post-operative period. Adhesive capsulitis could explain the late 
onset of pain after several weeks frequently seen in these patients and could also provide an 
explanation on the persistence of shoulder disability when there are no signs of SAN injury. 
Surprisingly, the patients with a lower TNM classification reported more shoulder discomfort. 
We hypothesize that this may be the case, in part, because in patients with high stage, with 
locally extensive disease and not completely removable tumor, one might prefer performing 
a more limited surgery aimed to preserve functionality and QoL. On the other hand we 
cannot exclude that psychological factors might induce a reporting bias as well. Patients 
with more extensive disease may be more burdened by the possible worse prognosis of the 
disease and pay less attention to less severe shoulder discomfort. In contrast, patients with 
less extensive disease with a better long-term prognosis may focus more on optimal QoL and 
functionality required, for instance for work rehabilitation. Not surprisingly, the regression 
analysis identified employment status to be significantly associated with shoulder complaints 
and DASH scores in the patients with thyroid carcinoma.  Because this is a cross-sectional 
study it is difficult to make causal inferences about the relation between employment status 
and DASH scores. It is however most logical to assume that patients with worse DASH scores 
are more often unemployed due to their complaints especially as a previous review article 
found that 46% of patients recovering from head and neck cancer surgery gave up work solely 
due to shoulder disability [19].
Postoperatively, clinicians should identify shoulder complaints, using questionnaires, for 
example the DASH, and clinical tests [20], and provide additional physiotherapy treatment. 
This treatment should not be delayed as appears to be the case in this study, where most 
patients only commenced additional therapy after more than a month postoperatively. We 
believe this treatment should continue following discharge from the hospital as these patients 
Discussion
In this study, the prevalence of self reported long-term shoulder complaints and its relation 
to QoL and clinical characteristics was investigated in a large historical cohort of patients who 
have been treated for thyroid carcinoma compared to a gender- and age matched control 
group consisting of healthy controls. The most important finding is that patients treated for 
thyroid carcinoma suffer from increased shoulder-related symptoms compared to healthy 
controls. Only a small proportion of patients recalled being informed preoperatively about 
the possibility of postoperative shoulder complaints. Furthermore, only a small proportion 
of patients received additional treatment for their problems. Correlation analysis showed 
that DASH scores and prevalence of shoulder complaints were significantly related to 
several EORTC-QLQ-C30 subscale scores, which implies that having shoulder complaints 
is significantly associated with a diverse range of aspects of QoL in these patients.  
As expected, SAN damage during surgery was significantly associated with worse DASH 
scores . The shoulder complaints resulting from neck dissections are characterized by 
shoulder droop, inability to shrug, limited forward flexion, limited active lateral abduction, 
constant dull ache and aberrant scapular rotation. The results of the current study in patients 
with thyroid carcinoma are comparable to the results of studies in patients undergoing 
surgical treatment for other head- and neck cancers that also used questionnaires on self-
reported QoL and complaints. One study in patients with thyroid carcinoma showed that 
especially extensive neck dissections are associated with shoulder complaints which is an 
important source of long-term morbidity and QoL impairment [3, 13-15]. Dissections 
extending into level V are known to cause a higher incidence of shoulder complaints [16]. 
This is consistent with the finding of an association between level V neck dissection and 
shoulder complaints/worse DASH scores in the bivariate analysis in the current study. This 
is, most likely, caused by the fact that the SAN is encountered in level V where it lies 
superficial and may suffer local trauma or unintentional division [17]. The previous study in 
patients with thyroid carcinoma did not take this specific relation with level V dissections 
and SAN damage into account [15]. 
However, we were surprised to find that a large proportion of patients in our series who did 
not have extensive neck dissection reported shoulder-related complaints still many years 
after the primary treatment. Moreover, we were surprised that a lower TNM classification 
was associated with reporting more shoulder complains. This has led us to consider that 
apart from the obvious possible causes of shoulder complaints after head and neck surgery 
such as SAN damage (sometimes intentionally sacrificed in patients with extensive disease) 
other factors may play a role as well. One can envisage that, even in the absence of a 
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can proceed to lose function and develop adhesive capsulitis/reduced shoulder stability due to 
loss of trapezius muscle function, especially when the SAN has been damaged. Maintenance of 
normal active movement and passive stretch are beneficial to prevent adhesive capsulitis and 
help to gain muscle strength in order to regain full range of motion and avoid the occurrence of 
joint fibrosis [21, 22]. These interventions have already proven their worth in decreasing shoulder 
complaints and improving QoL after neck dissections [23]. In addition, the use of botulinum 
toxin type A has been reported to give significant reduction of shoulder pain with only 1 session 
of injections in trigger points of painful muscles [24]. Further research is needed to prove the 
utility of such interventions in patients with thyroid carcinoma, even when no ND is performed. 
This study has some limitations. Because of the cross-sectional design, no baseline questionnaire 
scores or follow-up across time are available and therefore it is impossible to draw causal 
inferences. However, to compensate for this limitation we have included the control group. The 
prevalence of complaints of 13,6% in the control group was according to our expectations based 
on the point prevalence in the general Dutch population [25, 26]. Therefore we conclude that 
the control population included in our study is representative of the normal Dutch population. 
The complaints in the general Dutch population are based on a wide variety of etiologies such 
as impingement, bursitis, tendinitis, rotator cuff lesion, frozen shoulder, capsulitis, arthritis, 
glenohumeral instability. Recall bias in the patients might have caused underreporting of 
preoperatively provided information about shoulder complaints and the ad-hoc questionnaire 
on shoulder complaints, information provision and additional care could not be validated. Our 
future research is aimed at the prospective assessment of shoulder complaints and analysis of 
the specific aetiology of the shoulder complaints, by means of physical examination, in order 
to be able to tailor the treatment and prevention strategies.  As the subjects were assessed 
an average of 10 years after treatment, with a wide range of time since last treatment, it is 
important to notice that findings may not be generalized to other groups of patients evaluated 
earlier in recovery, despite the fact that time since last treatment was not associated with 
shoulder complaints and DASH scores in this study. Furthermore, it was decided not to correct 
for multiple testing in this explorative study to reduce the incidence of type-2 errors. This 
implies that we cannot exclude that some of the significant differences/associations may be a 
finding by chance (i.e., a type-1 error).
In conclusion, the results of this study suggest that the prevalence of self-reported shoulder 
complaints after thyroid carcinoma surgery is high. It represents an important issue in the 
management of these patients and is associated with QoL. The patients should be informed 
about this preoperatively, postoperative physical examination of the shoulder is warranted 
and physiotherapy should be started as soon as possible when complaints are present or can 
be expected.  
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Abstract 
Context: Acromegaly is associated with impaired quality of life (QoL) and causes anatomical 
disproportions, which may contribute to the decreased QoL after successful treatment. The 
Derriford appearance scale 59 (DAS59) is a questionnaire measuring psychological distress 
and disruptions to everyday life associated with self-consciousness of appearance.
Objective: Investigate the psychological distress and dysfunction related to self-
consciousness about appearance and its effect on QoL in patients in long-term remission 
of acromegaly. 
Patients, design and methods: Patients (>18 years old) treated for acromegaly at the 
Department of Endocrinology of the Radboud University Medical Center Nijmegen 
were invited to participate. A gender-, age- and body mass index (BMI) matched control 
group was provided by the patients themselves. Participants were asked to complete the 
modified DAS59-, research and development 36- (RAND-36), acromegaly quality of 
life questionnaire (AcroQoL) and a sociodemographic questionnaire. Differences between 
patient- and control groups and correlations between questionnaire scores and clinical 
characteristics collected from medical records were analyzed. 
Main outcome measures: Questionnaire scores.
Results: Of the 120 respondents, 73 agreed to participate [all cured or under biochemical 
control, median remission time 10.5 years (range 2.3-43.6 years)]. Of these, 34 (46.6%) 
reported self-consciousness about their appearance. Twenty-nine of these patients (85.3%) 
pointed out their face to be a prominent source of self-consciousness. Fifty-seven matched 
control subjects were included as well. Significant correlations were found between the 
scores of the DAS59 and the AcroQoL, RAND-36 and VAS in patients.
Conclusions: Even after long-term remission of acromegaly, a large number of patients are 
self-conscious about their appearance, leading to psychological distress and disruptions to 
everyday life and decreased QoL. Facial features were the most important source of self-
consciousness. This stresses the importance of addressing self-consciousness of appearance 
and the need for additional support in this regard during follow-up in these patients. 
Introduction
Craniofacial disproportions due to soft tissue swelling and new bone formation are 
highly prevalent in patients with active acromegaly [1]. Although clinically there is a 
slight improvement in facial appearance after biochemical control of growth hormone 
(GH) hypersecretion, we have recently shown that significant differences in craniofacial 
characteristics persist even after long-term remission [2]. It has been suggested that these 
changes in appearance can lead to self-consciousness about appearance, leading towards 
self-esteem disintegration, social withdrawal, body image distortion and an impaired quality 
of life (QoL) [3]. 
Previous studies, which used the disease specific AcroQol questionnaire, have shown that 
patients with both active and controlled acromegaly have an impaired QoL. Remarkably, 
the appearance subscale of the AcroQol was the most affected subscale in these studies [4-
7]. Moreover, the patients in remission of acromegaly had only slightly better scores on the 
appearance subscale than patients with active disease [4, 6, 8]. However the appearance 
subscale of the AcroQol is limited and does not investigate which aspect of appearance 
specifically causes the self-consciousness related distress.
 The Derriford appearance scale 59 (DAS59) is a psychological questionnaire, developed 
for research in plastic surgery and oncology. It measures self-consciousness about one’s 
appearance and identifies the anatomical source of this self-consciousness. It is validated 
for both clinical and research settings. It has an excellent validity and reliability, and has been 
independently recommended as a measure of choice for the assessment of feelings about 
appearance [9, 10]. However, the DAS59 had never been used in patients with acromegaly. 
The primary aim of the present study was to investigate, by using the DAS59 questionnaire 
, whether patients in long-term remission of acromegaly suffer from more psychological 
distress and psychological- and social dysfunction related to self-consciousness of 
appearance than a gender-, age- and BMI matched control group and whether this affects 
QoL. In addition we aimed to identify the anatomical sources of self-consciousness in 
these patients. We hypothesised that (irreversible) changes in craniofacial characteristics 
caused by the previous period of GH hypersecretion are related to the distress related to 
appearance in patients in long-term remission of acromegaly.
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Subjects and methods
Patients
All patients (18-80 years old) treated at the Department of Medicine, Division of 
Endocrinology of the Radboud University Medical Center Nijmegen who had been in 
remission of acromegaly for more than 2 years were invited to participate in this study by 
letter. 
Exclusion criteria were active malignancy, cardiovascular disease (unstable coronary artery 
disease, heart failure NYHA III-IV), (recent) pregnancy (within 1 year prior to the study), 
depression, psychosis and personality disorder.
Because the assessment of one’s own appearance differs in relation to gender, age and BMI, 
participants were asked to find their own control subject with the same gender and roughly 
the same age and BMI [9, 11, 12]. 
The study was approved by our institutional ethics committee and conformed to the 
declaration of Helsinki. All participants gave written informed consent for participation in 
the study.
Questionnaires
DAS59 
The DAS-59 is a self-reporting questionnaire that generates a series of valid and reliable 
measures of the specific psychological distress and disruption to everyday life that are 
associated with self-consciousness of appearance. It is intended for use in an adult population 
(> 16 years) [9]. An introductory section identifies whether a subject is self-conscious 
about their appearance and the aspect of appearance that is of the greatest concern to the 
respondent. This is referred to as the respondent’s ‘feature’ in the rest of the questionnaire. 
The DAS59 contains 59 statements and questions with response categories in a Likert 
format to measure frequency of symptomatology (‘almost never’… ‘almost always’) and 
levels of associated distress (‘not at all distressed’…’extremely distressed’). Fifty-seven 
items assess relevant psychological distress and dysfunction, and two items assess physical 
distress and physical dysfunction. The following subscales were examined as described by 
the questionnaire manual [13]: general self-consciousness (GSC), social self-consciousness 
(SSC), facial self-consciousness (FSC), Sexual and bodily self-consciousness (SBSC) and 
negative self-concept (NSC). A higher score on the DAS59 is associated with a greater 
degree of self image related distress and dysfunction. The format of the introductory 
section and a ‘not applicable’ response category for most items make the scale acceptable 
for respondents who are not concerned about appearance at all. 
In this study a linguistic and cultural translation of the DAS59 from English to Dutch was 
performed following internationally accepted guidelines [14, 15] and used with permission 
of the original authors [9]. The translation into Dutch was successful. The backward-
translation was compared to the original English version and did not show conceptual 
discrepancies. During piloting the items were assessed as conceptually and linguistically 
meaningful and appropriate, and in line with the original (English) items.
The DAS59 questionnaire was modified for the purpose of this study by including a self-
rated Visual Analogue Scale (VAS) for the participants to score the level of satisfaction with 
their facial appearance in general. The VAS is a 10 cm ‘ruler’ scaled 0 (not at all satisfied) 
to 10 (very satisfied) [16]. 
RAND – 36
For the assessment of general QoL the Dutch translation of the RAND-36 was used [18]. 
It comprises 36 items regarding general well being during the past 30 days. The items are 
formulated as statements or questions with Likert scale or yes/no response options to assess 
9 health concepts: 1) physical functioning; 2) social functioning; 3) role limitations because 
of physical health problems; 4) role limitations because of emotional problems; 5) mental 
health; 6) vitality; 7) bodily pain, 8) general health perceptions, 9) health change in the last 
year. Scores are calculated for each health aspect on a 0-100 scale, in which higher scores 
represent a better QoL. 
AcroQoL
This is a disease-specific questionnaire developed to asses health related QoL in patients with 
acromegaly [17]. It comprises 22 items. Responses are given as the frequency of occurrence 
(ranging from always to never) or degree of agreement (ranging from completely agree to 
completely disagree) on a five-point scale. The questionnaire includes two different scales; 
a physical performance scale and a psychological well-being scale. The psychological scale 
is further subdivided into 2 subscales regarding appearance and personal relationships, 
containing seven items each. The highest achievable score is 110 (100%), which is indicative 
of an excellent QoL, while the lowest score is 22 (0%) [5]. 
Sociodemographical and clinical variables
Sociodemographical and clinical characteristics of patients were collected by means of a 
sociodemographical questionnaire and medical chart review in the patient group. 
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Definitions
Remission was subdivided into 2 groups and defined as: 1. cure: successful surgical and/or 
radiotherapeutical treatment of the GH producing adenoma followed by a normalization 
of the IGF-1 concentration (≤ mean + 2 SDS for age) and suppression of serum GH levels 
<1.0μg/l during OGTT (after surgical treatment)[18] and 2. disease control: normal IGF1 
concentrations (≤ mean +2  S.D.S for age) during the use of somatostatin analogues, 
dopamine agonists and/or GH receptor antagonists. 
Hormonal deficiency was defined as deficiency of one or more pituitary hormones. 
Hypothyroidism was defined as the use of thyroid hormone substitution therapy. 
Hypogonadism was defined as use of testosterone substitution in men and use of oestrogen 
in women. GH deficiency was defined as the need for GH substitution therapy as defined 
by a maximal GH response <15.3mU/l during an insulin tolerance test (ITT) or a maximal 
GH response of <12.3 mU/l during an arginine/GHRH test [19]. Glucocorticoid deficiency 
was defined as the need for glucocorticoid substitution therapy as defined by a plasma 
morning cortisol <100nmol/l, after withdrawal of glucocorticoids for 24 hours, or a maximal 
cortisol response <550nmol/l during an ITT [20].
Regarding current disease status, cure or biochemical disease control had been confirmed 
by a recent (<1 year) normal IGF-1 level in all participating patients.
Statistical analysis
All data are presented as means and standard deviations (SD) or median and range. Data 
were tested for normality of distribution by means of the Kolmogorov-Smirnov test. T-tests 
or Mann-Whitney U tests depending on normality of distribution or χ2 tests (for categorical 
variables) were performed to compare the variables age, gender and BMI of the patient- and 
control group. T-tests or Mann-Whitney U tests were performed to compare the scores on 
the subscales of the  DAS59, RAND, AcroQoL and VAS of the patient- and control group. 
To investigate the presence of correlations between sociodemographic characteristics, 
clinical characteristics and outcomes of the questionnaires Spearman’s rank correlation 
testing or point-biserial correlation was used as appropriate. Statistical significance was 
set at the 5% level (p<0.05). All statistical analyses were performed using SPSS software 
(version 20.0; SPSS Inc., Chicago, IL, USA). 
Results
Patient characteristics
The clinical characteristics of the patients and control subjects are depicted in Table 1. 
One hundred and thirty-one patients were invited to participate. Of these, 120 subjects 
responded (response rate 91.6%). Forty-seven of the patients who responded decided not 
to participate because of a lack of time (n=6), a lack of interest (n=14), physical or emotional 
problems (n=19) or because they did not have a problem with their appearance (n=5). Three 
of the patients who responded did not report their reason for refusal to participate. No 
statistically significant differences were found between the participants and the subjects 
who refused to participate in this study with respect to clinical parameters, with the 
exception of age, with the non-participants being slightly older than the participants. 
A total of 73 patients (45.2% female, mean age 59.4 ±10.5 years and BMI 28.1 ± 4.7 kg/
m2) agreed to participate. Mean age at diagnosis was 41.6 (11.2) years. Regarding current 
disease status, cure or biochemical disease control had been confirmed by a recent (<1 
year) normal IGF-1 level in all participating patients. Median remission time was 10.5 
(2.3-43.6) years. The treatment processes of all patients are depicted in Figure 1. Sixty-
three (86.3%) patients had undergone primary pituitary surgery and 3 (4.1%) patients had 
undergone primary radiotherapy. At the time of the study acromegaly was controlled by 
medical therapy in 43.8% of the patients: 20 patients (27.4%) used somatostatin analogues 
(SA) monotherapy, 4 (5.5%) dopamine agonists (DA) monotherapy, 2 (2.7%) GH receptor 
blockers (GHRB) monotherapy, 6 were using combination therapy. The other 41 (56.2%) 
patients were in remission of acromegaly without medical therapy. In 41 (56.2%) patients 
no substitution of pituitary hormones was necessary after surgery or radiotherapy, 32 
(43.8%) had some kind of hormonal deficiency, of whom 15 (20.5%) had a hypopituitarism. 
Fifty-seven control subjects were included in this study (47.4% female, age 58.6 ± 11.3 
years, BMI 26.4 ±3.5 kg/m2). There was no significant difference between the patient- and 
the control group regarding age (p=0.510), gender (p=0.860) and BMI (p=0.050), which 
confirmed the adequate matching.
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Derriford appearance scale scores
Table 2 shows the sources of self-consciousness and scores of the two groups on the DAS59. 
Thirty-four (46,6%) of the patients in long-term remission of acromegaly were self-
conscious about their appearance compared to 13 (22.8%) of the control subjects (p<0.01). 
Twenty-nine (85.3%) of the patients indicated that their face was the most prominent 
source of self-consciousness compared to 3 (23.1%) controls (p<0.01). Compared to the 
control group the patient group had statistically significant higher scores on all subscales 
(p<0.01). No statistically significant correlations were found between the DAS59 scores of 
the patient group and clinical characteristics like age, gender and BMI (Table 1). However 
a statistically significant correlation was found between the DAS59 scores of the control 
group and age (r=-0.327, p<0.05). Furthermore, in the patient group no correlation was 
found between the duration of remission and the DAS59 scores (r=-0.169, p=0.153) and 
between disease status (cure versus biochemical disease control) and the DAS59 scores 
( r=0.021, p=0.860). A slight but significant correlation was found between pituitary 
function and the DAS59 score ( r=0.279, p<0.05) with patients with a preserved pituitary 
function scoring lower amounts of self image related distress. Another correlation was 
found between hypothyroidism and the full scale DAS59 score (r=-0.249, p<0.05) 
(Table 1) with patients with hypothyroidism scoring higher. More specifically, a significant 
correlation was found between hypothyroidism and the GSC-subscale (r=-0.262, p<0.05). 
In the patient group, no correlations were found between the DAS59 score in patients and 
having a partner (r=0.040, p=0.739), education level (r=-0.038, p=0.749) or employment 
status (r=-0.037, p=0.756). In the control group, these correlations were also not found 
to be statistically significant; having a partner (r=0.003, p=0.368), education level 
(r=-0.006, p=0.963), employment status (r=-0.122. p=0.368).
The scores of the AcroQoL and the RAND-36 are shown in Table 3. The DAS59 score 
correlates inversely with all subscales of the AcroQoL (p<0.01). The DAS59 scores were 
also inversely correlated with most of the subscales of the RAND-36 (p<0.01 or p<0.05).
Figure 2 shows the visual analogue scale scores. Scores of the patients were significantly 
lower than the scores of the control-subjects (p<0.01). The total satisfaction score ranged 
from 0 to 10 in the patient group (mean score = 6.2 ± 2.4). Twenty-five patients (34.2%) 
scored the satisfaction with their facial appearance below 6. Scores in the control subject 
group ranged from 6-10 (mean score 7.8 ± 0.8). In the patient group the scores on the 
VAS-scale also showed an inverse correlation with the DAS59 score (r=-0.567, p<0.01). 
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Table 1. Subject characteristics and correlation with patient’s full scale DAS59 score
 Correlation to DAS59 score
Patients treated for 
acromegaly 
(N=73)  
Control 
subjects
(N=57)
p-value Spearman’s-rho  p-value
Gender (n): male/ female 40/ 33 30/27 0.860       0.139  0.240
Age: mean (SD) (years)
BMI (kg/m²): mean (SD) 
59.4(10.5)
28.1(4.7)
58.6(11.3)
26.4(3.5) 
0.510
0.050
   - 0.085
      0.087
 0.504
 0.466
Age at diagnosis: mean (SD) (years) 41.6(11.2)    - 0.095  0.425
Duration since cure: median (range) (years) 10.5 (2.3-43.6)    - 0.169     0.153
               2-5 years remission n (%)     
              5-10 years remission n (%)      
             10-15 years remission n (%)
              > 15 years remission n (%)
8(11.0)
27(37.0)
20(27.4)
18(24.7)
Treatment modality n (%) (n):
            Surgery
            Medical
                  SA
                  DA
                  GHRA
            Irradiation
64(87.7)
39(53.4)
26(35.6)
8(11.0)
5(6.8)
14(19.2)
      0.071
   - 0.115
   - 0.111
0.549
0.189
0.351
Disease status: n (%)
             Cure                                          
             Biochemical remission
Hormonal deficiencies: n (%)
             Preserved pituitary function                     
             Hypothyroidism         
             Hypocortisolism
             Growth hormone deficiency
             Hypogonadism
             Diabetes insipidus
             Hypopituitarism
Co-morbidities: n (%)
             Hypertension
             Diabetes mellitus
             Joint related complaints
41(56.2)
32(43.8)
41(56.2)
26(35.6)
19(26.0)
17(23.3)
19(26.0)
17(23.3)
15(20.5)
29(39.7)
14(19.2)
12(16.4)
      0.021
      0.279
   - 0.249
    - 0.106
    - 0.082
    - 0.150
    - 0.068 
    - 0.077
    -0.042
     0.007
    -0.109
  0.860
< 0.05*
< 0.05*
     0.372
     0.493
     0.206
     0.565
     0.516
     0.725
     0.956
    0.360
*P <0.05 by Spearman’s rho
SA, somatostatin analogues; DA, dopamine agonists; GHRB, growth hormone receptor antagonists.
Table 2. Derriford appearance scale 59
Patients
(N=73)
Controls
(N=57)
p-value
Prevalence of self-consciousness, n(%):
Sources of self-consciousness, n (% of self-conscious subjects):
Face/facial features 
Large/coarse feet
Curved back
Unsightly skin
Overweight
Breasts
Scalp hair
General aging
Abdomen
34 (46.6)
29 (85.3)
1 (2.9)
1 (2.9)
2 (5.9)
3 (8.8)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
13 (22.8)
3 (23.1)
0 (0.0)
0 (0.0)
4 (30.8)
1 (7.7)
1 (7.7)
1 (7.7)
1 (7.7)
2 (15.4)
< 0.01*
< 0.01*
Mean score (SD)
Patients
(N=73)
Mean score (SD)
Controls
(N=57)
p-value
Full-scale (FS) 
General self-consciousness of appearance (GSC) 
66.6 (33.7) 
21.3 (16.3)
38.3 (22.7)
8.8 (8.5)
< 0.01*
< 0.01*
Social self-consciousness of appearance (SSC) 
Sexual and bodily self-consciousness of appearance (SBSC)     
Negative self-concept (NSC)
Facial self-consciousness of appearance (FSC)
Not loading on a specific factor
   53. how irritable do you feel?
   59. how hostile do you feel?
15.2 (12.3)
7.8 (6.8)
14.4 (3.9)
2.8 (2.3)
2.2 (1.0)
1.7 (1.0)
8.2 (8.9)
4.2 (5.0)
12.2 (2.6)
1.7 (2.6)
1.7 (0.7)
1.3 (0.8)
< 0.01*
< 0.01*
< 0.01* 
< 0.01*
< 0.01*
< 0.01*
*P < 0.01, by Mann-Whitney U test
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Figure 2. Visual Analogue Scale (VAS) scores
RAND36 scores
Mean scores of the patients in long-term remission of acromegaly were significantly lower 
than the scores of the control group (Table 3). Subscale scores of patients and controls and 
comparisons between the groups are depicted in Table 3.
AcroQoL scores
In the patient group, the mean (SD) AcroQoL score was 64.0% (16.6%). The most affected 
scale was the subscale ‘appearance’ mean (SD) 57.1% (19.5%). The AcroQol appearance 
subscale score was significantly correlated to the DAS59 full scale score (r=-0.597, 
p<0.01). Other mean subscale scores are further depicted in Table 3. 
Table 3. The Derriford Appearance Scale (DAS59) scores and patient group correlations to the scores of the 
RAND-36 and the scores of AcroQoL
Mean score (SD) Mean score (SD) Correlation to DAS59-score
Questionnaire Patients treated for 
acromegaly (N=73)
Controls
(N=57)
P-value Spearman’s 
rho
P-value
RAND-36
Physical functioning
Social functioning
Role limitations
   due to physical problems
Role limitations  
   due to emotional problems
Vitality
Mental health 
Bodily Pain     
General Health Perception
Change in health
AcroQol 
Total
Physical performance
Psychological well- being
Appearance
Personal relations
72.8 (23.1)
75.7 (23.1)
53.8 (44.8)
78.1 (38.2)
57.5 (20.2)
74.9 (17.5)
71.5 (21.7)
54.8 (20.8)
50.0 (17.2)
64.0 (16.6)
61.3 (20.0)
65.5 (17.4)
57.1 (19.5)
73.9 (18.2)
91.2 (13.3) 
93.0 (11.1)
94.7 (14.7)
94.7 (18.7)
77.1 (12.5) 
84.4 (10.4)
89.0 (14.9)
73.9 (16.6)
56.1 (17.2)
   
< 0.01* 
< 0.01*
< 0.01*
< 0.01* 
< 0.01*
< 0.01*
< 0.01*
< 0.01*
    0.064
 
-0.114
-0.236
-0.234
-0.262
-0.225
-0.322
-0.159
-0.189
-0.086
-0.570
-0.365
-0.638
-0.597
-0.570
    0.335
< 0.05**
< 0.05**
< 0.05**
    0.055
< 0.01*
    0.179
    0.109
    0.470
< 0.01*
< 0.01*
< 0.01*
< 0.01*
< 0.01*
*P < 0.01, **P <0.05 by Mann-Whitney U test or Spearman’s rho 
Sociodemographic characteristics
Of the patients in remission 55 (75.3%) were married or engaged into a relationship versus 
47 (82.5%) of the controls (p=0.528), 18 (24.7%) of the patients in remission had no 
relationship, were divorced or a widow/widower versus 10 (17.5%) of the controls. Two of 
the patients in remission (2.7%) had less than eight years of education versus 1 (1.8%) of the 
controls, 6 (8.2%) of the patients in remission versus 6 (10.5%) of the controls had 8-12 
years of education, 45 (61.6%) of the patients in remission versus 21 (36.8%) of the controls 
had 12-16 years of education, 10 (13.7%) of the patients in remission versus 19 (33.3%) of 
the controls had 16-21 years of education and 10 (13.7%) of the patients in remission versus 
9 (15.8%) of the controls had a university degree. Twenty-two of the patients in remission 
(30.1%) had full- or part-time employment versus 30 (52.6%) of the controls (p<0.05), 
29 (39.7%) of the patients in remission versus 18 (31.6%) of the controls were retired, and 
22 (30.1%) of the patients in remission versus 9 (15.8%) of the controls were unemployed. 
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Discussion
In this study we evaluated self-consciousness about appearance and its relation with Qol in 
73 patients in long-term remission of acromegaly, and determined which physical aspects 
have the most influence on the self-consciousness about appearance. 
The main finding of the present study is that compared to a matched control group a 
significantly larger proportion of the patients, are still self-conscious about their appearance 
(46.6% vs. 22.8%), even after more than 12 years of remission. This is regardless of most 
clinical and sociodemographic characteristics. The significant correlations between the 
DAS59 scores and the AcroQol and RAND-36 scores indicate that the concerns about 
appearance are clearly related to an impaired quality of life and general well-being. In 
addition, this is the first study that investigates the association between specific “features” 
and self-consciousness about appearance in patients in long-term remission of acromegaly. 
An impressing 85.3% of the patients who reported self-consciousness of appearance in our 
cohort indicated that their face is the main source of discontent. In the general population 
the distribution of ‘features’ that cause self-consciousness of appearance is much more 
evenly distributed throughout the body with only 25-27% focus on the face [11]. This is in 
concordance with the results of our control group. Moreover, 34 % of the patients scored 
their facial appearance below 6 on the 0-10 VAS scale compared to 0% in the control group 
(Figure 2).  Our study therefore clearly demonstrates that patients in long-term remission 
of acromegaly still have significant problems with their facial appearance.
The findings in this study are in line with the findings of previous studies that found that the 
most affected dimension of the AcroQol was appearance [4, 5]. Matta et al. [6] and Paisley 
et al. [7] showed an improvement in the appearance subdomain of the AcroQoL after 
treatment-induced improvement in IGF-1 levels. However they did not compare these 
“after treatment” outcomes with the normal population, because the AcroQol is a disease-
generated questionnaire specifically designed for patients. Furthermore, previous studies 
were not able to point out the specific anatomical features that caused the concern and 
discontent about appearance, while the DAS-59 clearly identifies the face as the primary 
source of self-consciousness.  
Studies about the prevalence of concern about appearance in the general population showed 
that concern about physical appearance is twice as common among women as among men. 
The prevalence of concern about appearance is highest during the late teens and early 
twenties, while it normally decreases with age [8, 11]. In our series there was no correlation 
between the DAS59 score and gender or age in the patient group, but a statistically 
significant correlation between the DAS59 scores and age was found in the control 
group (r=-0.327, p=<0.05). This indicates that, in contrast to the general population, the 
individuals in the patient group remained self-conscious about their appearance despite the 
fact that they aged and men and women are equally affected.
A positive perception of appearance is related to successful psychological functioning 
and well-being [11]. Therefore, the self-consciousness about appearance and impaired 
QoL in patients in long-term remission of acromegaly are even more concerning, as these 
patients are already in remission and these disturbances seem to persist. The concerns 
about appearance in patients in remission of acromegaly are probably caused by persisting 
anatomical alterations as craniofacial disproportions remain present, even after long-term 
remission [2]. A delay in initial diagnosis, often by several years, probably is the major cause 
of the irreparable changes and damage [6, 21]. In our study persisting co-morbidities may 
have also contributed to decreased QoL as previously reported [22] as hypertension was 
present in 39.7% of our patients, diabetes mellitus in 19.2% and joint related complaints 
in 16.4% of our patients. However no correlations were found between co-morbidities and 
DAS59 scores. 
When the results of the DAS59 mean subscale score on facial self-consciousness of 
appearance (FSC) of our patient group are compared to the results of previously described 
clinical subgroups it is notable that the score of our patients (2.8) is comparable or worse than 
the scores in males considered suitable for rhinoplasty (2.6) , and other cosmetic surgery 
(2.5) and females considered suitable for a facelift (2.5) and other cosmetic surgery (2.5) [9]. 
Surprisingly plastic/craniofacial surgery is not widely performed in (ex)acromegaly patients, 
especially not in Europe. Only a limited number of case reports about corrections of the 
acromegalic face have been published in literature. However individualized procedures, for 
example reduction of the vertical dimension of the body of the mandible, rhinoplasty, posterior 
displacement of the prominent frontal bone, recession and remodeling of cheeks (zygoma) or 
correction of mandibular prognathism can greatly improve appearance and potentially reduce 
self-consciousness and associated distress about appearance [23-26]. Another method to 
support patients that still have concerns about their appearance after remission of acromegaly 
could be psychological support or psychotherapeutical interventions to prevent evolution of a 
maladjusted coping style [27-29]. 
An additional finding in this study is that patients in remission are more likely to be 
unemployed. This could be a result of the previous illness, but it is interesting to consider the 
possibility that their appearance could play a role in their unemployment. Literature shows 
that faces are key to our perception of others and people widely believe that the character 
of a person can be recognized from his or her face. This phenomenon is commonly labeled 
the halo effect [30]. In addition the slightly higher education level in the control group could 
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also in part explain the differences we observed. Furthermore, an interesting correlation 
was found between hypothyroidism and the DAS59 full scale score. Especially the GSC 
subscale of the DAS59 turned out to be correlated with hypothyroidism, which could be 
explained by the fact that hypothyroidism, even when adequately treated, is known to be 
associated with depressive symptoms [31]. 
Some limitations of this study should be acknowledged. A cross-sectional design was used, 
which did not account for variability of QoL and perception of appearance over time. 
However good test-retest reliability for both the AcroQol and DAS59 has previously 
been demonstrated [4, 9]. The refusal of 5 patients to participate because they did not 
have any problems with their appearance might have introduced some bias. However even 
when these patients would have participated the proportion of patients that reported to 
be self-conscious about a ‘feature’ would still be 43.6%. The difference in BMI between 
both groups was at the limit of significance (p=0.05). However, no correlation was found 
between BMI and full scale DAS59 score. Therefore, we believe that this cannot explain the 
difference in DAS59 scores found between patients and controls.
In conclusion, even after long-term remission of acromegaly, a large number of patients 
are self-conscious about their appearance, leading to psychological distress and disruptions 
to everyday life and a decreased QoL. The facial features were the most important source 
of self-consciousness. The findings in this study highlight the importance of the fact that 
physicians should not ignore self-consciousness about appearance in patients treated 
for acromegaly but have to address these concerns during follow-up. Patients should 
be encouraged to discuss their concerns about their appearance and should be offered 
individualized advice about corrective interventions to improve not only their appearance 
but also functionality. There is a lot of potential for improvement in the support of people 
with acromegaly regarding their difficulties concerning their appearance and therefore 
their QoL as shown by a recent study that detected a significant effect of exercise on 
body self-perception in patients with acromegaly [32]. To optimize management, not only 
biochemical and radiological parameters but also dimensions like appearance that reflect 
Qol should be evaluated. In practice the DAS59 is easy to use by physicians and can be an 
excellent instrument during follow-up. For patients, the DAS59 provides the opportunity 
to more easily address problems with their appearance and to discuss possible treatment 
options like psychological support or plastic/craniofacial surgery.  
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Abstract
Context: Glucocorticoid receptor (GR) polymorphisms modulate glucocorticoid (GC) 
sensitivity and are associated with altered metabolic profiles. 
Objective: To evaluate the presence of GR polymorphisms (BclI (rs41423247), N363S 
(rs56149945), ER22/23EK (rs6189/rs6190) and 9β (rs6198) and investigate their 
associations with metabolic alterations in patients in long-term remission of Cushing’s 
syndrome (CS).
Design and setting: Cross-sectional case-control study. 
Patients and methods: Sixty patients in long-term remission of CS were genotyped. 
Associations between GR polymorphisms and multiple vascular, body composition and 
metabolic parameters were investigated.
Main outcome measures: Allelic frequencies of the polymorphisms and their associations 
with several cardiometabolic risk factors.
Results: This study shows that carriers of the 9β polymorphism have a higher systolic blood 
pressure and lower resistin levels. The GC sensitizing BclI polymorphism is associated with 
an adverse cardiometabolic risk factor profile: higher fat percentages of extremities and 
legs, higher serum leptin and E-selectin levels and higher intima media thickness in carriers 
versus non-carriers. 
Conclusions: The 9β and BclI polymorphisms of the GR adversely affect the cardiometabolic 
profile in patients who are in remission after treatment of CS. This suggests that genetically 
altered GC sensitivity modulates the long-term adverse cardiometabolic effects resulting 
from (endogenous) hypercortisolism.
Introduction
Cushing’s syndrome (CS) is a disorder resulting from chronic exposure to increased levels 
of glucocorticoids (GC), frequently caused by an ACTH-producing pituitary adenoma 
(Cushing’s disease (CD)) or by primary adrenal overproduction of cortisol (adrenal CS 
(ACS)) [1]. CS is associated with body composition changes, cardiometabolic abnormalities 
such as type 2 diabetes mellitus (T2DM), hypertension and dyslipidemia, and ultimately 
cardiovascular disease [2]. We [3] and others [4, 5] have shown that many adverse metabolic 
and cardiovascular characteristics and body compositional changes persist after treatment, 
even after long-term remission. Although these adverse metabolic and cardiovascular 
characteristics are common in these patients, their incidence and severity vary among 
patients. This variation seems not to be explained by differences in cortisol excess or disease 
duration alone. Therefore a variable sensitivity to GC possibly plays a role in modulating the 
effect of cortisol excess [6]. 
Several investigations in healthy subjects have shown that GR polymorphisms are associated 
with altered GC sensitivity and alterations in metabolic profiles and body composition. The BclI 
and N363S polymorphisms of the GR gene have been associated with enhanced sensitivity 
to GC, increased abdominal obesity, an adverse lipid profile and hyperinsulinemia [7-10]. In 
contrast, the ER22/23EK GR polymorphism has been associated with GC resistance and a 
favorable metabolic profile and body composition [11, 12]. The 9β polymorphism is associated 
with increased expression and stabilization of the dominant-negative splice variant GR-β. 
Enhanced GR-β expression results in greater inhibition of GR-α transcriptional activity, and, 
as GR-α is the functional GR isoform, in relative GC resistance [13-15]. This polymorphism is 
associated with increased serum levels of inflammatory parameters and cardiovascular disease 
despite a more favorable lipid profile in men and body composition in women [16, 17]. 
The functional role of GR polymorphisms has been extensively studied in the general healthy 
population. In contrast, only a small number of studies have been performed on the functional 
role of GR polymorphisms in active CS and CS in remission. These few studies have found 
an association of the 9β polymorphism with the risk of developing diabetes mellitus [18] 
and of the BclI polymorphism with increased skeletal GC sensitivity and worse cognitive 
performance [19, 20]. 
We hypothesize that differences between patients in the severity of the adverse metabolic 
and vascular profile after cure of CS are related to differences in GC sensitivity due to 
GC receptor polymorphisms. Therefore, we investigated the associations of these genetic 
variants with the presence/persistence of the adverse metabolic and vascular profile and body 
composition after long-term remission of CS. 
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Subjects and methods
Sixty adult (>18 years old) patients in long-term remission (>4 years) of CS were recruited 
from the outpatient clinic of the department of internal medicine. Remission was defined 
as suppression of plasma cortisol to ≤ 50 nmol/L after 1 mg dexamethasone overnight [21] 
or, if a patient had received radiotherapy of the pituitary gland, a 24-hour urinary free 
cortisol excretion of < 240 nmol/24h for men or <150 nmol/24h for women (upper levels 
of normal free cortisol excretion). Clinical history was collected and a physical examination, 
biochemical and hormonal evaluation, dual-energy X-ray absorptiometry scanning 
(DXA) and non-invasive vascular function measurements were performed in all subjects. 
All subjects were genotyped for the presence of four GR polymorphisms; BclI, N363S, 
ER22/23EK and 9β. 
Patients with untreated hormonal deficiencies, or hormonal deficiencies that had not been 
treated adequately in the last 4 years according to international standards, were excluded. 
Furthermore, patients with active malignancy or systemic therapy for malignancy in the 
past, auto-inflammatory diseases and psychiatric pathology were excluded. Hypothyroidism 
was defined as free thyroxine (fT4) plasma concentrations < 8 pmol/l (reference range 8-22 
pmol/l). Testosterone deficiency in men was defined as early morning testosterone levels 
< 11 nmol/l (reference range 11-45 nmol/l). In women, estrogen deficiency was defined as 
secondary hypogonadotropic hypogonadism or a postmenopausal state without the use of 
chronic estrogen substitution therapy. Growth hormone (GH) deficiency was defined as a 
maximal GH response of < 15.3 mU/l during an insulin tolerance test (ITT), or as a maximal 
GH response of < 12.3 mU/l during an arginine/GHRH test [22]. Glucocorticoid deficiency 
was defined as a maximal cortisol response < 550 nmol/l during an ITT [23]. All patients 
underwent a new 1 mg dexamethasone suppression test (or a 24-hour urinary free cortisol 
measurement in case of pituitary RT) before entering the study to confirm remission. All 
subjects were of Caucasian (Dutch) origin.
Clinical history
Clinical history included the etiology of CS, treatment strategies (surgery, radiotherapy, 
medication), treatment for coexisting hormonal deficiencies, co-morbidities and smoking 
habits. 
Physical examination
Anthropometric measurements included weight and height, supine systolic and diastolic 
blood pressure (average of 10 measurements, every 3 minutes with an oscillometric 
sphygmomanometer (Criticon model 1846; Criticon Inc., Tampa, FL)) measured at 
09:00AM. 
Biochemical evaluation
Biochemical evaluation included plasma level measurements of fasting glucose, glycated 
hemoglobin (HbA1c), total cholesterol, triglycerides, high-density lipoprotein (HDL), low-
density lipoprotein (LDL) and insulin. Insulin sensitivity was assessed by homeostasis model 
assessment (HOMA) [24]. Furthermore, serum adipokines adiponectin, leptin and resistin 
were measured. In addition, a number of markers of vascular health were measured in 
serum; soluble vascular cell adhesion molecule-1 (VCAM-1), soluble intercellular adhesion 
molecule-1 (ICAM-1), plasminogen activator inhibitor-1 (PAI-1) and soluble E-selectin. 
Increased levels of these parameters are indicators of endothelial dysfunction and worse 
vascular health.
Vascular evaluation
Carotid intima media thickness (IMT) was determined using an AU5 ultrasound machine 
(Esaote Biomedical) with a 7.5 MHz linear array transducer. Measurement of IMT 
was performed off-line by the sonographer at the time of the examination, using semi-
automatic edge-detection software (M’Ath® Std version 2.0, Metris). IMT was defined as 
the mean IMT of the four measured segments of the common carotid artery: far wall left, 
near wall left, far wall right, near wall right. 
Body composition
Total body DXA was performed using a Hologic QDR 4500 densitometer (Hologic, Bedford, 
MA). Standard procedures supplied by the manufacturer for scanning and analyses (using 
Hologic software version 12.1) were followed. Calibration procedures were performed every 
day using the appropriate phantoms provided by the manufacturer. Total body fat mass 
was determined and fat percentage was calculated as the total body fat mass in percent of 
body weight. Furthermore, trunk-, leg- and extremities fat percentages were determined 
in order to discriminate between different body regions. Different regions were determined 
by manually placing regions of interest as defined by the manufacturers software manual. 
The trunk fat depot is defined as the region between two horizontal lines placed on the 
lower border of the head and the upper border of the iliac crest and two vertical lines placed 
against the outer margins of the chest . These lines exclude the arms from the trunk. The 
leg fat depot is defined by two vertical lines placed against the outer margins op both legs. 
The pelvis is excluded from the legs by a line trough the femoral neck. Leg fat percentage 
is depicted as the average of both legs. Extremity fat percentage is depicted as the average 
of both arms and both legs.
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Laboratory measurements 
Serum concentrations of leptin, resistin, PAI-1, sICAM-1 and soluble E-selectin 
were measured by Multiplex Fluorescent Bead Immunoassays (xMAP technology, 
Millipore, Billerica, MA) and a Bio-plex microbead analyzer (Luminex, Austin, TX) according 
to the manufacturers protocol. Serum concentrations of adiponectin and sVCAM-1 were 
determined by enzyme-linked immunosorbent assays (R&D Systems, Minneapolis, MN). 
Fasting plasma glucose, HbA1c, insulin and total serum cholesterol, triglycerides, LDL-
cholesterol and HDL-cholesterol were measured by standard procedures. According to the 
manufacturer’s information, intra-assay precision coefficients of variation for all laboratory 
measurements were equal or below 5%.
Genetic analyses
DNA was isolated from whole blood using the Gentra Puregene isolation kit (Qiagen, Valencia, 
CA, USA), according to the manufacturers protocol. Genotyping for the four selected 
genetic variants of the glucocorticoid receptor (GR) gene (official gene name NR3C1) was 
performed as follows. The presence of the 9β (rs6198) and N363S (rs56149945) genetic 
variants was assessed by applying the predesigned TaqMan SNP assays C_8951023_10 and 
C_26841917_40, respectively, on a 7300 ABI Real-Time polymerase chain reaction (PCR) 
system (all from Life Technologies, Applied Biosystems, Foster City, CA). 
For the detection of the GR ER22/23EK (rs6189 / rs6190) genetic variant conventional PCR 
and Sanger sequencing analysis was performed with forward primer 5’-CTG-CCT-CTT-ACT-
AAT-CGG-ATC-A-3’ and reverse primer 5’-AGA-GTG-AAA-CTG-CTT-TGG-ACA-G-3’. 
To determine the GR BclI genotype (rs41423247), DNA was amplified with forward primer 
5’-AAG-CAA-TGC-AGT-GAA-CAG-TGT-AC-3’ and reverse primer 5’-AAC-AAT-TTT-
GGC-CAT-CAG-TTA-TC-3’. Also these PCR products were subjected to Sanger sequencing 
analysis. 
Statistical analyses
Data are expressed as mean ± 95% confidence intervals unless stated otherwise. Data 
distributions were analyzed using the Kolmogorov-Smirnov test and logarithmic transformation 
was performed before statistical testing when appropriate. Based on data distribution, 
comparison of continuous variables was performed using Student’s t-test or Mann-Whitney 
rank sum test. The associations between genotypes and outcome measurements were 
evaluated using analysis of covariance (ANCOVA) with genotypes as a factor and age, 
gender and BMI as covariates. Categorical variables were analyzed using the χ2 test followed 
by Fisher’s exact test if appropriate. Hardy-Weinberg equilibrium for all polymorphisms was 
determined using a χ2 test. Significance was set at a p-value of <0.05. Statistical analysis was 
performed using SPSS Software version 20.0 (SPSS, Inc., Chicago, IL).
Table 1. Subject characteristics
(n=60)
Gender (n): male/female 12/48
Age in years: mean (SD) 50.7(12.4)
Duration of remission in years: mean (SD) 13.8 (8.5)
BMI in kg/m2 : mean (SD) 26.9(5.3)
Waist circumference in cm: mean (SD) 91.8 (14.7)
Smoking (n): yes/no 14/46 
Treatment modalities: n (%)
  Unilateral adrenalectomy
  Bilateral adrenalectomy
  Pituitary surgery
  Pituitary radiotherapy
20 (33.3)
12 (20.0)
38 (63.3)
13 (21.7)
Hormonal deficiencies: n (%)
  Glucocorticoid deficiency*
  Growth hormone deficiency*
  Thyroid hormone deficiency*
  Testosterone deficiency*
  Mineralocorticoid deficiency* 
  Estrogen deficiency
22 (36.7)
15 (25.0)
26 (43.3)
6 (10.0)
11 (18.3)
26 (54.2)
Cardiometabolic co-morbidities: n (%)
  Hypertension**
  Diabetes mellitus**
  Hypercholesterolemia**
19 (31.7)
4 (6.7)
12 (20.0)
Cushing type: n (%)
  Pituitary
  Adrenal
40 (66.7)
20 (33.3)
BMI, body mass index; CS, Cushing’s syndrome.
* Adequately substituted according to international standards
** Actively treated for this co-morbidity
Results
Forty eight (80%) subjects were female. Mean (SD) age was 50.7 (12.4) years with a mean 
(SD) BMI of 26.9 (5.3) kg/m2. Mean (SD) duration of remission was 13.8 (8.5) years. Nineteen 
(31.7%) subjects were treated for hypertension, 4 (6.7%) were treated for diabetes mellitus 
and 12 (20.0%) were treated for hypercholesterolemia. Complete subject characteristics of 
all subjects are depicted in Table 1. Allelic frequencies of the four polymorphisms are depicted 
in Table 2. All polymorphisms were in Hardy-Weinberg equilibrium. Because of low allele 
frequencies the N363S and ER22/23EK polymorphisms were not included in the association 
analysis. The minor allele of the 9β polymorphism showed a statistically significant association 
with higher systolic blood pressure (P = 0.007) and lower resistin levels (P = 0.027) in carriers 
(Table 3 and Fig. 1a). No associations were detected for the other measured parameters. The 
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minor allele of the BclI genotype showed statistically significant associations with higher mean 
IMT (P = 0.048), higher extremities fat percentage (P = 0.007), higher leg fat percentage 
(P = 0.029), higher leptin level (P = 0.038) and higher soluble E-selectin level (P = 0.037) 
in carriers (Table 3 and Fig. 1b). No associations with the other measures were detected in our 
CS patients (data not shown). 
Table 2. Genotype distributions and allele frequencies of the GR gene polymorphisms in patients cured of 
Cushing’s syndrome (CS) 
CS (n=60)
BclI
CC 32 (53%)
CG 20 (33%)
GG 8 (13%)
Allele frequency 0.300
9β (A3669G)
AA 40 (67%)
AG 19 (32%)
GG 1 (2%)
Allele frequency 0.175
N363S
AA 55 (92%)
AG 5 (8%)
GG 0 (0%)
Allele frequency 0.042
ER22/23EK
GG 55 (92%)
GA 5 (8%)
AA 0 (0%)
Allele frequency 0.042
Table 3. Associations between glucocorticoid receptor polymorphisms and outcome measurements. Data 
are expressed as mean and 95% confidence intervals.
Carrier minor allele Non-carrier minor allele P-value
9β 
Fasting glucose (mmol/l) 5.1 (4.7-5.4) 5.0 (4.7-5.2) 0.578
HbA1c (mmol/mol) 40.9 (38.4-43.6) 38.4 (36.7-40.1) 0.117
Total cholesterol (mmol/l) 5.3 (5.0-5.7) 5.2 (4.8-5.5) 0.596
Triglycerides (mmol/l) 1.4 (1.2-1.8) 1.5 (1.3-1.7) 0.850
HDL-cholesterol (mmol/l) 1.3 (1.2-1.5) 1.4 (1.3-1.4) 0.919
LDL-cholesterol (mmol/l) 3.2 (2.9-3.6) 3.1 (2.9-3.3) 0.498
Insulin(mE/l) 6.0 (4.6-7.8) 7.2 (6.0-8.7) 0.266
HOMA-IR 1.4 (1.1-1.9) 1.6 (1.3-2.0) 0.574
Mean IMT(mm) 0.73 (0.70-0.77) 0.76  (0.73-0.78) 0.254
Systolic blood pressure (mmHg) 138.7 (131.2-146.5) 126.2 (121.5-131.1) 0.007*
Total body fat (%) 32.6 (30.8-34.3) 34.3(33.1-35.2) 0.114
Trunk fat (%) 32.3 (30.4-34.3) 33.2(31.8-34.5) 0.471
Extremities fat (%) 35.8 (34.2-37.5) 38.1(36.9-39.2) 0.340
Leg fat (%) 34.0 (32.1-36.1) 35.4(34.0-36.9) 0.271
Leptin (pg/ml) 3374.5(2289.3-4974.1) 4213.3(3206.7-5535.9) 0.356
Resistin (pg/ml) 2248.5  (1618.1-3124.4) 3558.2  (2824.3-4482.8) 0.020*
Adiponectin (pg/ml) 706.3 (458.1-1089.0) 1087.9 (802.7-1474.4) 0.108
PAI-1 (pg/ml) 1884.7 (1377.2-2392.3) 2384.8 (2027.4-2742.2) 0.114
VCAM-1 (pg/ml) 666.5 (576.5-770.5) 674.5 (609.7-746.2) 0.888
ICAM-1 (pg/ml) 253.4 (177.0-362.9) 304.3 (236.3-391.9) 0.410
E-selectin (pg/ml) 46.2 (37.9-54.5) 42.2 (36.3-48.1) 0.436
BclI 
Fasting glucose  (mmol/l) 5.2 (4.9-5.5) 4.8 (4.6-5.1) 0.097
HbA1c (mmol/mol) 40.6 (38.5-42.8) 38.1 (36.2-40.0) 0.089
Total cholesterol (mmol/l) 5.2 (4.9-5.6) 5.2 (4.9-5.5) 0.837
Triglycerides (mmol/l) 1.6 (1.4-1.9) 1.3 (1.1-1.6) 0.198
HDL-cholesterol (mmol/l) 1.4 (1.2-1.5) 1.4 (1.3-1.4) 0.969
LDL-cholesterol (mmol/l) 3.1 (2.9-3.4) 3.2 (2.9-3.4) 0.879
Insulin (mE/l) 7.4 (5.9-9.2) 6.3 (5.1-7.8) 0.313
HOMA-IR 1.8 (1.4-2.3) 1.4 (1.1-1.7) 0.125
Mean IMT (mm) 0.77 (0.74-0.80) 0.73 (0.70-0.76) 0.048*
Systolic blood pressure (mmHg) 126.0 (120.2-132.0) 134.0 (128.3-140.1) 0.060
Total body fat (%) 34.5 (33.0-36.0) 33.1 (31.7-34.4) 0.167
Trunk fat (%) 33.3 (31.7-34.9) 32.5 (31.0-34.1) 0.488
Extremities fat  (%) 38.7 (37.3-40.1) 36.1 (34.8-37.4) 0.007*
Leg fat  (%) 37.5 (35.8-39.1) 35.0 (33.5-36.5) 0.029*
Leptin (pg/ml) 4999.0 (3644.6-6856.8) 3155.8 (2869.8-3470.3) 0.038*
Resistin (pg/ml) 3630.0 (2738.1-4812.6) 2625.4 (2016.3-3418.7) 0.099
Adiponectin (pg/ml) 1166.8 (811.6-1677.4) 781.3 (556.1-1097.7) 0.112
PAI-1 (pg/ml) 2301.6 (1866.2-2737.1) 2145.0 (1737.8-2552.2) 0.602
VCAM-1 (pg/ml) 726.3 (645.5-817.3) 627.7 (562.3-700.6) 0.075
ICAM-1 (pg/ml) 282.3 (208.5-382.2) 289.5 (218.1-384.1) 0.904
E-selectin (ng/ml) 45.2 (38.8-52.7) 36.1 (31.3-41.7) 0.037*
IMT, intima media thickness; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density 
lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance; PAI, plasminogen activator 
inhibitor; VCAM, vascular cell adhesion molecule; ICAM, intracellular adhesion molecule. P*: ANCOVA 
was used to assess the statistical differences between genotype groups.
All data are adjusted for age, gender and BMI.
* P <0.05
Table 3. Continued
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Figure 1a. Associations of the 9β genotype and clinical outcome 
* (P<0.05)
Figure 1b. Associations of the BclI genotype and clinical outcome 
* (P<0.05)
Discussion
This study investigated the prevalence of GR polymorphisms in patients in long-term 
remission of CS and the associations of these polymorphisms with metabolic, vascular 
and body compositional characteristics. In this study we found that carriers of the 9β 
polymorphism have a higher systolic blood pressure and lower resistin levels and that the 
GC sensitizing BclI polymorphism is associated with a number of metabolic and vascular 
adverse effects: higher fat percentages of extremities and legs, higher serum leptin and 
E-selectin levels and higher intima media thickness in carriers versus non-carriers. 
It has been shown that in patients in long-term remission of CS, cardiovascular and 
metabolic risk remains increased [3, 5]. In the general population it has been demonstrated 
that cardiovascular and metabolic risk and body composition are affected by lifelong 
overactivation or relative inactivation of GC signaling due to GR polymorphisms [25]. Our 
observation that altered glucocorticoid sensitivity due to GR polymorphisms modulates 
cardiometabolic risk factors in cured CS patients is in line with these well-known findings 
in the general population.
Remitted CS patients carrying the minor allele of the 9β polymorphism had a higher 
systolic blood pressure, which is concordant with previous findings of an increase in 
carotid atherosclerosis, and a higher incidence of coronary heart disease in carriers of this 
polymorphism [17]. Systolic hypertension is normally especially seen in the elderly population 
due to increased arterial stiffening. Arterial stiffness is central to the pathogenesis of isolated 
systolic hypertension and directly impacts left ventricular afterload, pressure pulsatility in 
the arterial tree, and its penetration into the microvasculature of target organs such as the 
brain and kidney. This means that systolic hypertension in carriers of the polymorphism may 
lead to increased ageing of the vascular tree, but further studies are needed to elucidate 
whether the polymorphism increases cardiovascular risk. Furthermore, an association was 
found between the 9β polymorphism and resistin levels, with carriers of the minor allele of 
the 9β polymorphism having lower resistin levels. It can be hypothesized that this is caused 
by the fact that subjects with a relative decrease in glucocorticoid sensitivity have less 
central adiposity. Central adiposity causes local ischemia of the adipose tissue which leads 
to infiltration of M1-macrophages, which are the main producers of resistin. This hypothesis 
is however speculative and not supported by the data, since no association between truncal 
fat and the 9β polymorphism was observed.
The minor allele of the BclI polymorphism was associated with an increased fat percentage 
of the extremities and legs in the remitted CS patients. These body areas only contain 
subcutaneous adipose tissue. As leptin is preferentially produced in subcutaneous adipose 
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tissue (SAT), carriers also had higher leptin levels [26]. High leptin levels have been widely 
recognized as an independent cardiovascular risk factor associated with insulin resistance. It 
also has a pathogenic role in atherothrombosis and endothelial dysfunction. Furthermore, a 
higher level of E-selectin was found in carriers of the minor allele of the BclI polymorphism. 
This may reflect increased endothelial activation and progressing atherosclerosis in the BclI 
carriers. This is supported by our observation that the IMT is higher in BclI carriers. 
In women with CS in remission, the BclI polymorphism was previously shown to be 
associated with altered GC sensitivity as the polymorphism was associated with reduced 
total and femoral neck bone mineral density [27]. Furthermore, in patients in remission of 
CS, the BclI polymorphism was also independently associated with increased fatigue and 
worse performance on cognitive testing [20]. The findings in literature combined with the 
findings in the current study suggest that hypercortisolism in patients carrying the BclI 
polymorphism may have more pronounced effects on patient wellbeing in the long-term.
This study has some limitations. Because of the low incidence of CS only a relatively 
small cohort could be studied. This could influence genetic associations and that is why 
only polymorphisms with a relatively high frequency were included in the association 
analysis. In genetic association studies inhomogeneity of study population with regard to 
ethnicity, gender, age and environmental factors is a frequent limiting factor. This study 
included Caucasians only and associations were corrected for gender and age. Duration 
of hypercortisolism likely represents another factor in long-term cardiometabolic effects 
in CS patients, which however is rather difficult to estimate since diagnosis of CS is 
generally delayed. Furthermore, it was decided not to correct for multiple testing because 
of the hypothesis-driven nature of this study. Indeed, from a biological perspective our 
findings are in line with the expected corticosteroid effects, suggesting that SNPs of the 
GR gene leading to either hypo- or hypersensitivity to GC, indeed modulate long-term 
cardiometabolic outcome after treatment of CS. However, because of the limited sample 
size and, hence, limited statistical power, we cannot exclude that some of the significant 
differences between carriers and non-carriers may be a finding by chance, i.e., a type-1 
error. 
In conclusion, this study is one of the first to suggest that glucocorticoid receptor 
polymorphisms modulate cardiometabolic risk factors in patients in long-term remission 
of CS [27]. In the context of personalized healthcare, this may implicate that, after 
treatment of CS, carriers of these polymorphisms are candidates for a more stringent 
follow-up regarding cardiovascular and metabolic health as our findings suggest that GR 
polymorphisms may play a role in susceptibility to cardiovascular disease in CS patients. 
Furthermore, patients treated with glucocorticoids for other diseases and even healthy 
subjects, carrying these polymorphisms, are candidates for a more stringent follow-up 
regarding cardiovascular and metabolic health and the development of metabolic syndrome 
as was recently debated in literature [28]. However, the results of this study need to be 
interpreted with caution and further research into these findings in larger CS populations is 
needed to replicate these findings. In addition, future studies should delineate to what extent 
the observed associations also apply to prolonged episodes of exposure to physiologically 
elevated cortisol levels (e.g. severe stress) or exogenous glucocorticoids.
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Context: In active Cushing’s syndrome (CS), patients suffer from endothelial dysfunction 
and premature atherosclerosis. However, it is uncertain to what extent vascular health 
recovers after long-term remission. This is highly relevant because this topic relates to 
future development of cardiovascular disease.
Objective: The objective of the study was to investigate whether micro- and macrovascular 
health is impaired after long-term remission of CS in patients with no or adequately treated 
comorbidities.
Design and Setting: This was a cross-sectional case-control study in two tertiary referral 
centers.
Patients and Main Outcome Measures: Sixty-three patients (remission of CS for ≥ 
4 y) and 63 healthy, well-matched controls were compared. In group A (58 patients and 
58 controls), serum biomarkers associated with endothelial dysfunction, intima media 
thickness, pulse wave velocity, and pulse wave analysis were studied. In group B (14 patients 
and 14 controls), endothelium-dependent and -independent vasodilatation was studied 
in conduit arteries (flow mediated dilation of the brachial artery) and forearm skeletal 
muscle resistance arteries (vasodilator response to intraarterial acetylcholine, sodium-
nitroprusside, and NG-monomethyl-L-arginine using venous occlusion plethysmography).
Results: There were no significant differences between the outcome measures of vascular 
health of patients and controls in groups A and B.
Conclusion: The vascular health of patients in long-term remission of CS seems to be 
comparable with that of healthy gender-, age-, and body mass index-matched controls, 
provided that the patients have no, or adequately controlled, comorbidities. Therefore, the 
effects of hypercortisolism per se on the vasculature may be reversible. This accentuates 
the need for the stringent treatment of metabolic comorbidities in these patients. 
Patients with chronic hypercortisolism due to endogenous Cushing’s syndrome (CS) have 
a very high mortality rate, with an estimated 5-year survival of 50% in untreated patients 
[1]. Cardiovascular disease is the main cause of mortality [1]. Multiple studies have shown 
that endothelial function is impaired in these patients [2–5], with an increased incidence 
of atherosclerosis [6, 7]. It has been suggested that this is mainly caused by the fact that 
most patients with CS have centripetal obesity, impaired glucose tolerance, systemic 
hypertension, hypercoagulability, and dyslipidemia [8]. All these factors are associated 
with impaired endothelial function and premature atherosclerosis, especially if they occur 
simultaneously [9]. In addition, one should realize that the hypercortisolism itself has a 
direct effect on the vasculature (via both the glucocorticoid and the mineralocorticoid 
receptor) [10, 11].
Successful surgical treatment of CS, resulting in normalization of cortisol secretion, significantly 
decreases cardiovascular risk and reduces mortality rate [1, 12]. However, it is unclear to what 
extent vascular health recovers in patients in long-term remission of CS. Full recovery is not 
self-evident because centripetal obesity and an adverse adipokine profile (which is known to be 
associated with endothelial dysfunction and eventually macrovascular disease [13, 14]) persists, 
even after long-term remission of CS [15, 16]. Furthermore, it is questionable whether the 
direct effects of hypercortisolism on the vasculature are fully reversible.
A number of studies have previously investigated vascular health in small groups of patients 
in remission of CS [17–23]. These studies reported inconsistent results, which may partly 
be explained by the small group size and/or selection of single markers of vascular health 
that therefore cannot provide a broad insight.
The aim of this study was to investigate micro- and macrovascular health in a large group 
of patients in long-term remission of CS with adequately treated comorbidity if present, 
in comparison with a matched healthy control group. We measured serum biomarkers 
associated with endothelial dysfunction, performed gold standard measurements of 
endothelial function, and investigated the presence of overt atherosclerosis.
Subjects and Methods
Subjects
All adult patients of Radboud University Medical Center Nijmegen and Leiden University 
Medical Center, who had been successfully treated for CS (caused by either an ACTH 
producing pituitary adenoma or a benign adrenal adenoma) and were in remission for at least 
4 years, were eligible for inclusion in this multicenter cross-sectional matched case-control 
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study. Remission was defined as absence of clinical signs and symptoms of hypercortisolism 
and suppression of plasma cortisol to 50 nmol/L or less after 1 mg dexamethasone overnight 
or, if a patient had received radiotherapy of the pituitary gland, a 24-hour urinary free 
cortisol value of less than 240 nmol per 24 hours for men or less than 150 nmol per 24 
hours for women. The medical records of all patients were retrospectively reviewed to assess 
clinical data regarding the etiology of CS, the type of treatments that patients had received, 
duration of remission, presence of hormonal deficiencies, and comorbidities. Information 
on the treatment of comorbidities of the patients can be found in Supplemental Table 1.
In our study we investigated 63 patients, divided into two different patient groups. Group 
A comprised 58 patients and group B 14 patients. Nine patients were included in both 
groups. Group A was the same group of patients that we previously described in our study 
on body composition, and extensive information about the patient selection can be found 
in that article [16]. In short, the following exclusion criteria were applied: untreated (or 
inadequately treated) hormonal deficiencies, active malignancy or systemic therapy for 
malignancy in the past, severe inflammatory diseases, and psychiatric pathology. Each 
patient was matched to a control subject with the same gender, age (±2 y), and body mass 
index (BMI; ±2 kg/m2). Control subjects, recruited via advertisements in a local newspaper, 
had to be healthy and without current use of medication.
For the second group of patients (group B, n = 14), even stricter exclusion criteria were used: 
all subjects with hormonal deficiencies, except for adequately treated hypothyroidism (free 
T4 range 8.0 –22.0 pmol/L), were excluded. Furthermore, in addition to the comorbidities 
applied for exclusion in group A, all patients with comorbidities that are known to affect 
vascular function or who used medication that may interfere with the cardiovascular system 
were excluded. In addition to gender, age, and BMI, the healthy control subjects were 
also matched for smoking, ethnicity, and physical activity levels (estimated via metabolic 
equivalent of task scores and measured for 1 week with a SenseWear Pro Armband (Body 
Media). Female controls were matched for estrogen status and oral contraceptive use.
The medical ethics committees of our institutions approved this study, and all participants 
provided written informed consent prior to participation.
Methods
All subjects refrained from smoking, alcohol, caffeine, chocolate, and vitamin C for at least 
18 hours, and vigorous physical exercise for at least 24 hours before testing. Subjects fasted 
at least 6 hours before testing.
Biochemical markers associated with endothelial dysfunction (group A)
Serum concentrations of plasminogen activator inhibitor-1 (PAI-1), intracellular adhesion 
molecule-1 (ICAM-1), and soluble E-selectin were measured by Multiplex fluorescent bead 
immunoassays (xMAP Technology) and a Bio-plex microbead analyzer (Luminex) according 
to the manufacturer’s protocol. Serum concentrations of vascular cell adhesion molecule-1 
(VCAM-1) were determined by an ELISA (R&D Systems).
Noninvasive measurements of atherosclerosis and arterial stiffness (group A)
Measurements of carotid intima media thickness (cIMT), pulse wave velocity (PWV), 
and pulse wave analysis were performed according to a highly standardized protocol and 
performed by the same experienced technician (S.H.) in all patients [24]. Mean cIMT was 
calculated from the mean of four measured segments of the vessel: far wall left, far wall 
right, near wall left, and near wall right. Subsequently the presence of plaques and size was 
evaluated at the level of the common, internal, and external carotid arteries. Plaque was 
defined as any focal protrusion above the surrounding intima of at least 1.5 X mean cIMT.
PWV and pulse wave analysis were measured with applanation tonometry, using SphygmoCor 
system version 7.1 (Atcor Medical). Central arterial pressure (CAP) and central systolic 
pressure were derived and central augmentation index (AIx) was calculated. As AIx is 
influenced by heart rate, an index normalized for a heart rate of 75 beats/min was used. To 
determine pulse wave velocity, pulse wave forms were recorded at the right carotid artery 
and left femoral artery sequentially. Wave-transit time was calculated using the R-wave 
of a simultaneously recorded electrocardiogram as a reference frame. The coefficient of 
variation (CV) for measuring PWV is 5%–10% [25].
Endothelial function (group B)
Brachial artery flow-mediated dilation (FMD) is widely accepted to reflect endothelium-
dependent and largely nitric oxide mediated function of conduit arteries [26]. Measurements 
were performed by two experienced vascular sonographers (D.H.J.T. and T.H.A.S.). A 10-
MHz multifrequency linear array probe attached to a high-resolution ultrasound machine 
(T3000; Terason) was used for imaging of the brachial artery in the distal third of the 
upper arm. Subjects rested in a supine position for at least 15 minutes to enable baseline 
assessment of arterial diameter and blood flow. The arm was extended and positioned at an 
80o angle from the torso. A rapid inflation pneumatic cuff (Hokanson) was positioned on 
the forearm immediately distal to the olecranon to provide the forearm ischemic stimulus. 
After obtaining an optimal image, the probe was manually stabilized and the ultrasound 
parameters were set to optimize longitudinal B-mode imaging of the lumen-arterial wall 
interface. Continuous Doppler velocity was measured using the lowest possible insonation 
angle (<60o). The forearm cuff was inflated to 220 mm Hg for 5 minutes. Diameter and 
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flow recordings resumed 30 seconds prior to cuff deflation and continued for 5 minutes 
thereafter. After a 15-minute resting period, a 1-minute baseline recording of the brachial 
artery diameter and flow was taken.
Subsequently, brachial artery endothelium-independent vasodilatation was examined 
after administration of a single spray of sublingual glyceryl trinitrate, which serves as a 
direct nitric oxide donor, to detect endothelium-independent vasodilator capacity. This 
was followed by 5 minutes of continuous recording of brachial artery diameter and blood 
flow. Posttest analysis of brachial artery diameter was performed using customized edge 
detection and wall-tracking software [27]. Baseline diameter, flow, and shear rate were 
calculated as the mean of data acquired across the 1-minute preceding the cuff inflation 
period. Peak diameter after the cuff deflation was automatically detected as previously 
described [28]. FMD was calculated as the percentage rise of this peak diameter from the 
preceding baseline diameter.
The time to peak diameter (seconds) was calculated from the point of cuff deflation to 
the maximum postdeflation diameter. According to a recent study, inadequate scaling 
for FMD would be present if the upper confidence limit of the regression of the relation 
between logarithmically transformed base diameter and peak diameter is less than 1.0 [29]. 
In such an event, the FMD percentage is not an appropriate measure for the estimation of 
endothelial function. Data were checked for this phenomenon and subsequently allometric 
modeling was applied [29]. Furthermore, the FMD percentage was corrected for shear rate 
stimulus by adding this factor as a covariate in our analysis [30]. The CV for measuring 
FMD with our protocol is 6.7% [30].
Forearm blood flow (FBF) measurements using venous occlusion plethysmography 
measures changes in blood flow (mainly determined by arteriolar resistance arteries in the 
muscle bed) in response to the infusion of intraarterial vasoactive medications [25, 31]. It 
therefore mainly assesses microvascular function. FBF was measured at the forearm using 
electrocardiogram-triggered bilateral strain-gauge venous occlusion plethysmography 
[31]. Measurements were performed at 9:00 AM in a quiet, temperature-controlled room 
(22°C). Mercury in silastic brand strain gauges (Dow Corning) placed around the widest 
portion of the upper third of both forearms were electrically coupled to a plethysmograph 
calibrated to measure normalized changes in volume. For each measurement, venous flow 
was occluded just proximal to the elbow by rapidly inflating a blood pressure (BP) cuff to 
60 mm Hg. A wrist cuff was inflated to suprasystolic (220 mm Hg) pressures to exclude 
the hand circulation from the blood flow during the measurement starting 30 seconds prior 
to each measurement. A brachial artery catheter (angiocatheter 20 gauge, 1.88 in.; BD 
Angiocath) was inserted into the nondominant arm after local anesthesia (lidocaine 2%), 
which was elevated slightly above the right atrium. Systolic BP, diastolic BP, mean arterial 
BP, and heart rate were monitored continuously. The other arm was used as a control for 
systemic changes in vasomotor tone.
Table 1. Group A: Clinical Characteristics of Patients in Long-Term Remission of CS and Healthy Controls
Patients (n = 58) Controls (n = 58) P Value
Gender, male/female, n 12/46 12/46
Age, y, mean (±SD) 50.8 (12.3) 51.2 (12.4) .863
BMI, kg/m2, mean (±SD) 26.5 (4.2) 26.3 (4.1) .793
Duration of remission, y, 
median (±range)
13.6 ± 8.0
Smoking, yes/no 14/44 5/53 .024a
Pack-years (±SD) 11.5 (15.6) 6.9 (13.9)
Alcohol consumption, yes/no 10/48 13/45 .485
Treatment modalities, n, %
Unilateral adrenalectomy 19 (32.8)
Bilateral adrenalectomy 12 (20.7)
Pituitary surgery 38 (65.5)
Pituitary radiotherapy 13 (22.4)
Hormonal deficiencies, n, %
Glucocorticoid deficiency 21 (36.2)
GH deficiency 15 (25.9)
Thyroid hormone deficiency 25 (43.1)
Mineralocorticoid deficiency 11 (19.0)
Testosterone deficiency 6/12 (50.0)
Estrogen deficiencyb 25/46 (54.3) 29/46 (63.0)
Comorbidities, n, %
Hypertension 18 (31.0)
Diabetes mellitus 4 (6.9)
Hypercholesterolemia 12 (20.7)
Cushing type, n, %
Pituitary 40 (69.0)
Adrenal 18 (31.0)
a P < .05.
b Secondary hypogonadotropic hypogonadism or a postmenopausal state without the use of chronic estrogen 
replacement. 
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To establish resting FBF, we administered 0.9% saline for 30 minutes. Vasoactive agent 
infusions were then started. Between each series of drug infusions, FBF was allowed to 
return to basal value during a 20-minute resting period, during which solvent (0.9% saline 
for acetylcholine [Ach] and 5% glucose for sodium nitroprusside [SNP]) was infused to 
maintain a constant infusion rate. Ach (Miochol-E intraocular solution, 20 mg; Bausch 
& Lomb; 1–2-4 µg/dL forearm volume/min) was used to explore endothelium-dependent 
vasodilatation. SNP (25 mg/mL, 2 mL; Sigma-Aldrich; 0.2– 0.4 – 0.8 µg/dL forearm 
volume/min) was used to explore nonendothelium dependent vasodilatation. Finally, the 
nitric oxide synthase inhibitor NG-monomethyl-L-arginine acetate (250 mg, Clinalfa 
Basic; Bachem; 0.2– 0.4 – 0.8 µmol/dL forearm volume/min) was infused to investigate 
the contribution of nitric oxide to basal vascular tone. Each substance-dose was infused for 
5 minutes. FBF values are reported in milliliters per minute per 100 mL of forearm volume. 
The baseline value is a mean of all measurements during the baseline measurement period. 
The values during drug infusion are a mean value of the last six measurements per drug dose 
during a measurement period. In addition to changes in blood flow, the blood flow ratio 
between the infusion and control arm was also calculated to correct for possible systemic 
effects [32]. The CV of FBF has been reported to be 8%–10% during stimulation [31, 33].
Statistical methods
Data were analyzed using SPSS 20.0 statistical package for Windows (SPSS Inc). Data were 
expressed as mean ± SD, unless mentioned otherwise. Data distributions were analyzed 
and logarithmic transformation was performed before statistical testing when appropriate. 
Differences between patients and controls were tested with paired t tests. Differences in 
categorical variables were analyzed using the x2 test. In group A, stepwise backward multiple 
linear regression analysis was performed in the patients to detect clinical characteristics 
(etiology of CS, treatment strategies, presence of hormonal deficiencies, use of alcohol, 
smoking, and comorbidity) that are predictors of vascular function. A stepwise backward 
multiple linear regression analysis could not reliably be performed in group B because of the 
small sample size. P < .05 was considered statistically significant.
Results
Subject characteristics
Table 1 shows the clinical characteristics of the patients and control subjects for group 
A and Table 2 for group B. Intraarterial cannulation was not successful in three patients, 
and therefore, the vasomotor response to intraarterial drug infusions was investigated in 
11 patients and controls (Table 3). Adequate matching was reflected by the fact that no 
differences between patients and controls were present in both groups in gender, age, and 
BMI. In group A patients differed from controls only with respect to smoking habits (more 
smokers in the patient group, P < .05).
Table 2. Group B (FMD): Clinical Characteristics of Patients in Long-Term Remission of CS and Healthy 
Controls
Patients (n = 14) Controls (n = 14) P Value
Gender, male/female, n 2/12 2/12 1.00
Age at time of test, y, mean (SD) 46.8 (11.8) 45.7 (10.9) .79
Duration of remission, y, median (range) 12.9 (4.8 –29.4)
BMI, kg/m2, mean (SD) 25.6 (2.3) 25.6 (2.5) .98
CS type, n
Pituitary 7
Adrenal 7
Treated hypothyroidism, n 4
Estrogen status in females, n 1.00
Sufficient 7 7
Insufficient 5 5
Table 3. Group B (Venous Occlusion Plethysmography): Clinical Characteristics in Long-Term Remission 
of CS and Healthy Controls
Patients (n = 11) Controls (n = 11) P Value
Gender, male/female, n 2/9 2/9 1.00
Age at time of test, y, mean (SD) 45.6 (13.2) 45.8 (12.1) .98
Duration of remission, y, median (range) 12.8 (4.8 –28.8)
BMI, kg/m2, mean (SD) 25.7 (1.7) 25.3 (2.7) .62
CS type, n
  Pituitary 5
  Adrenal 6
Treated hypothyroidism, n 3
Estrogen status in females, n 1.00
  Sufficient 5 5
  Insufficient 4 4
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Biochemical markers associated with endothelial dysfunction (group A)
No statistically significant differences in soluble VCAM-1 (sVCAM-1), soluble ICAM-1, 
E-selectin, and PAI-1 were detected between patients and controls (Table 4).
Noninvasive measurements of atherosclerosis and arterial stiffness (group A)
cIMT, PWV, and CAP were not different between patients and controls (Table 4). A trend 
toward a statistically significant difference between the two groups was found for the AIx 
(P = .056). Atherosclerotic plaques were detected in 10 patients and 10 controls. Plaque 
thickness was not significantly different between patients and controls.
Table 4. Micro- and Macrovascular Health Parameters in Patients in Long-Term Remission of CS and 
Matched Controls
Patients Controls
Variable Mean 95% CI n Mean 95% CI n P Value
Group A
Serum biomarkers
ICAM-1, pg/mLa 280.4 226.7–346.7 57 314.9 234.7– 422.4 57 .545
PAI, pg/mLa 1810.8 1505.8 –2163.1 57 1940.5 1653.9 –2276.7 57 .497
VCAM-1, pg/mLa 670.0 615.1–729.9 57 682.4 637.3–730.6 57 .721
E-selectin, pg/mLa 40.0 35.7– 44.6 57 38.5 34.6 – 43.0 57 .661
Noninvasive measurements of arterial stiffness and atherosclerosis
CAP, mm Hg (HR75) 10.1 8.8 –11.5 52 9.4 7.6 –11.3 52 .457
Aortic AIx (HR75) 26.0 23.2–28.8 53 23.1 19.6 –26.6 53 .056
PWV, m/sec 8.4 8.0 – 8.9 58 8.3 7.8 – 8.8 58 .648
Mean cIMT, mm 0.75 0.72– 0.78 58 0.75 0.72– 0.77 58 .617
Plaque thickness, mmb 2.66 1.94 –3.38 10 1.95 1.71–2.18 10 .092
Group B
Measurements of FMD
Baseline diameter, mm 3.60 3.33–3.86 14 3.56 3.30 –3.82 14 .839
FMD, % 5.13 4.10 – 6.15 14 6.22 4.72–7.72 14 .125
GTN, % 18.6 15.5–22.0 14 19.4 15.0 –22.9 14 .691
Time to peak diameter, sec 40.3 33.4 – 47.3 14 54.3 42.1– 66.6 14 .059
SRAUC, sec, 10
3 30 323 25 530 –35 115 14 32 164 26 471–37 857 14 .597
Abbreviations: CI, confidence interval; HR75, corrected for a heart rate of 75 beats per minute; GTN, 
glyceryltrinitrate; SRAUC, shear rate area under the curve.
a For ln-transformed data, the geometric means and backtransformed 95% CI were calculated to enable 
clinical interpretation of the outcomes.
b For plaque thickness the comparison between the groups was performed using an unpaired t test.
Figure 1. Change in forearm blood flow from baseline in response to infusion of different vasoactive agents in increasing dosages. 
Note: On group level, no acute vasomotor responses were observed in the control arm after drug infusions. Error bars, 95% CI.
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Endothelial function (group B)
No statistically significant differences were found between patients and controls in all FMD 
measurements (Table 4). Furthermore, no statistically significant differences were found 
between patients and controls regarding FBF or blood flow ratio responses at baseline or in 
response to the incremental doses of Ach, SNP, and NGmonomethyl-L-arginine (all P > .09) 
(Figure 1).
Stepwise backward multiple linear regression analysis (group A)
Having diabetes mellitus (DM) predicted both a higher PWV (P = .01) and higher sVCAM-1 
levels (P < .01). Subgroup analysis was performed for these two outcomes after exclusion 
of all matched patient-control couples containing a patient with DM. This did not lead 
to significant differences between patients and controls (PWV, P =.796; sVCAM-1, 
P = .865). Being a smoker was a predictor for a higher AIx (P < .01). Subgroup analysis, 
after exclusion of all patient-control couples with a smoker, did not lead to a significant 
difference between patients and controls (AIx; P = .078). Mineralocorticoid replacement 
was a predictor for higher E-selectin levels (P < .01). Subgroup analysis, after exclusion of 
all couples with mineralocorticoid users, did not lead to a significant difference between 
patients and controls (E-selectin; P = .913). Thyroid hormone replacement was a predictor 
for higher sVCAM-1 levels (P < .01). Subgroup analysis after exclusion of couples with 
thyroid hormone users did not lead to a significant difference between patients and controls 
(sVCAM-1; P = .504).
Discussion
In this study we investigated micro- and macrovascular health in patients in long-term 
remission of CS who had no, or adequately treated, comorbidities using a combination of 
state-of-the-art methods that has not been used in any previous study. We compared the 
patient group to a strictly one-to-one-matched healthy control group. The main finding 
of our study is that the vascular health of patients in remission of CS is not significantly 
different from that seen in healthy control subjects matched for age, gender, and BMI. This 
suggests that the direct effect of the period of hypercortisolism per se on the vasculature 
during the active disease is potentially reversible.
Our findings that endothelial function recovers after remission of CS are in line with the 
study of Akaza et al [22], who investigated arterial endothelial function, with FMD, in a 
group of 12 patients shortly after remission (>3 mo) of CS. They found that the impaired 
FMD in active CS was reversible after remission. Previous studies have shown that in vitro 
(cell culture) and in vivo (mouse) exposure of endothelial cells to glucocorticoids reduced 
the mRNA and/or protein content of endothelial nitric oxide synthase [34, 35] and reduced 
acetylcholine-induced vasodilation of mouse resistance arteries [34] and rat aortas [36]. 
Therefore, Akaza et al [22] proposed that endothelial dysfunction in active CS is largely 
accounted for by the direct effect of hypercortisolism on vascular endothelium and that 
this is reversible after treatment.
On the other hand, five other studies observed persistent impaired vascular health after 
remission of CS [17, 18, 20, 21, 23]. However, in three of these studies, there was either a 
short period of remission [17] or a pediatric study population [20, 21], so these studies are not 
comparable with our study. The studies reported by Colao et al [18] and Barahona et al [23] 
are more comparable. They both found a higher prevalence of atherosclerosis (measured 
by cIMT and the presence of coronary artery disease detected by computed tomography, 
respectively) compared with gender-, age-, and BMI-matched controls [18, 23]. However, 
the patients in these studies had significantly more uncontrolled metabolic comorbidities 
than their matched controls. In our study population, the comorbidities in group A were 
adequately treated [16], and the patients in group B had no known comorbidities (except 
for treated hypothyroidism in four patients).
A more recent publication of Faggiano et al [19] also supports our findings. This study 
measured differences in cIMT and artery stiffness between active disease and 1 year after 
remission of CS in 25 patients. There was a significant decrease in both variables between 
active disease and remission. After 1 year of remission, both variables did not differ from 
a gender-, age-, and BMI-matched control group as used in our study, but they were still 
higher than in controls with a lower BMI, matched only for gender and age. Moreover, 
diastolic BP and low-density lipoprotein- and high-density lipoprotein-cholesterol levels 
were not different between the patients and the BMI-matched control group, but they 
were significantly more adverse in the patients compared with the controls with a lower 
BMI. This emphasizes the importance of strict matching of each patient to a healthy 
individual of at least the same gender, age, and BMI if one wants to investigate the effect 
of the previous period of hypercortisolism per se. Taken both our results and the previous 
findings into account, we conclude that patients in remission of CS, who are equally well 
controlled for comorbidities as age-, gender-, and BMI-matched healthy subjects, have 
comparable vascular health. This accentuates the need for stringent treatment of metabolic 
comorbidities in these patients. Interestingly, the normalized vascular health seems to be 
irrespective of the fact that these patients have, as we have previously shown, a more 
centripetal adipose tissue distribution and adverse adipokine profile than their age-, 
gender-, and BMI-matched controls [16]. However, the patients in our study are relatively 
young, and vascular problems are more frequent as age increases. So even though we did 
not find indications for impaired vascular health at approximately 50 years of age, the 
127126
Chapter 6 | Vascular health in patients in remission of Cushing’s syndrome is comparable with that in 
BMI-matched controls
6
fact that persistent central adiposity and an adverse adipokine profile are still present after 
long-term remission of CS may mean that patients still are at higher vascular risk later in 
life.
As could be expected in group A, DM was associated with a higher PWV and higher 
sVCAM-1 levels and smoking predicted a higher AIx, but this did not affect the results of the 
total group. Moreover, the trend toward a higher AIx in the patient group disappeared after 
correcting for smoking. Interestingly, except for an association between mineralocorticoid 
replacement and E-selectin levels and the use of thyroid hormone replacement and 
VCAM-1 levels, no other patient characteristic (eg, etiology of CS, treatment strategies, 
hormonal deficiencies) negatively affected vascular health parameters. This is in contrast to 
previous studies, in which, for example, the use of glucocorticoid replacement therapy was 
associated with an increased cardiovascular risk [10].
The major strength of our study is the broad spectrum of methodologies we used to 
investigate vascular health. All techniques are well validated and reproducible [25, 30, 31]. 
Furthermore, this is the first study that investigates endothelial function in patients in 
long-term remission of CS both in conduit arteries (FMD) and forearm resistance arteries 
(FBF, which is considered the gold standard procedure to measure endothelial dysfunction) 
[25]. Thus, we have investigated both the macrovasculature and the microvasculature.
A possible limitation of this study is the relatively small sample size for group B. For FBF 
and FMD, a number of about 10 patients was found to be adequate to detect a relevant 
difference [31, 37] and that, however, the subjects within our patient group (and thus also 
the control group) were more heterogeneous than in most previous studies, leading to a 
greater SD. Therefore, it is possible that we missed subtle but relevant differences. For 
example, there seems to be a nonsignificant trend toward a lower baseline FBF in the 
patients, which could indicate a reduction in muscle microvascular density. The latter might 
explain the exercise intolerance experienced by the patients [38]. Because blood flow 
in the skin and subcutaneous adipose tissue also contribute to FBF [31], future research 
measuring microvascular density in muscle biopsies will have to confirm whether skeletal 
muscle microvascular density is indeed lower in patients in remission of CS.
A multitude of epidemiological studies reported an increased cardiovascular risk and 
standardized mortality in patients in long-term remission of CS compared with an age- 
and gender- but not BMI-matched reference population [1]. Because patients in remission 
of CS tend to have an overall higher BMI and waist circumference than the general 
population, this may negatively affect cardiovascular risk and standardized mortality. 
Furthermore, these studies did not analyze potential differences between patients with 
and without comorbidities. However, it may be possible that cardiovascular risk is still 
elevated in the healthiest patients in remission of CS because of a persistent effect of 
the prior hypercortisolism on other organs than the vasculature, eg, the myocardium [10, 
11]. However, this was not supported by a small study (39). Therefore, further research is 
necessary to investigate these issues.
In conclusion, the vascular health of patients in longterm remission of CS seems to be 
comparable with that of healthy gender-, age-, and BMI-matched controls, provided that 
the patients have no, or adequately controlled, comorbidities. Therefore, the effects of the 
previous hypercortisolism per se on the vasculature may be reversible. This accentuates the 
need for stringent individualized treatment of metabolic comorbidities in these patients.
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Supplemental table 1: Outcomes of other cardiovascular risk factors in patients and controls in Group A. 
Variable Controls (n=58) 
(mean) 
SD Patients (n=58) 
(mean) 
SD P-value
Total serum cholesterol (mmol/l) 5.38 0.198 5.16 0.165 0.188 
HDL-cholesterol (mmol/l)  1.44 0.242 1.33 0.216 0.061 
LDL-cholesterol (mmol/l)  3.38 0.255 3.05 0.236 0.055 
Triglycerides (mmol/l)  1.01 0.445 1.43 0.531 <.001*** 
Creatinin (μmol/l)  68.10 0.144 70.81 0.188 0.194 
Insulin (mE/l) 6.51 0.552 6.51 0.722 0.933 
Hba1c (mmol/mol) 37.49 0.088 39.10 0.151 0.355 
Fasting glucose (mmol/l) 4.98 0.107 4.99 0.172 0.973 
HOMA_IR 1.71 0.99 2.36 5.08 0.371 
fT4 (pmol/l) 12.28 0.136 15.20 0.202 <.001*** 
IGF-1 (nmol/l) 16.02 0.353 13.25 0.434 0.011* 
Systolic blood pressure (mmHg) 132.37 19.06 126.04 14.55 0.095 
Diastolic blood pressure (mmHg) 77.24 9.27 73.85 9.02 0.134 
Heart rate (bpm) 64.03 8.42 66.81 9.48 0.151 
Differences were tested by means of paired t-tests. For ln-transformed data the geometric means were calculated using 
back transformation to enable clinical interpretation of the outcomes. HDL, high density lipoprotein; LDL, low density 
lipoprotein; Hba1c, glycated hemoglobin; HOMA_IR, homeostatic model assessment _ insulin resistance; IGF-1, insulin like 
growth factor type 1* p<0.05, ** p<0.01, *** p<0.001. 
Note 1: In our hospitals patients continue to visit our outpatient clinic at least once a year after remission of Cushing’s 
syndrome (CS). During that visit patients are screened for the presence of hypertension, diabetes mellitus and 
hypercholesterolemia. If needed treatment is initiated. (If they already had hypertension, diabetes mellitus or 
hypercholesterolemia during the active phase of CS, we try to taper medication and if possible to stop medication to see if 
it is still needed).The choice of which medication is used was dependent on the preferences of the individual physicians and 
patients, but usually metformin was the first choice for diabetes mellitus type 2, simvastatin was the first choice for 
hypercholesterolemia and a thiazide diuretic or an ace-inhibitor were the first choice for hypertension. The effect of 
treatment was monitored regularly (each 3-6 months) and treatment was adjusted till treatment goals (a blood pressure of 
< 140/90 mmHg, a HbA1c < 53 mmol/mol and a LDL-cholesterol of < 3.5 mmol/l) were reached. 
Note 2: In case a patient had CS of pituitary origin biochemical evaluation is carried out on the fourth day postoperatively to 
evaluate the function of the pituitary gland (after glucocorticoid substitution had been stopped for at least 24 hours), by 
measurement of fasting (08:00 h) plasma cortisol, ACTH, thyrotropin, free thyroxine, gonadotropins, testosterone or 
estradiol and insulin-like growth factor type-1.  If basal plasma cortisol is lower than 200 nmol/l substitution therapy with 
hydrocortisone, 30 mg a day, was prescribed. Patients were re-evaluated every 2–4 weeks during the first 3 months after TS 
and thereafter at 2–3 months intervals during the first year. The fasting plasma cortisol concentration was measured at 
each visit. If a patient received glucocorticoid substitution therapy postoperatively, the dose was reduced and stopped, if 
possible, between 3 and 12 months after TS. Thereafter the integrity of the hypothalamic–pituitary–adrenal axis was 
assessed by an insulin tolerance test. Growth hormone deficiency is tested with a growth hormone stimulation test. If a 
hormonal deficiency is present substitution is initiated to reach reference values.  
Note 3: Hypertension is defined as a blood pressure ≥140/90 mmHg. Diabetes mellitus is defined as a  HbA1c ≥ 6.5% (≥ 48 
mmol/mol), a fasting glucose of  ≥7.0 mmol/L  (126 mg/dL ) or a non fasting glucose ≥11.1 mmol/l (199 mg/dl). 
Hypercholesterolemia is defined as a LDL cholesterol of > 3.5 mmol/l or non-HDL cholesterol of > 4.0 mmol/L (in case no 
other co-morbidities are present; otherwise we use stricter criteria).  
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Abstract 
Background: Although major improvements are achieved after cure of Cushing’s syndrome 
(CS), fatigue and decreased quality of life persist. This is the first study to measure aerobic 
exercise capacity in patients in remission of CS for >4 years in comparison with matched 
controls, and investigate whether the reduction in exercise capacity is related to alterations 
in muscle tissue.
Methods:  17 patients were included. A control subject, matched for gender-, estrogen 
status-, age-, BMI-, smoking-, ethnicity-, and physical activity level was recruited for 
each patient. VO2peak was assessed during incremental bicycle exercise to exhaustion. In 
8 individually matched patients and controls, a percutaneous muscle biopsy was obtained 
and measures were made of cross-sectional areas, capillarization, and  oxphos complex IV 
(COXIV) protein content as indicator of mitochondrial content. Furthermore, protein 
content of eNOS and eNOS phosphorylated on serine1177 and of the NAD(P)H-oxidase 
subunits NOX2, p47phox and p67phox were measured in the microvascular endothelial 
layer.
Findings: Patients showed a lower mean VO2peak (SD) (28.0 (7.0) vs. 34.8 (7.9) ml O2/kg 
bw/min, P<0.01), -maximal workload (SD) (176 (49) vs. 212 (67) watt, P=0.01) and -oxygen 
pulse (SD) (12.0 (3.7) vs. 14.8 (4.2) ml/beat, P<0.01) at VO2peak. No differences were seen 
in muscle fiber type specific cross-sectional area, -capillarization measures, -mitochondrial 
content and -protein content of eNOS, eNOS-P-ser1177, NOX2, p47phox and p67phox. 
Interpretation: As differences in muscle fiber and microvascular outcome measures are not 
statistically significant, we hypothesize that cardiac dysfunction, seen in active CS, persists 
during remission and limits blood supply to muscles. 
Introduction
Cushing’ syndrome (CS), in most cases, is of pituitary or adrenal origin. Skilled surgeons 
supported by expert endocrinologists have high success rates in reducing plasma cortisol 
levels to the normal range and achieving substantial improvements in phenotype in patients. 
However, after remission most of the patients, independent of the origin of CS, report 
subjective feelings of fatigue and limitations in their ability to perform exercise [1-3]. 
The current study aimed to be the first to measure aerobic exercise capacity during 
incremental cycling exercise to exhaustion in patients in remission of CS for 4-28 years. 
The second aim was to investigate whether the patients for a given habitual physical activity 
level (to include exercise activities) have a lower VO2peak than healthy matched controls. 
The third aim was to investigate whether the mechanisms limiting VO2peak in the patients 
reside at the level of the vastus lateralis muscle taken as representative of the major muscles 
used during walking, running and cycling exercise. The major determinants of VO2peak during 
incremental exercise at the level of the contracting muscles are mitochondrial content, 
capillary density and the vasodilatory response of terminal arterioles (TAs). 
In this study we measured VO2peak in patients in long-term remission of CS using the 
gold standard method measuring VO2 during a stepwise incremental exercise test until 
exhaustion. A comparison was made with a control group individually matched for age, 
gender, body mass index (BMI), smoking, physical activity level and ethnicity.  These 
conditions/characteristics were selected as they are known to affect VO2peak independent 
of previous CS. Therefore, this design, with all other conditions being equal, allowed us to 
investigate whether previous CS is an independent condition reducing VO2peak and not just 
the result of e.g. a lower physical activity level or a higher BMI. 
To investigate the potential mechanism(s) that lead to a reduction in VO2peak in the patients 
compared to their controls we measured in percutaneous muscle biopsies 1) mitochondrial 
content; 2) several measures of capillary density and structure; 3) the cross-sectional area 
of type 1 and type 2 fibers as measure of potential muscle fiber atrophy.  
Previous reviews of research [4, 5] have shown that intra-abdominal (visceral) obesity and 
hypertriglyceridemia in sedentary obese individuals leads to an impairment in the exercise 
induced vasodilation of TAs in the muscles. This then leads to a reduction in the exercise 
induced recruitment of additional capillaries and capillary surface area and, consequently, 
to a reduction in the transendothelial transport rate of oxygen and nutrients/fuels from 
the blood in the capillary lumen into the contracting muscle fibers. Previous research [6] 
suggests that in sedentary obese young men with metabolic syndrome, an imbalance exists 
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between the protein content of eNOS and the NAD(P)H-oxidase complex. A reduction 
in protein content and serine1177 phosphorylation of eNOS reduces eNOS activity and the 
production of the vasodilator NO, while increased expression of subunits of the NAD(P)
H-oxidase protein complex (NOX2, p47phox and p67phox) increases the production of 
superoxide anions and subsequent quenching of NO. These measurements were made in 
the current study to test the hypothesis that the eNOS/NAD(P)H-oxidase protein ratio 
is lower in the patients than the matched controls and, therefore, may limit the exercise 
induced vasodilation of TAs and recruitment of additional capillaries during exercise.
Subjects and methods
Subjects
In this cross-sectional matched case-control study, patients who were successfully treated 
for CS in the period between 1985 and 2009 in the Radboud University Nijmegen Medical 
Center and Leiden University Medical Center, both in the Netherlands, could be included. 
Medical records of all patients were reviewed to assess data on demographics, diagnosis 
of CS, etiology of CS, type and number of treatments received, and follow-up data 
on remission, recurrences, and hormonal deficiencies. Adult patients (>18 years old) in 
long-term (>4 years) remission of CS were eligible for this study. Remission was defined 
as suppression of plasma cortisol to ≤ 50 nmol/l after 1 mg dexamethasone overnight 
and absence of clinical signs and symptoms of active hypercortisolism, documented no 
longer than 1 year before the inclusion [7]. Subjects with hormonal deficiencies, except 
for adequately treated hypothyroidism (free T4 range 8.0-22.0 pmol/l), were excluded 
from this study. All eligible pituitary CS subjects had been tested, after their last pituitary 
surgery, for growth hormone (GH) deficiency by means of an insulin tolerance test (ITT), 
because GH deficiency is known to have a strong influence on VO2 peak [8]. GH deficiency 
was defined as a maximal GH response <15.3mU/l during an ITT [9]. Serious co-morbidity 
(i.e. active malignancy, serious psychiatric pathology and known diabetes mellitus), 
pregnancy, use of medication interfering with the cardiovascular system (angiotensin 
converting enzyme inhibitors, calcium antagonists, angiotensin II receptor antagonists, beta 
blockers), severe cardiopulmonary disease, and orthopedic and/or neurological diseases 
were exclusion criteria. 
For each patient, a gender-, age-, BMI-, smoking- (yes/no), ethnicity- and physical 
activity level-matched control was recruited from the general population by means of an 
advertisement in a newspaper. Female patients were matched for estrogen status and oral 
contraceptive use. 
Physical activity was estimated, before exercise testing, using metabolic equivalent of task 
scores (METS). Subjects reported their weekly physical activities, enabling the estimation 
of their daily average METS-score using the 2011 compendium of physical activities [10]. 
Daily energy expenditure (EE) was assessed using an activity monitor (Sensewear Pro3 
Armband, SWA, Body Media, Pittsburgh, PA, USA) after inclusion in order to assure 
adequate matching on physical activity level. 
This study was approved by the institutional medical ethics committees and conformed to 
the declaration of Helsinki. All participants provided written informed consent.
Methods
Aerobic exercise capacity 
Aerobic exercise capacity was assessed using an exercise stress test on a stationary bicycle 
ergometer (Lode, Excalibur Sport, Groningen, the Netherlands) using a progressive 
incremental exercise protocol. All subjects refrained from alcohol, caffeine, and intensive 
physical exercise for at least 24 h prior to testing. All tests were performed in laboratory 
conditions with constant temperature (18-20°C) and humidity (35%). All tests started at 
the same time of the day (9:00 AM). Participants were instructed to cycle at 60-80 
rotations per minute (rpm) to volitional fatigue or until they reached symptom-limited 
exhaustion. Spiro-ergometric equipment (Oxycon alpha, Jaeger, Breda, the Netherlands) 
was used to continuously measure breath-by-breath minute ventilation (VE), respiratory 
rate, oxygen consumption (VO2) and carbon dioxide production (VCO2) with calculations 
of the respiratory exchange ratios (RER, VCO2/VO2). Aerobic exercise capacity was 
determined as the peak oxygen uptake in ml O2/min/kg (VO2peak). Oxygen pulse, a 
noninvasive estimate of cardiac stroke volume, was calculated as the ratio of peak VO2 (ml/
min) to peak heart rate (bpm) [11]. Values were obtained from expired air as 30 seconds 
averages. A 12-lead electrocardiogram was used to observe heart rate. Blood pressure 
was measured manually before testing to ensure volunteer safety. Capillary blood lactate 
(Accutrend plus, Roche, Woerden, the Netherlands) was measured before and 2 minutes 
after the test. Upon cessation of exercise, participants reported their rating of perceived 
exertion (RPE) using a 0-10 Borg scale [12]. VO2peak was deemed to have been reached and 
the test data was included in the analysis when 3 of the following 4 criteria were met: 1) 
clinical signs of full exhaustion including Borg scale score ≥8, 2) RER ≥ 1.10 at cessation, 3) 
maximal heart rate within 10 beats of the maximum predicted heart rate (220 – age), and 
4) flattening of VO2 uptake curve (≤150ml increase during the last minute of exercise) [13]. 
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Physical activity levels
Average daily energy expenditure (EE; mean total calories used per day), average active 
EE (mean total calories used during activities >3 METS), average daily sedentary hours 
(activity < 1.5 METS) and average daily active hours (activity >3 METS) was assessed using 
an activity monitor (Sensewear Pro3) around the upper right arm. The activity monitor 
measured physical activity 24 hour per day for 7 consecutive days close to the exercise 
stress test. Each 24 hour interval was analyzed from 12:00 PM to 12:00 PM the following 
day and was included when the monitor recorded at least 90% of the time in each 24 
hour cycle. The activity monitor has been validated to examine EE and activity behavior in 
humans [14].
Muscle biopsy
A muscle biopsy was taken from vastus lateralis muscle using percutaneous needle biopsy 
technique under local anesthesia (1% lidocaine) as previously described [15]. The vastus 
lateralis muscle was chosen as it is easy to access by percutaneous biopsy and the fact that 
this muscle makes a significant contribution to the work load of the upper leg muscles during 
exercise, especially during cycling. Furthermore, this is the muscle that has previously been 
investigated in active CS [16]. Samples were embedded in Tissue-Tek OCT Compound 
(Sakura Finetek Europe, Zoeterwoude, Netherlands) and frozen in liquid nitrogen cooled 
isopentane (Sigma-Aldrich, Dorset, UK). Samples were stored at -80°C. 
Skeletal muscle mitochondrial content and capillarization
The method to make a fiber type specific quantitative estimate of mitochondrial content 
from the fluorescence intensity of oxphos complex IV (COXIV) has been described 
previously [17].  Briefly, muscle sections were first incubated with primary antibodies 
targeting oxphos complex IV (COXIV) (Invitrogen, UK) and myosin heavy chain type I 
(A4.840-c, DSHB, developed by Dr Blau), followed by incubation with appropriate 
secondary antibodies (Alexa Fluor goat anti-mouse IgG2a 488 and Alexa Fluor goat anti-
mouse IgM 546, respectively) and a wheat germ agglutinin (WGA) Alexa Fluor 350 
conjugate (to visualize the cell border) (Invitrogen, UK). 
The method to assess fiber type specific capillarization has been described previously 
[6]. Muscle cross-sections were first incubated with the same myosin heavy chain type 
I primary antibody to identify the type I fibers. This was followed by incubation with a 
goat anti-mouse IgM 546 secondary antibody in combination with Ulex Europaeus-FITC 
conjugate (UEA-I-FITC; Sigma-Aldrich, UK) and the WGA-350 conjugate.  A Leica 
DMI600B microscope with a 40x/0.6 NA objective, coupled to a Leica DFC365 FX CCD 
microscope camera (Leica Microsystems, UK) was used to obtain digital images of cross-
sectionally orientated muscle.  Both DAPI UV (340-380 nm) and FITC (465-495 nm) 
excitation filters were used to view the Alexa Fluor 350 and 488 fluorophores, respectively, 
and a Texas red (540-580 nm) excitation filter was used to view sections stained with Alexa 
Fluor 546.  Image processing and analysis was undertaken using Image Pro Plus 5.1 software 
(Media Cybernetics Inc, Bethesda, MD, USA).  A total of 50±11 fibers per muscle cross-
section were analyzed.  Fluorescence staining intensity was used to indicate differences 
between the patients and their matched control in mitochondrial content of each fiber 
type.  Capillaries were also quantified in a fiber type specific manner manually, using the 
UEA-I, WGA-350 and myosin heavy chain images [6]. The following indexes of muscle 
tissue fibers and capillarization were measured: 1) total fiber cross sectional area of type I 
and type II fibers, 2) number of capillaries around a fiber (capillary contacts), 3) capillary 
density and 4) capillary-fiber perimeter exchange index. 
Quantitative immunofluorescence microscopy to estimate skeletal muscle 
eNOS, eNOS-P- ser1177, NOX2, p47phox and p67phox protein content
Endothelial specific eNOS content and eNOS ser1177 phosphorylation were assessed using 
previously established methods [18, 19], with the modification that the method was adapted 
such that the eNOS-P-ser1177/eNOS ratio was calculated for individual vessels. Methods 
to assess endothelial and membrane specific NOX2 content have also been described 
previously [18, 19]. Assessment of endothelial specific p47phox and p67phox apart from 
using different primary antibodies use the same method as described for NOX2.
Sections were fixed in acetone and ethanol (3:1). For assessment of eNOS ser1177/eNOS 
ratio, sections were triple stained with antibodies against eNOS (Transduction Laboratories, 
Lexington, KY, USA), and p-eNOS ser1177 (Cell Signaling Technology, Beverly, MA, USA). 
For assessment of NOX2, p47phox and p67phox content, sections were double stained 
with antibodies against either NOX2, p47phox, or p67phox (all kind gifts from prof Mark 
Quinn, Montana State University). All sections were then incubated with appropriate 
secondary antibodies (Invitrogen, Paisley, UK) in combination with the endothelial marker 
UEA-I-FITC (Sigma-Aldrich, UK). A plasma membrane marker, WGA-633 (Invitrogen, 
Paisley, UK), was also included when staining samples for NOX2.
Images were acquired using an inverted confocal microscope (Zeiss LSM-710, Carl Zeiss, 
Germany) with a 40x NA oil immersion objective. Alexa Fluor 405 was excited using the 
405 nm line of the diode laser and detected with 371-422 nm emission. FITC fluorescence 
was excited with a 488 nm line of the argon laser and detected with 493–559 nm emission. 
Alexa Fluor 546 and 633 fluorophores were excited with 543 nm and 633 nm lines of the 
helium–neon laser and 548–623 nm and 638–747 nm emission, respectively. Identical 
settings were used for all image capture within each participant.
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All image analysis was performed using ImagePro Plus 5.1 (Media Cybernetics Inc, Bethesda, 
MD, USA). The endothelial (UEA-I-FITC) outline was overlaid onto the corresponding 
vascular enzyme image. Fluorescence intensity of the vascular enzyme signal was then 
quantified within the endothelial specific area. As eNOS and eNOS ser1177 phosphorylation 
had been stained on the same sections it was possible to establish eNOS ser1177/eNOS 
ratio on an individual vessel basis, as the same endothelial outline could be placed over 
both eNOS and eNOS ser1177 images. Cell membrane specific fluorescence for NOX2 
was determined using the WGA-633 stain to create an outline of the cell membrane. This 
mask was then overlaid onto the corresponding image to determine membrane specific 
fluorescence intensity for NOX2.
Statistical analysis
Statistical analysis was performed using SPSS (version 22.0, Chicago, Ill. USA). Data is 
expressed as mean and standard deviation (SD) unless stated otherwise. Before analysis, 
data was checked for normality of distribution using the Shapiro-Wilk test. Differences 
between the groups were analyzed using paired t-tests after confirmation of adequate 
group matching using independent t-tests. Correlations between aerobic exercise capacity 
and clinical parameters were determined using Spearman’s correlation coefficient. The level 
for significance was set at α ≤ 0.05. 
Results
Baseline characteristics
Seventeen patients in long-term remission of CS, and 17 healthy controls matched for 
gender, age, BMI, estrogen status, ethnicity, physical activity level and smoking habits, 
were included (Table 1). Ten (58.8%) patients had CS of pituitary origin, and were treated 
by selective transsphenoidal pituitary adenomectomy. Seven (41.2%) patients had CS of 
adrenal origin, and were treated by unilateral adrenalectomy. 
Aerobic exercise capacity 
Mean VO2peak of patients in long-term remission of CS was significantly lower compared 
to matched controls (P<0.01) (Figure 1). A significantly lower maximal workload (P=0.01) 
and shorter test duration (P=0.02) was observed in patients in long-term remission of CS 
compared to the control group. VE was significantly lower in patients in long-term remission 
of CS (P=0.02). This lower VE consisted of a lower respiratory rate (P=0.047) with 
comparable tidal volumes in the patients and their controls. Furthermore, oxygen pulse was 
lower in the patients compared to their controls (P=0.01). The peak heart rate, RER, and 
post-test blood lactate concentrations were not statistically different between the groups 
(Table 2), but occurred at a lower absolute workload (P=0.01) in the former CS patients.
Table 1 Characteristics of patients and controls.
Patients (n=17) Controls (n=17) P
Gender (n): female/ male 15/2 15/2 1.00
Age at time of test: (years) 45.7 ± 11.1 45.2 ± 10.1 0.89
Age at diagnosis: (years) 34.0 ± 10.2 - -
Duration of remission: median (range) (years) 11.3 (4-28) - -
Height: (cm) 171.6 ± 6.3 174.1 ± 6.3 0.25
Weight: (kg) 73.9 ± 8.1 76.1 ± 9.8 0.50
BMI: (kg/m2) 25.1 ± 2.4 25.1 ± 2.6 0.95
Systolic BP: (mmHg) 126 ± 13 130 ± 12 0.32
Diastolic BP: (mmHg) 81 ± 7 82 ± 2 0.70
Cushing’s syndrome type: n (%) 
Pituitary
Adrenal
10 (58.8)
7 (41.2)
- -
Treated hypothyroidism: n (%) 4 (23.5) - -
Estrogen status in females: n (%)
Sufficient (premenopausal)
Insufficient (postmenopausal)
10 (66.7)
5 (33.3) 
10 (66.7)
5 (33.3)
1.00
Smoking: n (%)
Yes
No
1 (5.9)
16 (94.1)
1 (5.9)
16 (94.1)
1.00
Data are presented as means ± SD unless stated otherwise. BMI, body mass index; BP, blood pressure
Figure 1 VO2peak of patients in long-term remission of CS compared to matched controls.
Tukey boxplot with whiskers indicating 1.5 interquartile range of the lower and upper quartile and black dot 
indicating an outlier. 
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Physical activity levels
No differences were found in the current average daily total EE, active EE, total daily 
sedentary time and total daily active time (Table 2). 
Correlations between aerobic exercise capacity and clinical characteristics
In the patient group, older age (r=-0.62, P<0.01) was significantly associated with a lower 
VO2peak. Adequately treated hypothyroidism in patients was also associated with a lower 
VO2peak (r=-0.65, P < 0.01). CS subtype, BMI, smoking, age at diagnosis, estrogen status 
and duration of remission were not significantly correlated with VO2peak. In the control 
group, older age (r= -0.55, P=0.02) was significantly associated with a lower VO2peak. After 
exclusion of the 4 patients with treated hypothyroidism and their controls, VO2peak remained 
significantly lower in patients (25.2 ± 3.8) vs. controls (32.5 ± 5.5) (P<0.01)) (Table 3). 
Skeletal muscle capillarization and mitochondrial content
Thirteen paired couples provided informed consent to undergo skeletal muscle biopsy.  Due 
to technical problems (frost damage) and/or a small biopsy sample size in one of the 2 
members of a paired couple, mitochondrial content and skeletal muscle capillarization could 
not be determined in five paired couples. No differences were found between the patients 
and their matched controls with regard to muscle total fiber cross sectional area, capillary 
contacts, capillary density and capillary-fiber perimeter exchange index. In addition, no 
differences were found between patients and controls in mitochondrial content (Table 4). 
The range for the mitochondrial contents and each of the capillary measures was large 
in both groups, but the mean patient/control ratio for each of these measures in the 
individually matched pairs was close to 1 (Table 3 and Table 4).
Table 2 Peak exercise responses and daily energy expenditure of patients and controls (n=17)
Patients Controls P/C ratio P
VO2peak: (ml O2/kg/min) 28.0 ± 7.0 34.8 ± 7.9 0.80 <0.01**
HR: (bpm) 174 ± 16 180 ± 13 0.97 0.22
Work load: (watt) 176 ± 49 212 ± 67 0.83 0.01*
VE: (l/min) 89.4 ± 27.3 101.0 ± 19.8 0.89 0.02*
Respiratory rate: (b/min) 38 ± 8 42 ± 6 0.90 <0.05*
RER 1.22 ± 0.09 1.17 ± 0.08 1.04 0.11
Lactate: (mmol/l) 9.8 ± 2.8 11.0 ± 3.1 0.89 0.16
Test duration: (minutes) 12.0 ± 2.4 14.3 ± 3.8 0.84 0.02*
VO2/HR: (ml/beat) 12.0 ± 3.7 14.8 ± 4.2 0.83 0.01*
Daily EE: (cal) 2498 ± 594 2567 ± 570 0.97 0.25
Daily active EE: (cal) 556 ± 527 606 ± 530 0.92 0.45
Daily sedentary hours (<1.5 METS) 10.7 ± 1.7 10.4 ± 1.6 1.03 0.54
Daily active hours (>3 METS) 4.1 ± 1.6 4.9 ± 1.8 0.84 0.12
Data are presented as mean ± SD. VO2peak, maximal aerobic capacity; RER, respiratory exchange ratio; HR, 
heart rate; cal, calories; EE, energy expenditure; VE, minute ventilation; P/C ratio, mean of the ratio of the 
indicated variable measured in the patient and its matched control. 
* P<0.05 ** P<0.01
Table 3 Peak exercise responses and daily energy expenditure of patients and controls after exclusion of 
couples containing a patient with treated hypothyroidism (n=13)
Patients Controls P/C ratio P
VO2peak: (ml O2/kg/min) 25.2 ± 3.8 32.5 ± 5.5 0.78 <0.01**
HR: (bpm) 173 ± 18 178 ± 15 0.98 0.43
Work load: (watt) 158 ± 33 192 ± 35 0.82 0.01*
VE: (l/min) 80.8 ± 19.4 95.1 ± 15.9 0.85 0.02*
Respiratory rate: (b/min) 37 ± 8 42 ± 6 0.88 0.06
RER 1.23 ± 0.08 1.17 ± 0.08 1.05 0.10
Lactate: (mmol/l) 9.1 ± 2.6 10.3 ± 2.6 0.88 0.24
Test duration: (minutes) 11.5 ± 2.2 14.0 ± 3.9 0.82 0.03*
VO2/HR: (ml/beat) 10.6 ± 1.8 13.9 ± 3.4 0.76 <0.01**
Daily EE: (cal)  2288 ± 308 2374 ± 257 0.96 0.24
Daily active EE: (cal)  408 ± 247 459 ± 250 0.89 0.52
Daily sedentary hours (<1.5 METS) 11.1 ± 1.3 10.7 ± 1.4 1.04 0.53
Daily active hours (>3 METS) 3.8 ± 1.4 4.6 ± 1.9 0.83 0.17
Data are presented as mean ± SD. VO2peak, maximal aerobic capacity; RER, respiratory exchange ratio; HR, 
heart rate; cal, calories; EE, energy expenditure; VE, minute ventilation; P/C ratio, mean of the ratio of the 
indicated variable measured in the patient and its matched control.
* P<0.05 ** P<0.01
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Figure 2 Comparison of the eNOS and eNOS-P-ser1177 (eNOS phosphorylated on serine1177) content 
in skeletal muscle capillaries and arterioles in a former patient and its matched control.
Cross-sectional images of muscle fibers were generated with a confocal immunofluorescence microscope. 
Capillaries and arterioles were visualized with Ulex europaeus-FITC conjugated lectin (UEA-I in green; left 
panels) creating an endothelial mask for each individual microvessel. eNOS and PeNOS were visualised with 
specific primary and secondary antibodies on the same section, so that the eNOS/PeNOS fluorescence 
intensity ratio could be measured in each individual microvessel. 
Figure 3 Comparison of the p47phox content (images in the middle) in skeletal muscle capillaries and 
arterioles (stained with UEA-I in images on the left) and in the plasma membrane of the skeletal muscle 
fibers (stained with WGA in images on the right) in a former patient and its matched control.
The 3 stains were applied to a single cross-section for each individual. P47phox is present both in the 
endothelial mask of the capillaries and arterioles and mask of the plasma membrane of the skeletal muscle 
fibres (both in the former patient and its matched control). 
Table 4 Skeletal muscle capillarization and mitochondrial content
N Patients Controls P/C ratio P
Mitochondrial content type 1 fibers 7 18.9 ± 4.3 19.4 ± 5.3 0.97 0.89
Mitochondrial content type 2 fibers 7 13.8 ± 4.1 14.4 ± 4.2 0.96 0.84
Capillary contacts type 1 fibers 8 4.3 ± 1.1 4.9 ± 1.5 0.88 0.43
Capillary contacts type 2 fibers 8 3.3 ± 0.9 3.5 ± 1.0 0.94 0.58
Average total fiber cross-sectional area  (mm2) 8 4527 ± 897 4846 ± 2364 0.93 0.71
Average type 1 fiber cross-sectional area (mm2) 8 5220 ± 1205 5251 ± 1836 0.99 0.97
Average type 2 fiber cross-sectional area (mm2) 8 3834 ± 1221 4439 ± 3033 0.86 0.53
Average total fiber perimeter (mm2) 8 320 ± 57 310 ± 90 1.03 0.76
Average type 1 fiber perimeter  (mm2) 8 350 ± 84 322 ± 77 1.09 0.48
Average type 2 fiber perimeter (mm2) 8 290 ± 53 297 ± 108 0.97 0.81
Total capillary-fiber perimeter exchange 8 4.9 ± 0.9 5.6 ± 1.1 0.88 0.20
Type 1 capillary-fiber perimeter exchange 8 5.1 ± 1.3 6.4 ± 1.4 0.80 0.14
Type 2 capillary-fiber perimeter exchange 8 4.6 ± 1.0 4.7 ± 1.0 0.98 0.74
Capillary density (capillaries/mm2) 8 569 ± 91 596 ± 93 0.95 0.58
Mitochondrial content in type 1 and type 2 fibers was measured as the fluorescence intensity of COXIV. 
Data are presented as mean ± SD. P/C ratio, mean of the ratio of the indicated variable measured in the 
patient and its matched control.
Table 5 Skeletal muscle eNOS, eNOS ser1177, NOX2, p47phox and p67phox protein content. The content 
of these proteins was measured as their fluorescence intensity as described in detail in the methods section.
N Patients Controls P/C ratio P
eNOS protein content 8 86.0 ± 29.5 75.5 ± 21.7 1.14 0.13
eNOS ser1177 phosphorylation 8 81.8 ± 14.5 75.9 ± 17.6 1.08 0.16
eNOS ser1177/ eNOS ratio 8 1.14 ± 0.4 1.20 ± 0.4 0.95 0.59
NOX2 protein content (endothelial specific) 7 86.3 ± 28.5 88.0 ± 36.7 0.98 0.72
NOX2 protein content ratio (membrane specific) 7 66.9 ± 22.1 70.6 ± 23.9 0.95 0.22
p47phox 7 118.9 ± 38.3 120.7 ± 45.6 0.99 0.95
p67phox 7 100.9 ± 24.3 112.3 ± 19.4 0.90 0.23
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Skeletal muscle eNOS, eNOS-P-ser1177, NOX2, p47phox and p67phox protein 
content
In 8 paired couples skeletal muscle eNOS and eNOS-P-ser1177 protein content and eNOS 
ser1177 phosphorylation (Figure 2), and in 7 paired couples NOX2, p47phox and p67phox 
protein content were determined specifically in the endothelial layer of muscle capillaries 
and terminal arterioles (Figure 3). NOX2 was also quantified on the same slides in the plasma 
layer of the skeletal muscle fibers. No statistically significant differences were detected in 
the mean protein content of eNOS, eNOS-P-ser1177 and the NAD(P)H-oxidase subunits 
between the patients and controls (Table 5). The range for each of these proteins was large 
in both groups, but the mean patient/control ratio for each of the quantified proteins in the 
individually matched pairs was close to 1 (Table 5). 
Discussion
In this study, aerobic exercise capacity of 17 patients in long-term remission of CS was 
compared to aerobic exercise capacity of 17 healthy participants individually matched for 
gender, age, BMI, smoking behavior, ethnicity and physical activity level. The rationale of 
matching for these variables was that they are major determinants of VO2peak.  The main 
finding of this study is that the former CS patients have a significantly lower aerobic 
exercise capacity (VO2peak) than their individually matched control. To investigate whether 
this lower VO2peak is the result of 1) a reduced mitochondrial content, 2) differences in the 
structure and density of the muscle capillary network  and/or 3) an increased imbalance 
between the protein content and phosphorylation state of eNOS and of the subunits of 
the NAD(P)H-oxidase protein complex in the muscle microvasculature, muscle biopsies 
were collected to make these measurements in 7-8 patient/matched control pairs. As the 
patient/matched control ratio for each of the measured  variables was close to 1.0 (Table 4 
and Table 5) this leads to the conclusion that the reduction in VO2peak in the patients must 
be the result of impairments in the blood supply to the exercising muscle or of a reduction 
in the efficiency of mitochondrial respiration (lower ATP/O ratio) in the exercising muscle.. 
This conclusion is important as it may explain the persistent complaints of fatigue and lack 
of energy reported by this patient population [1].
The lower aerobic exercise capacity in patients was independent of gender, age, BMI, and 
current physical activity level as careful matching for these variables between individual 
patients and their control was performed. The lower aerobic exercise capacity also did not 
correlate with CS subtype, age at diagnosis, estrogen status and duration of remission. 
Aerobic exercise capacity in the CS patients and controls was inversely related to age in 
accordance with existing literature [13]. The patient group studied was not receiving any 
medical treatment at the time of testing, except for thyroid hormone substitution in four 
patients. None of the patients had other hormonal deficiencies, nor other co-morbidities, 
like hypertension or impaired glucose tolerance/diabetes. Therefore, the treatment outcome 
of these specific patients can be considered as ‘best case scenario’, and any observed 
difference in outcome is likely to be, at least in part, a persisting effect of pre-exposure 
to cortisol excess, potentially affecting long-term outcome. Decreased aerobic exercise 
capacity has also been demonstrated in untreated hypothyroidism. This is (at least partially) 
reversible when adequately treated [20]. This effect may have negatively influenced 
VO2peak in the patient group. Indeed, in our patients with treated hypothyroidism VO2peak 
was lower than in patients without hypothyroidism. However, after excluding patients with 
treated hypothyroidism, VO2peak in patients in remission of CS remained significantly lower 
compared to the matched controls (Table 3).
One could argue that an explanation for our findings could be that patients in remission 
of CS are physically deconditioned during their previous episode of active CS and/or have 
a more sedentary lifestyle. However, the individual patients were matched for physical 
activity levels with their controls and they had a similar daily EE, active EE and the same 
amount of sedentary and active hours as their individual controls. This study does not provide 
information about the period shortly after surgery and, therefore, prospective studies are 
needed to determine whether a physical rehabilitation program short-term after surgery 
may improve long-term aerobic exercise capacity in these patients.
One could also argue that the interpretation of our data is influenced by still improving 
health status in the patients as the duration of remission is variable. However, there are 
some facts arguing against this. In one of our previous publications, quality of life was 
investigated in patients in remission of CS >2 years compared to matched controls [1]. 
The study used the RAND-36 questionnaire which includes questions regarding changes 
in general health status. The RAND-36 subdomain “health change” was the only domain 
that was not different between patients (in remission of CS for > 2 years) and controls. In 
addition, the patients in the present study have been in remission for > 4 years and did not 
have comorbidities so it is unlikely that their health status is still improving. Furthermore, 
in active Cushing’s syndrome there is muscle atrophy with  a diminished cross-sectional 
diameter of the muscle fibers [16]. In the current study, muscle fiber cross-sectional area 
of type I and type II fibers is exactly the same in patients and their individually matched 
control independent of the length of time that the patients were in remission and no 
significant correlation between duration of remission and VO2peak was found.
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Several mechanisms could explain our finding of the lower aerobic exercise capacity (VO2peak) 
of the patients in long-term remission of CS. First, it could be the result of a reduced supply 
of arterial blood and, therefore, of oxygen and blood borne fuels to the skeletal muscle 
fibers during exercise. With regard to this explanation our group has previously shown that 
the vasodilator response to acetylcholine, sodium nitroprusside  and NG-monomethyl-L-
arginine compared to individually matched controls was normal using venous occlusion 
plethysmography to measure total blood flow in patients with long-standing remission of 
CS [21]. This implies that functioning of the larger conductance and resistance vessels in 
adequately treated patients in remission of CS is comparable to that of healthy controls [21]. 
However, this does not exclude that impaired exercise-induced vasodilation of the muscle 
TAs reduces the recruitment of additional capillaries and of additional capillary surface area 
available for transendothelial transport of oxygen and nutrients into the interstitium of the 
muscle for uptake and oxidation by the contracting muscle fibers [4]. 
This study did not show a statistically significant difference in the cross-sectional area of 
type I and type II fibers, the mitochondrial content of type I and type II fibers and all the 
capillary measures that were performed in the muscle biopsies of the patients and their 
individual controls. There was also no difference in the ratio of the protein content of eNOS 
seen in the patients and their controls and this also applies to the NOX2, p47phox and p67phox 
protein cluster. This implies that the protein balance between NO production by eNOS and 
scavenging of NO by superoxide anions generated by NAD(P)H-oxidase in the endothelial 
layer of TAs and capillaries is not different between the patients and their individually 
matched controls and that they, with 24 h EE and number of physical activity hours being 
equal, are receiving the same training stimulus. The underlying assumption, that the protein 
expression of eNOS increases with training load and that of the subunits of the NAD(P)H- 
oxidase protein complex decreases with training,  is confirmed by previous observations 
of the authors in exercise training studies in previously sedentary healthy lean men [19] 
and previously sedentary obese men with and without metabolic syndrome [6].  Exercise 
training interventions inducing increases in VO2peak of 10-20% led to significant 5-10% 
increases in eNOS protein content in both studies [6, 19], while the NOX2 protein content 
remained at the same low expression level in the healthy lean men [19] and was significantly 
reduced in the obese men by 10% [6]. The absence in the current study of a significant 
difference in the protein content of eNOS and of the NOX2, p47phox and p67phox protein 
cluster supports the assumption that the metabolic adaptation of the endothelial layer to an 
equal physical activity level and 24 h EE was the same in the patients in remission of CS and 
their individually matched controls.  We also matched the patients and their controls for 
BMI as there is convincing evidence in the literature that the protein expression of p47phox 
(cytosolic activator of NAD(P)H-oxidase) increases with BMI in vascular endothelial cells 
obtained from sedentary overweight and obese adults [22]. 
Although we did not find a lower mitochondrial COXIV content in type I and type II muscle 
fibers in the patients compared to their controls (Table 4), we cannot exclude that the lower 
VO2peak is caused by a lower functional capacity (eg the ADP/O ratio) of the mitochondria 
in the patients. However, the finding of comparable lactate levels immediately after exercise 
at VO2peak in the patients and their matched controls pleads against this option. 
A previous publication from our group provided evidence that the lower leg muscle mass was 
reduced in patients in long-term remission of CS in comparison to the general population 
[23]. This theoretically could also explain the reduction in VO2peak that we observe in the 
patients during incremental exercise. We, however, can exclude that this is the case in the 
current study as the patients and controls investigated in the present study were matched 
for the most important factors and conditions that affect VO2peak to include physical 
activity levels. The observation that the cross-sectional area (CSA) of the type I and type 
II fibers did not differ between patients and their matched controls also excludes a lower 
muscle mass in the patients. As explained by previous research [24] a lower muscle mass in 
sedentary compared to trained men and women (called disuse atrophy) always is the result 
of muscle fiber atrophy with by far the largest decrease in CSA occurring in type II fibers. 
Obesity and inflammation leading to skeletal muscle insulin resistance will enhance the 
severity of disuse atrophy via larger increases in CSA. 
In our study we focused on changes at the level of skeletal muscles that might cause a 
reduced aerobic exercise capacity. In addition, other factors such as cardiac output can 
also negatively affect aerobic exercise capacity. A lower oxygen pulse was detected in the 
patients in long-term remission. This finding might be caused by a limitation in exercise 
cardiac output [25, 26]. There is evidence that, despite long-term remission of CS, these 
patients have more coronary artery disease [27], subclinical biventricular and left atrium 
systolic dysfunction [28, 29] and increased left ventricular mass, diastolic dysfunction [29] 
and increased myocardial fibrosis [30]. It is also known that these structural and functional 
abnormalities ameliorate already in the first year after remission, but do not fully disappear 
[28-31]. These persistent abnormalities could in theory reduce cardiac contractility and 
cardiac output and therefore reduce the supply of oxygen to the active muscles. 
In conclusion, this is the first study that demonstrates that patients in long-term remission 
of CS have a lower aerobic exercise capacity when compared to a well-matched healthy 
control group. In addition, this study demonstrates that this finding is independent of 
current daily activity levels. The study is the first to generate evidence that there are no 
differences between patients and matched controls in the cross-sectional area of muscle 
fiber types, any of the capillary measures, and mitochondrial content. There were also no 
significant differences in the protein content of eNOS, eNOS-P-ser1177, NOX2, p47phox 
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and p67phox. These findings need validation in a prospective study with a larger cohort of 
patients making multiple measurements over a 6-7 year period. The finding of a decreased 
oxygen pulse in patients during exercise testing warrants further investigation into cardiac 
function in this future prospective study.  Although CS is a rare disorder, glucocorticoids 
are frequently used as therapeutic agents in a wide spectrum of diseases. Therefore, our 
observations are relevant for medicine in general.
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Abstract 
Objective: To analyze changes in fat cell size, macrophage infiltration and local adipose 
tissue adipokine profiles in different fat depots in patients with active Cushing’s syndrome.
Methods: Subcutaneous (SC) and perirenal (PR) adipose tissue of 10 patients with Cushing’s 
syndrome was compared to adipose tissue of 10 gender-, age- and BMI-matched controls 
with regard to adipocyte size determined by digital image analysis on hematoxylin-eosin 
stainings, macrophage infiltration determined by digital image analysis on CD-68 stainings 
and adipose tissue leptin and adiponectin levels using fluorescent bead immunoassays and 
ELISA techniques. 
Results: Compared to controls mean adipocyte size was larger in  PR adipose tissue in 
patients. The percentage of macrophage infiltration of the PR adipose tissue and PR 
adipose tissue lysate leptin levels were higher and adiponectin levels were lower in SC 
and PR adipose tissue lysates in patients. The adiponectin levels were also lower in the SC 
adipose tissue supernatants of patients. Associations were found between the severity of 
hypercortisolism and PR adipocyte size.
Conclusions: Cushing’s syndrome is associated with hypertrophy of PR adipocytes and 
a higher percentage of macrophage infiltration in PR adipose tissue. These changes are 
associated with an adverse local adipokine profile. 
Introduction
One of the main physical features in Cushing’s syndrome is a centripetal adipose tissue 
distribution. Previous findings suggest that centripetal adipose tissue expansion in 
Cushing’s syndrome is predominantly caused by hypertrophy of visceral adipocytes and 
that this adipocyte hypertrophy is a direct consequence of hypersecretion of cortisol [1,2]. 
In contrast, adipose tissue expansion in generalized obesity is caused by both adipocyte 
hypertrophy and hyperplasia, in subcutaneous and visceral adipocytes [3].
Adipocyte hypertrophy has been linked to numerous metabolic alterations, including 
a disturbed blood lipid profile, independent of total adiposity or body mass index (BMI) 
[4-7], and insulin resistance via reduced activation of insulin receptor substrate (IRS-1) 
and expression of glucose transporter 4 (GLUT4) protein [8]. There is evidence that the 
adverse metabolic alterations caused by adipocyte hypertrophy in obesity are mediated 
by infiltration of macrophages, resulting in a proinflammatory state with an increase in 
systemic concentrations of proinflammatory cytokines [9-11]. 
Increased adipocyte size has also been linked to an adverse secretion profile of adipokines [12]. 
Adiponectin and leptin in particular are of interest, as they are almost exclusively secreted 
by adipocytes. Multiple reports have shown negative associations between subcutaneous 
(SC) and visceral adipocyte size and adiponectin release [12,7,13]. Adipocytes, especially 
in the SC compartment, secrete more leptin as their size increases [12]. These alterations 
represent an adverse adipokine profile which is related to insulin resistance, endothelial 
dysfunction and cardiovascular disease [14]. 
Little is known about adipocyte size, macrophage infiltration and the secretion of adipokines 
in different fat depots in active Cushing’s syndrome. Only one study showed enlarged 
abdominal fat cells in women with Cushing’s syndrome compared with non-obese women 
and obese women with the android and gynoid types of fat distribution [1]. We hypothesized 
that, in active Cushing’s syndrome, hypercortisolism leads to increased adipocyte size, a 
secondary increase in macrophage infiltration due to microhypoxia in the rapidly expanding 
adipose tissue [15] and a disturbed local adipokine profile, especially in the visceral adipose 
tissue compartments, as in generalized obesity. Therefore, we investigated adipocyte size, 
macrophage infiltration and the secretion of adipokines in SC and perirenal (PR) adipose 
tissue compartments in active Cushing’s syndrome as compared to gender-, age- and BMI-
matched controls. 
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Methods
Subjects
Adult (>18 years) patients with active Cushing’s syndrome (pituitary-dependent Cushing’s 
syndrome, ectopic ACTH production or a cortisol-producing adrenal adenoma) that were 
scheduled for unilateral or bilateral adrenalectomy were recruited from the Department 
of Medicine, Division of Endocrinology, Radboud University Medical Center. Active 
Cushing’s syndrome was confirmed in all patients by means of an increased 24-hour urine 
excretion of cortisol and a lack of suppression of plasma cortisol to ≤50 nmol/l after 1 
mg dexamethasone overnight. Control subjects were recruited from all patients that 
underwent surgery for kidney donation (8 controls) or bariatric surgery (2 controls, the 
latter needed in order to match for the 2 patients with Cushing’s syndrome with the highest 
BMI; 44.6 kg/m2 and 40.9 kg/m2 respectively) . Control subjects were matched for gender, 
age (± 2 years) and BMI (±2 kg/m2) and were included in the study before the surgery was 
done in order to perform matching before analysis of the adipose tissue samples started 
The Medical Ethics Committee of our institution approved this study (trial registration 
number: NL3282809110) and all participants provided written informed consent prior to 
participation.
Procedures
The medical records of all patients with Cushing’s syndrome were reviewed to assess clinical 
data regarding the duration of Cushing’s syndrome related physical complaints before the 
start of medical treatment, the etiology of Cushing’s syndrome, comorbidities, the use and 
duration of medical treatment for Cushing’s syndrome before surgery, efficiency of medical 
treatment defined as the last 24-hour urine excretion of cortisol before adrenalectomy and 
the severity of hypercortisolism defined as the mean of all 24-hour urine excretions of 
cortisol measured before adrenalectomy.
Adipose tissue sampling
In the patients with active Cushing’s syndrome, the PR and SC adipose tissue depots were 
sampled by the surgeon during adrenalectomy.  In the control subjects, the kidney donation 
procedures (n=8) yielded SC and PR adipose tissue samples and the bariatric surgery 
procedures (n=2) yielded only SC  adipose tissue samples. 
Biopsies consisted of approximately 60 mg of adipose tissue. Tissue samples were 
immediately immersed in 30 ml of transport medium (DMEM Glutamax 5.4g/L, 1% 
penicillin-streptomycin (p/s) and 1% bovine serum albumin (BSA)) and transported to the 
laboratory on ice. Adipose tissue was subsequently cleaned by removing visible blood and 
rinsed with wash buffer (DMEM Glutamax 5.4g/L + 1% p/s + 0,1% BSA). Approximately 
20 mg of adipose tissue of each depot was stored in formaldehyde 4% for later histological 
evaluation. Another 20 mg was snap frozen in liquid nitrogen and stored in -80°C for 
later determination of adipokine levels. The remaining adipose tissue was immediately cut 
into very small pieces and incubated for 24h at 37°C in DMEM (Gibco Life technologies, 
Bleiswijk, the Netherlands) in the presence of 10% fetal calf serum (FCS). After 24 h the 
supernatant was collected and stored in -20°C upon use. Each tissue sample mass was 
measured to correct for differences in adipose tissue weight. 
Adipose tissue morphometry and macrophage infiltration
Adipocyte size was assessed in a blinded fashion by a single observer with KS-400 digital 
image analyses. The formaldehyde 4%-fixed samples were embedded in paraffin and 8 µm 
sections were mounted on glass slides, deparaffinized in xylene and stained with hematoxylin-
eosin. Representative examples of this staining are depicted in Figure 1.  Adipocyte size of 
each sample was calculated based on values of at least 500 adipocytes from four to ten 
microscopic 10x fields, and expressed as mean cross-sectional area per cell (µm2). 
Figure 1. hematoxylin-eosin staining of perirenal adipose tissue sections in a matched couple.
CD68 protein expression was evaluated by immunohistochemical staining of formalin-
fixed paraffin-embedded tissue sections. To remove the paraffin, tissues were incubated 
twice in xylene and successively in 100%, 96% and 70% of alcohol for 5 minutes each step. 
Antigens were retrieved with citrate buffer for 2 minutes in the microwave (800 W) and 10 
minutes at room temperature (Citrate buffer: pH=6.0, 16.4 ml sodium citrate (0.1 M) with 
Control Patient
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3.6 ml citric acid (0.1M) in 180 ml H2O). The endogenous peroxidase activity was blocked 
with 3% of H2O2  in methanol for 15 minutes at room temperature. Additionally, any 
potential endogenous biotin in the samples was blocked in the tissue sections by an avidin/
biotin blocking kit according to the manufacturers’ protocol (Vector Laboratories, CA, 
USA). Sections were incubated with 20% goat serum diluted in PBS for 10 minutes and 
subsequently with the anti-CD68 antibody KP1 (DAKO, 1:8000) diluted in PBS 
supplemented with 5% goat/rabbit serum, overnight at 4°C. After washing with PBS, 
sections were incubated with a second HRP-conjugated antibody 1:200 diluted in PBS for 
1h at room temperature. The ABC-HRP complex (ABCkit-HRP Vector PK-6101), 1:500 
diluted in PBS, was applied to the sections for 30 minutes at room temperature. The 
substrate solution was added for 7 minutes at room temperature: 0.5 ml of DAB in 9.5 ml 
of PBS and 10 μl of H2O2. Tissues were counterstained with haematoxylin for 30 seconds 
at room temperature. Slides were dehydrated with consecutive incubation in 70%, 96%, 
100% of alcohol and xylene (two times) for 5’ each step.  Sections were mounted in 
Permount. Negative controls were used by omitting the primary antibody. Macrophages 
were counted manually in five microscopic (20x) fields per tissue block, blinded for the 
analyst. A representative example of this staining is shown in Figure 2. Macrophage count 
was expressed as a percentage of the total adipocyte number counted per slide.
Figure 2. CD68 protein expression on immunohistochemical staining of formalin-fixed paraffin-embedded 
tissue sections.
Adipokine levels in supernatants and adipose tissue lysates 
The snap frozen adipose tissue samples were homogenized. Tissues were weighed and for 
every 3 mg of tissue, 10µl lysis buffer (Millipore, Billerica, USA), supplemented with 
cOmplete and PhosSTOP (both Roche diagnostics, Mannheim, DE), was added in order 
to correct for weight differences between samples. Leptin concentrations in lysates and 
supernatants were measured by using multiplex fluorescent bead immunoassays (Luminex 
xMAP technology, Millipore, Billerica, USA), according to the manufacturer’s instructions. 
Total adiponectin concentrations in lysates and supernatants were determined by ELISA, 
according to the manufacturer’s instructions (R&D systems, Minneapolis, USA). 
Statistical analysis
Data are expressed as mean ± standard deviation (SD). Only the paired adipose tissue samples 
were analyzed because of the meticulous matching on gender, age and BMI. Comparison 
between matched patients and controls was performed using a paired t-test. Comparisons 
of categorical variables were performed using the χ2-test. Pearson’s correlations were 
performed in order to explore the associations between different parameters. Outcomes 
were considered statistically significant at a P-value < 0.05. All statistical analyses were 
performed with SPSS 22.0 statistical analysis package. 
Results
Subject characteristics 
Table 1 shows the subject characteristics for the patients with Cushing’s syndrome and their 
controls. Adequate matching was confirmed by the observation that no statistically significant 
differences between patients and controls were observed for gender, age and BMI. 
Adipose tissue morphometry and macrophage infiltration
Due to different surgical techniques that were used not all adipose tissue compartments 
could be sampled in all subjects. The SC compartment was sampled in 10 patients and 10 
controls and the PR compartment was sampled in 10 patients and 8 controls, yielding a 
total of 38 adipose tissue samples. Analyses were only performed when the samples of both 
the patient and the control were present for that specific adipose tissue compartment.
In the patients with active Cushing’s syndrome, mean±SD adipocyte size in the PR tissue depot 
was significantly higher compared to matched controls (3794±1994 µm2 versus 1950±881µm2, 
p<0.05) (Table 2). No difference was observed with respect to adipocyte size in the SC tissue 
depot between the patients with active Cushing’s syndrome and their controls.
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In the patients with active Cushing’s syndrome, a higher percentage of macrophage 
infiltration compared to the control group was seen in the PR adipose tissue depot 
(2.8±2.7% versus 0.5±0.5%, p<0.05). However, no difference was found with respect to 
macrophage infiltration in the SC tissue compartment in the patients versus controls.
Table 1. Clinical characteristics of patients with active Cushing’s syndrome and controls
Patients 
(n=10)
Controls
(n=10)
P-value
Gender (n): male/female 1/9 1/9 1.00
Age: mean (SD) (years) 45.3 (20.5) 44.5 (18.9) 0.93
Age at diagnosis: mean (SD) (years) 43.2 (21.5) - -
BMI : mean (SD) (kg/m2) 29.1 (8.5) 30.5 (8.0) 0.71
Cushing type: n (%)
Pituitary
Adrenal
Ectopic
5 (50)
2 (20)
3 (30)
-
-
-
-
-
-
Control type: n (%)
Kidney donation
Bariatric surgery
-
-
8 (80)
2 (20)
-
-
Fat depots sampled: n (%)
Subcutaneous
Perirenal
10 (100)
10 (100)
10 (100)
8 (80)
-
-
Comorbidities1: n (%)
Hypertension
Diabetes mellitus
Hypercholesterolemia
6 (60)
2 (20)
1 (10)
1 (10)
0 (0)
1 (10)
0.06
0.47
1.00
Medical treatment: n (%)
Ketoconazole
Ketoconazole and metopirone
None
7 (70)
1 (10)
2 (20)
-
-
-
-
-
-
Duration of medical treatment: mean (SD) (months) 14.9 (8.3) - -
Disease duration before treatment: mean (SD) (months) 15.0 (14.9) - -
Efficiency of medical treatment2: mean (SD) (nmol/24h) 197.7 (219.5)4 - -
Severity of hypercortisolism3: mean (SD) (nmol/24h) 402.1 (313.6)4 - -
BMI: body mass index.
1 Defined as the use of medication to treat these comorbidities.
2 Defined as the last 24-hour urine excretion of cortisol before adrenalectomy
3 Defined as the mean of all 24-hour urine excretions of cortisol measured before adrenalectomy
4 Normal values for 24-hour urine excretion: 30-150 nmol/24h (female), 35-240 nmol/24h (male)
Adipokine levels in adipose tissue supernatants and lysates
In the patients with active Cushing’s syndrome, a higher leptin level in PR adipose tissue 
lysates was detected compared to their controls (14389±8433 pg/ml versus 8413±11114 
pg/ml, p<0.05) (Table 2). This difference was not detected in the SC adipose tissue depot 
lysates or in the supernatants.
Table 2. Paired comparisons of adipose tissue measurements in patients with active Cushing’s syndrome 
and controls
N Patients Controls P-value
mean SD mean SD
Adipocyte size SC (µm2) 10 4819 915 3665 1572 0.102
Adipocyte size PR (µm2) 8 3794 1994 1950 881 0.025
Macrophages SC (%) 10 2.0 2.0 1.4 0.9 0.301
Macrophages PR (%) 8 2.8 2.7 0.5 0.5 0.031
Leptin SCS (pg/ml) 10 3307 4672 3913 3184 0.734
Leptin PRS (pg/ml) 8 874 1200 693 846 0.684
Leptin SCL (pg/ml) 10 14210 10979 21556 24787 0.359
Leptin PRL (pg/ml) 8 14389 8433 8413 11114 0.024
Adiponectin SCS (pg/ml) 10 14835 10097 27703 10571 0.020
Adiponectin PRS (pg/ml) 8 13794 10958 13904 9394 0.965
Adiponectin SCL (pg/ml) 10 26655 10987 54512 31291 0.005
Adiponectin PRL (pg/ml) 8 28015 12862 39021 11160 0.042
SCS, subcutaneous fat supernatant; PRS, perirenal fat supernatant; SCL, subcutaneous fat lysate; 
PRL, perirenal fat lysate.
Values in bold signify P <0.05
Note: the male couple was present in all comparisons. 
A lower adiponectin level in supernatants was detected in the patients with active 
Cushing’s syndrome in the SC tissue depot compared to their controls (14835±10097 
pg/ml versus 27703±10571 pg/ml, p<0.05). No difference was found in the PR depot. A 
lower adiponectin level was detected in the adipose tissue lysates of the SC and PR tissue 
depots compared to their controls (26655±10987 pg/ml versus 54512 ±31291 pg/ml and 
28015±12862 pg/ml versus 39021±11160 pg/ml respectively, p<0.05 in both depots). 
Correlation analysis in patients with active Cushing’s syndrome
In the patients with active Cushing’s syndrome, associations of PR adipocyte size with PR 
fat lysate leptin levels (r 0.692, p 0.026) and with PR fat lysate adiponectin levels (r -0.768, 
p 0.009) were found. No such associations were found for the SC compartment. No 
associations were found between adipocyte size and macrophage infiltration in the patients. 
An association was found between the severity of hypercortisolism and PR adipocyte size 
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(r 0.730, p 0.017). The duration of Cushing’s syndrome related physical complaints was not 
associated with any of the outcome measures.
Discussion
In this study we investigated adipocyte size, macrophage infiltration, and local adipose 
tissue levels of adipokines in different fat depots in active Cushing’s syndrome compared 
to age-, gender- and BMI-matched control subjects. We found that adipocyte size is larger 
in the PR adipose tissue compartment during active Cushing’s syndrome. There was also 
a higher percentage of macrophage infiltration in the PR adipose tissue compartment. 
With regard to the adipokine levels in active Cushing’s syndrome we found higher leptin 
levels in PR adipose tissue lysates, lower adiponectin concentrations in SC supernatants 
and lower adiponectin levels in SC and PR adipose tissue lysates. These findings are highly 
relevant because changes in the function of adipose tissue have been associated with the 
development of cardiovascular and metabolic adverse effects. 
This is the first study to show that PR adipocyte size is larger in patients with active 
Cushing’s syndrome. One previous study already described a larger omental adipocyte size 
during active Cushing’s syndrome [1]. We did not find a larger adipocyte size in SC adipose 
tissue of active Cushing’s syndrome. This can possibly be explained by the fact that most 
effects of glucocorticoids on adipose tissue activity and lipid accumulation in humans are 
seen on visceral rather than SC fat [16]. 
Macrophage infiltration into different adipose tissue compartments has not been studied 
before in active Cushing’s syndrome. This study showed a higher percentage of macrophage 
infiltration in PR adipose tissue in active Cushing’s syndrome compared to matched controls. 
This result is in concordance with the findings in generalized obesity where adipocyte 
hypertrophy is accompanied by death of adipocytes and macrophage recruitment [17]. It 
is suggested that, at least in part, this is caused by hypoperfusion leading to an inadequate 
oxygen supply in the face of expanding adipose tissue [15]. Adipose tissue expansion may 
occur even more rapidly in Cushing’s syndrome compared to common obesity. Infiltrated 
macrophages interact with adipocytes in a paracrine manner increasing the production of 
proinflammatory adipokines and reducing the production of anti-inflammatory adiponectin 
[18] as found in this study. Similar to the other parameters, these differences were not 
found in SC adipose tissue. The finding of a statistically significant association between the 
severity of hypercortisolism and PR adipocyte size supports the theory that this finding is 
a direct consequence of hypercortisolism. 
Local adipokine concentrations in different adipose tissue compartments have not been 
studied before in active Cushing’s syndrome. Increased serum leptin levels in obesity and 
Cushing’s syndrome are associated with insulin resistance, atherogenesis and cardiovascular 
disease [14,19]. In this study, the higher PR leptin levels in active Cushing’s syndrome 
adipose tissue lysates could be explained by the higher adipocyte size in this compartment, 
which is supported by the statistically significant correlation between adipocyte size and 
leptin levels in this compartment. Our result is in accordance with previous findings of 
increased serum leptin levels during active Cushing’s syndrome [20,21,19]. In our study no 
differences in local adipokine concentrations were seen in the SC compartments between 
patients and controls, which is in accordance with the preferential effect of glucocorticoids 
on visceral adipose tissue. Furthermore, this finding suggests that the increase in serum 
leptin levels previously found in Cushing’s syndrome in remission is probably caused by 
increased leptin production by the PR adipose tissue compartment [22]. 
Serum adiponectin levels are markedly decreased in obesity and are associated with 
insulin resistance [14]. In this study, we found lower adiponectin levels in SC supernatants 
and lower adiponectin levels of SC and PR fat lysates in patients with active Cushing’s 
syndrome. As with leptin levels, an association was found with adipocyte size. Adipocyte 
size was inversely correlated with PR fat lysate adiponectin levels. Multiple studies have 
investigated serum adiponectin levels in active Cushing’s syndrome. However, these studies 
have reported conflicting data [23-25]. The findings in the current study suggest that the 
lower serum adiponectin level in ex-patients with Cushing’s syndrome as recently described 
by our group [22] could be the result of decreased adiponectin production in SC and PR 
adipose tissue. 
A strength of the current study is that a broad spectrum of adipose tissue characteristics 
was investigated in different adipose tissue compartments of patients with active Cushing’s 
syndrome. Furthermore, the meticulous matching between patients and controls makes 
that our findings are independent of gender, age and BMI and are more likely to be an 
effect of the hypercortisolism per se. 
The main limitation of this study is the small sample size which is caused by the low incidence 
of Cushing’s syndrome on the one hand and the rarity of patients with Cushing’s syndrome 
that require adrenalectomy on the other hand. Therefore it is possible that we have missed 
relevant differences.  Furthermore, the cross-sectional character of this study limits our 
ability to establish causal relations. A final limitation is that ex-vivo adipokine production 
in this study does not necessarily correspond to the excretion in-vivo as the tissues are 
removed from their natural environment.
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In conclusion, the central adipose tissue distribution in active Cushing’s syndrome appears 
primarily to be caused by adipocyte hypertrophy. This is accompanied by and associated 
with an adverse local adipokine profile in these adipose tissue compartments. Furthermore, 
the number of macrophages in PR adipose tissue in active Cushing’s syndrome is 
increased. These combined findings could contribute to the disturbed blood lipid profile, 
insulin resistance, endothelial dysfunction and cardiovascular disease that are frequently 
seen during active Cushing’s syndrome. Future research should be performed to further 
elucidate the role of adipose tissue parameters as assessed in this study, both during active 
Cushing’s syndrome and after remission, as these mechanisms might also play a role in 
patients on chronic glucocorticoid treatment. 
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This thesis focuses on quality of life (QoL) and long-term physical consequences of endocrine 
diseases, specifically thyroid carcinoma, Cushing’s syndrome (CS) and acromegaly. 
Part 1 Long-term health related quality of life after 
treatment of thyroid carcinoma and acromegaly
Thyroid carcinoma
Cancer patients are at increased risk for distress [1-3]. The Distress Thermometer (DT) 
and Problem List (PL) are short tools validated and recommended for distress screening 
in cancer patients [1, 4]. The objective of chapter 2 was to investigate the level of distress 
and problems experienced by survivors of differentiated, non-medullary, thyroid carcinoma 
(DTC), using the DT and PL and whether this correlates with clinical and demographical 
variables. All 205 DTC patients under follow-up at our institution were asked to fill in the DT 
and PL, hospital anxiety and depression scale (HADS) and the illness cognition questionnaire 
(ICQ). Receiver Operator Characteristic analysis (ROC) was used to establish the optimal 
DT cut-off score according to the HADS. Correlations of questionnaire scores with data 
on diagnosis, treatment and follow-up collected from medical records were analyzed. 
Of the 159 respondents, 145 agreed to participate (118 in remission, median follow-up 
7.2 years (range 3 months to 41 years)). Of these, 34.3% rated their distress score ≥ 5, 
indicating clinically relevant distress according to ROC analysis. Patients reported physical 
(86%) more than emotional problems (76%) as sources of distress. DT scores correlated 
with HADS scores and ICQ subscales. No significant correlations were found between DT 
scores and clinical or demographical characteristics except for employment status. 
Subjective estimates of distress levels by medical professionals are often inaccurate 
and misleading [5, 6]. The DT is an easy-to-use instrument that helps identify treatable 
problems and specific issues that may cause distress, allowing physicians to address these 
issues more effectively. The use of the DT and PL potentially improves communication 
between patients and healthcare providers and thereby  patient care and satisfaction 
[7] . In addition, it  may also help to use limited consultation time more effectively [8]. 
Chapter 2 was the first study evaluating the level of distress using the DT and PL in DTC 
patients. Surprisingly, the 34.3% of subjects with distress score ≥ 5 was comparable to 
other studies with similar response rates, including patients with other types of cancer such 
as lung cancer, breast cancer and leukemia, having a more aggressive course and being 
associated with more physical burden than patients with DTC [7, 9-12]. In consistence 
with findings in other types of cancer [7], no significant correlations were found between 
level of distress and either clinical or demographic characteristics, with the exception of 
employment status. The role of employment status in impaired quality of life in patients 
with chronic conditions including  patients with cancer is not clear as literature data are 
lacking. It has been suggested that unemployment influences distress levels in patients with 
cardiovascular disease [13]. Although not completely comparable with DTC survivors, this 
might support the need for reintegration strategies for patients in the work process after 
they have been cured. In conclusion, the prevalence of distress is high in patients with DTC 
even after long-term remission. Physical and emotional problems were the main sources of 
distress. The DT and PL are useful and time efficient screening instruments for psychosocial 
distress in DTC patients and could easily be incorporated into daily practice. The findings 
in chapter 2 highlight the importance of routine psychological distress screening even in a 
later phase after treatment. 
Screening for distress has already been implemented in our clinic as an integral part of the 
follow-up of patients with thyroid carcinoma and it is currently recommended in the Dutch 
thyroid carcinoma treatment guidelines (with reference to chapter 2 of this thesis, www.
oncoline.nl/schildkliercarcinoom). Future research in this field should focus on the clinical 
benefits of prospective and systematic screening for distress in patients with DTC, as well 
as best intervention strategies to treat this distress. 
Shoulder complaints could be one of the physical sources of distress and are frequently 
reported after surgical treatment for thyroid carcinoma (TC). However, no specific 
literature on this topic was available for these patients and hence, its impact on QoL was 
unknown. Therefore, the objective of chapter 3 was to assess the prevalence of shoulder-
related complaints and its relation to QoL and clinical characteristics after TC surgery. The 
prevalence of shoulder complaints and its relation to clinical characteristics and QoL after 
TC surgery in 109 patients was compared to 81 healthy controls. Main outcome measures 
were prevalence of self-reported shoulder complaints, results of the Disabilities of the Arm, 
Shoulder and Hand questionnaire (DASH) and the European Organization for Research 
and Treatment of Cancer, Quality of Life Questionnaire-C30 (EORTC QLQ-C30). 
TC patients, on average 10.2 years after thyroid carcinoma surgery, reported a 58.7% 
prevalence of shoulder-related complaints, which was significantly more than the 13.6% 
reported by healthy controls (P<0.01). TC patients scored worse than healthy controls on 
most of the different subscales of the DASH and EORTC QLQ-C30. Bivariate association 
analysis identified level V neck dissection as being associated with the prevalence of shoulder 
complaints and DASH score. Furthermore, spinal accessory nerve (SAN) damage and 
employment status were associated with DASH score. Prevalence of shoulder complaints 
and DASH scores were significantly correlated to several EORTC-QLQ30 scores. Only 
11.9% of TC patients retrospectively reported having received preoperative information on 
possible shoulder complaints and only 34.9% of TC patients retrospectively reported having 
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received additional care for their shoulder complaints. As expected, SAN damage during 
surgery was significantly associated with worse DASH scores. 
The results reported in chapter 3 in TC patients are comparable to the results of studies in 
patients undergoing surgical treatment for other head and neck cancers. These studies also 
used questionnaires on self-reported QoL and complaints. One of these studies showed 
that especially extensive neck dissections are associated with shoulder complaints, which 
is an important source of long-term morbidity and QoL impairment [14-17]. Dissections 
extending into level V are known to cause a higher incidence of shoulder complaints 
[18]. This is consistent with the finding of an association between level V neck dissection 
and shoulder complaints with worse DASH scores in the bivariate analysis in chapter 3. 
However, we were surprised to find that a large proportion of patients in our series who 
did not undergo extensive ND reported shoulder-related complaints still many years after 
the primary treatment. This has led us to consider that, apart from the obvious possible 
causes of shoulder complaints after head and neck surgery, other factors may play a role 
as well. One can envisage that, even in the absence of a reported SAN damage, traction, 
devascularisation, transsection of the fine branches or adhesive capsulitis may contribute 
to a temporary or a persistent shoulder discomfort. The second unexpected finding was 
that patients with a lower TNM stage reported more shoulder discomfort. We hypothesize 
that this may be partially related to the fact that in higher stage, locally extensive disease 
and not completely removable tumor, one might prefer performing a more limited surgery 
aimed to preserve functionality and QoL. On the other hand, we cannot exclude that 
psychological factors might induce reporting bias as well. Patients with extensive disease 
may experience more burden because of the worse prognosis of the disease and may pay less 
attention to shoulder discomfort. In contrast, patients with less extensive disease, having 
a better long-term prognosis, may focus more on optimal QoL and functionality required 
for instance for work rehabilitation. Regression analysis identified employment status to 
be significantly associated with shoulder complaints and DASH scores in the TC patients. 
Because chapter 3 is a cross-sectional study it is difficult to make causal inferences about 
the relation between employment status and DASH scores. It is however possible that 
patients with worse DASH scores are more often unemployed due to their complaints 
especially as a previous review article found that 46% of patients recovering from head and 
neck cancer surgery gave up work solely due to shoulder disability [19]. In conclusion, the 
results of chapter 3 suggest that the prevalence of self-reported shoulder complaints after 
TC surgery is high. It represents an important issue in the management of these patients 
and is associated with a worse QoL.  
Patients undergoing TC surgery should be informed about the findings in chapter 3 
preoperatively. Postoperative physical examination of the shoulder is warranted and 
physiotherapy should be started as soon as possible when complaints are present or can 
be expected. Future research in this field should be aimed at the prospective assessment 
of shoulder complaints and analysis of the specific etiology of the shoulder complaints,  in 
order to tailor the treatment and prevention strategies. 
Acromegaly
Acromegaly is associated with impaired QoL and causes anatomical disproportions [20], 
which may contribute to the decreased QoL after successful treatment [21-25]. The 
Derriford appearance scale 59 (DAS59) is a questionnaire measuring psychological distress 
and disruptions to everyday life associated with self-consciousness of appearance. The aim 
of chapter 4 was to investigate the psychological distress and dysfunction related to self-
consciousness about appearance and its effect on QoL in patients in long-term remission of 
acromegaly. All patients (>18 years old) treated in our hospital for acromegaly in the past 
were invited to participate. A gender-, age- and body mass index-matched control group 
was provided by the patients themselves. Participants were asked to complete the modified 
DAS59- and research and development 36- (RAND-36) questionnaires, the acromegaly 
quality of life questionnaire (AcroQoL) and a sociodemographic questionnaire. Differences 
between patient- and control-groups and correlations between questionnaire scores and 
clinical characteristics were analyzed. Of the 120 respondents, 73 agreed to participate 
[all cured or under biochemical control, median remission time 10.5 years (range 2.3–43.6 
years)]. Of these, 46.6 % reported self-consciousness about their appearance compared 
to 22.8% of the 57 healthy controls. Twenty-nine of the patients (85.3 %) pointed out 
their face to be a prominent source of self-consciousness. Significant correlations were 
found between the scores of the DAS59 and the AcroQoL and RAND-36 questionnaires 
in patients.
The significant correlations between the DAS59 scores and the AcroQoL and RAND-
36 scores found in chapter 4 indicate that the concerns about appearance are clearly 
related to an impaired quality of life and general well-being. An impressing 85.3 % of 
the patients who reported self-consciousness of appearance in our cohort indicated that 
their face is the main source of discontent. Chapter 4 therefore clearly demonstrates that 
patients in long-term remission of acromegaly still have significant problems with their 
facial appearance. The findings in chapter 4 are in line with the findings of previous studies 
that found that the most affected dimension of the AcroQoL was appearance [22, 23]. A 
positive perception of appearance is related to successful psychological functioning and 
well-being [26]. Therefore, the self-consciousness about appearance and impaired QoL in 
patients in long-term remission of acromegaly are serious  as these patients are already in 
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disease remission and these disturbances seem to persist. The concerns about appearance 
in patients in remission of acromegaly are most likely caused by persisting anatomical 
alterations as craniofacial disproportions remain present, even after long-term remission 
[27]. Plastic/craniofacial surgery is not widely performed in (ex) acromegaly patients. 
However individualized procedures, for example reduction of the vertical dimension of the 
body of the mandible, rhinoplasty, posterior displacement of the prominent frontal bone, 
recession and remodeling of cheeks (zygoma) or correction of mandibular prognathism 
can greatly improve appearance and potentially reduce self-consciousness and associated 
distress about appearance [28-30]. In conclusion, even after long-term remission of 
acromegaly, a large number of patients are self-conscious about their appearance, leading 
to psychological distress and disruptions to everyday life and a decreased QoL. 
The findings in chapter 4 highlight the importance of the fact that physicians should not 
ignore self-consciousness about appearance in patients treated for acromegaly but have 
to address these concerns during follow-up. Patients should be encouraged to discuss 
their concerns about their appearance and should be offered individualized advise about 
corrective interventions to improve not only their appearance but also functionality. Future 
research in this field should be directed at prospective assessment of appearance in the 
follow-up of these patients and efficacy of further treatment options like psychological 
support or plastic/craniofacial surgery. Furthermore, it would be interesting to know when 
the reversible changes in facial features of acromegalic patients come to a halt, as this 
would be the moment most suitable for surgical treatment of remaining deformities. 
Part 2 Long-term physical sequelae of Cushing’s syndrome
Glucocorticoid receptor (GR) polymorphisms modulate glucocorticoid (GC) sensitivity 
and are associated with altered metabolic profiles. We [31] and others [32, 33] have 
shown that some adverse metabolic and cardiovascular characteristics, and changes 
in body composition persist after treatment of CS. Although these adverse metabolic 
and cardiovascular characteristics are common in these patients, their incidence and 
severity vary among patients. This variation seems not to be explained by differences in 
level of cortisol excess or disease duration alone. Therefore, a variable sensitivity to GC’s 
possibly plays a role in modulating the effect of cortisol excess [34]. Therefore, the aim 
of chapter 5 was to evaluate the presence of GR polymorphisms (BclI (rs41423247), 
N363S (rs56149945), ER22/23EK (rs6189/rs6190), and 9β (rs6198)) and investigate 
their associations with metabolic alterations in patients in long-term remission of CS. 
Sixty patients in long-term remission of CS were genotyped. Associations between GR 
polymorphisms and multiple vascular-, body composition- and metabolic-parameters were 
investigated. Chapter 5 showed that carriers of the 9β polymorphism have a higher systolic 
blood pressure and lower resistin levels. The GC sensitizing BclI polymorphism is associated 
with an adverse cardiometabolic risk factor profile: higher fat percentages of extremities 
and legs, higher serum leptin and E-selectin levels, and higher intima media thickness in 
carriers versus non-carriers.
In the general population, it has been demonstrated that cardiovascular and metabolic 
risk and body composition are affected by lifelong overactivation or relative inactivation 
of GC signaling due to GR polymorphisms. Our observation in chapter 5 that altered 
glucocorticoid sensitivity due to GR polymorphisms modulates cardiometabolic risk factors 
in cured CS patients is in line with these well-known findings in the general population 
[35-38]. CS patients in remission carrying the minor allele of the 9β polymorphism had 
a higher systolic blood pressure, which is concordant with previous findings of an increase 
in carotid atherosclerosis, and a higher incidence of coronary heart disease in carriers of 
this polymorphism [39]. The minor allele of the BclI polymorphism was associated with an 
increased fat percentage of the extremities and legs in the remitted CS patients. These 
body areas only contain subcutaneous adipose tissue. As leptin is preferentially produced in 
subcutaneous adipose tissue (SAT), carriers also had higher leptin levels [40]. High leptin 
levels have been widely recognized as an independent cardiovascular risk factor associated 
with insulin resistance. It also has a pathogenic role in atherothrombosis and endothelial 
dysfunction. Furthermore, a higher level of E-selectin was found in carriers of the minor 
allele of the BclI polymorphism. This may reflect increased endothelial activation and 
progressing atherosclerosis in the BclI carriers. This is supported by the observations in 
chapter 5 that the intima media thickness ( IMT) is higher in BclI carriers. In conclusion, 
the study in chapter 5 is one of the first to suggest that GR polymorphisms modulate 
cardiometabolic risk factors in patients in long-term remission of CS [41]. 
In the context of personalized healthcare, the findings in chapter 5 may implicate that, 
after treatment of CS, carriers of GR polymorphisms are candidates for a more stringent 
follow-up regarding cardiovascular and metabolic health. Furthermore, patients who 
were treated with glucocorticoids for other diseases and even healthy subjects, carrying 
these polymorphisms, might also be candidates for a more stringent follow-up regarding 
cardiovascular and metabolic health and the development of the metabolic syndrome, as 
was recently debated [42]. The results of chapter 5 need, however, to be interpreted with 
caution, and further research in larger CS populations is needed to validate these findings. 
In addition, future studies should delineate to what extent the observed associations also 
apply to prolonged episodes of exposure to physiologically elevated cortisol levels (e.g., 
severe stress) or exogenous glucocorticoids as medical treatment. 
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Patients with CS suffer from endothelial dysfunction and premature atherosclerosis 
[43-48]. However, it is uncertain to what extent vascular health recovers after long-
term remission. This is highly relevant as this topic relates to future development of 
cardiovascular disease. Therefore, the aim of chapter 6 was to investigate whether micro- 
and macrovascular health is impaired after long-term remission of CS, in patients without 
or adequately treated co-morbidities. Sixty-three patients (with remission of CS for ≥ 4 
years) and 63 healthy, well-matched controls were compared. In group A (58 patients and 
58 controls) serum biomarkers associated with endothelial dysfunction, IMT, pulse wave 
velocity and pulse wave analysis were studied. In group B (14 patients and 14 controls) 
endothelium-dependent and-independent vasodilatation was studied in conduit arteries 
(flow mediated dilation (FMD) of the brachial artery) and forearm skeletal muscle resistance 
arteries (vasodilator response to intra-arterial acetylcholine, sodium-nitroprusside and 
NG-monomethyl-L-arginine using venous occlusion plethysmography). There were no 
significant differences between the outcome measures of vascular health of patients and 
controls in group A and B.
Our finding in chapter 6 that after remission of CS endothelial function is comparable 
to that in healthy controls, is in line with previous research that investigated arterial 
endothelial function with FMD [49]. Previous studies have shown that in vitro  and in vivo 
exposure of endothelial cells to glucocorticoids reduced the mRNA and/or protein content 
of endothelial NO-synthase [50, 51] and reduced acetylcholine-induced vasodilation of 
resistance arteries [50] and the aorta [52]. Therefore, it can be proposed that endothelial 
dysfunction in active CS is largely accounted for by the direct effect of hypercortisolism 
on vascular endothelium and that this is reversible after cure of CS. In contrast, five other 
studies observed persistent impaired vascular health after remission of CS [32, 53-56]. 
However, three of these five studies included patients that were in remission for only a short 
period of time or a pediatric population and are therefore not comparable to the study in 
chapter 6. Two of the five studies can be compared with our study. They both found a higher 
prevalence of atherosclerosis (measured by carotid IMT and presence of coronary artery 
disease detected by computed tomography respectively) compared to gender-, age- and 
BMI-matched controls [32, 56]. However, the patients in these studies had significantly 
more uncontrolled metabolic comorbidities than their matched controls. In chapter 6 the 
comorbidities in group A were adequately treated [31], and the patients in group B had 
no known comorbidities (except for adequately treated hypothyroidism in 4 patients). 
Another publication supports our findings [57]. This study measured differences in cIMT 
and artery stiffness between active disease and one year after remission of CS. After 1 year 
of remission both variables did not differ from a gender-, age- and BMI-matched control 
group, but they were still higher than in controls with a lower BMI, matched only for gender 
and age.  We conclude that patients in remission of CS, who are equally well-controlled 
for comorbidities as age-, gender- and BMI-matched healthy subjects, have comparable 
vascular health. Interestingly, the normalized vascular health seems to be irrespective of 
the fact that these patients have, as we have previously shown, a more centripetal adipose 
tissue distribution and adverse adipokine profile than their age-, gender- and BMI matched 
controls [31]. However, the patients in chapter 6 are relatively young, and vascular problems 
are more frequent as age increases. So even though we did not find indications for impaired 
vascular health at approximately 50 years of age, the fact that persistent central adiposity 
and an adverse adipokine profile are still present after long-term remission of CS may 
suggest that patients still are at higher vascular risk later in life. In conclusion, vascular 
health of patients in long-term remission of CS seems to be comparable to that of healthy 
gender-, age and BMI-matched controls, provided that the patients have no, or adequately 
controlled comorbidities. Therefore, the effects of the previous hypercortisolism per se on 
the vasculature may be reversible. 
The findings in chapter 6 underscores the need for stringent individualized treatment of 
metabolic comorbidities in CS patients, even after remission. We need to be aware of the 
fact that cardiovascular risk is still elevated even in the healthiest patients in remission of 
CS because of a persistent effect of the prior hypercortisolism on other organs than the 
vasculature e.g., the myocardium [58, 59]. This might be a focus of future research. 
Although biochemical cure and concomitant improvement of phenotype can be achieved 
in most patients with CS, a decreased quality of life, mild cognitive impairment and a 
centripetal fat distribution often persist after biochemical cure [31, 60]. Whether the 
level of physical fitness is decreased in patients biochemically cured of CS has not been 
investigated. Therefore, the aim of chapter 7 was to investigate physical fitness level, as 
measured by peak oxygen uptake (VO2 peak) during a maximal exercise stress test, and 
to explore its relation with current daily activity level and skeletal muscle alterations, in 
patients in long-term (>4 years) remission of CS compared to matched controls. Of all 
patients treated for CS in our hospital and the Leiden University Medical Center between 
1984 and 2009, 17 patients were eligible for the study based on the preset inclusion 
criteria (long-term (>4 years) remission of CS without hormonal deficiencies, except for 
hypothyroidism adequately substituted with levothyroxine (4 patients)). For each patient 
a gender-, estrogen status-, age-, BMI-, smoking-, ethnicity-, and physical activity level- 
(confirmed by actometer data) matched control subject was recruited from the general 
population. Physical fitness was assessed in all patients and controls during a maximal 
exercise stress test on a bicycle ergometer with an incremental exercise protocol. In 8 
unselected patients who agreed to the procedure and their matched controls, skeletal 
muscle tissue of the vastus lateralis muscle was biopsied and measures were made of 
cross-sectional areas, capillarization, and oxphos complex IV (COXIV) protein content as 
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indicator of mitochondrial content. Furthermore, protein content of eNOS and eNOS 
phosphorylated on serine1177 and of the NAD(P)H-oxidase subunits NOX2, p47phox and 
p67phox were measured in the vascular endothelial layer. Patients showed a lower mean 
VO2peak (SD) (28.0 (7.0) vs. 34.8 (7.9) ml O2/kg bw/min, P<0.01), -maximal workload 
(SD) (176 (49) vs. 212 (67) watt, P=0.01) and -oxygen pulse (SD) (12.0 (3.7) vs. 14.8 (4.2) 
ml/beat, P<0.01) at VO2peak. No differences were seen in muscle fiber type specific cross-
sectional area, -capillarization measures, -mitochondrial content and -protein content of 
eNOS, eNOS-P-ser1177, NOX2, p47phox and p67phox. 
Our finding in chapter 7, that patients in long-term remission of CS demonstrate a lower 
level of physical fitness (VO2peak) compared to the matched group of healthy controls 
independent of daily physical activity levels, could have different explanations. The patient 
group was not receiving any medical treatment at the time of testing, except for thyroid 
hormone substitution in 4 patients, and none of the patients had further hormonal 
deficiencies. A subgroup analysis after exclusion of the patients on thyroid hormone 
substitution did not change our main findings. Chapter 7 does not provide evidence for the 
hypothesis that a lower physical fitness level could be caused by a difference in muscle fiber 
type specific cross-sectional area, -capillarization measures, -mitochondrial content and 
-protein content of eNOS, eNOS-P-ser1177, NOX2, p47phox and p67phox. We cannot exclude 
that the lower VO2peak, as found in our study, is caused by a lower functional capacity 
of mitochondria. The finding of comparable lactate levels immediately after exercise at 
VO2peak in the patients and their matched controls does not support this option, but patients 
had a lower work load and possibly an earlier rise in lactate. A lower VO2peak could also be 
explained by a decrease in recruited muscle mass during exercise [61] or deconditioning of 
the muscle. A previous publication of our group has provided evidence for the hypothesis 
that lower extremity muscle mass is decreased in patients in long-term remission of CS as 
these patients had an almost 3 cm smaller thigh circumference compared to gender-, age- 
and BMI-matched controls [31]. However, the observation that the cross-sectional area of 
the type I and type II fibers did not differ between patients and their matched controls in 
the current study excludes this explanation. With regard to blood supply, chapter 6 of this 
thesis showed that functioning of larger conductance- and resistance vessels in patients in 
remission of CS is comparable to that of healthy controls, making this explanation less likely. 
There are a number of other factors that can negatively influence physical fitness, such as 
decreases in pulmonary diffusing capacity and cardiac output. These parameters were not 
directly investigated in chapter 7. However, our patients showed no decreases in oxygen 
saturation during ergometry testing, which makes a decreased pulmonary diffusing capacity 
unlikely. With respect to the cardiovascular system, a lower oxygen pulse was detected in 
the patients in long-term remission. This finding might be caused by a limitation in exercise 
cardiac output [62, 63], e.g. due to coronary artery disease. There is evidence that, despite 
long-term biochemical cure of CS, these patients have more coronary artery disease [56]. 
However, caution is required in interpreting these results as the oxygen pulse might also be 
lower due to respiratory constraints and deconditioning. In conclusion, chapter 7 is the first 
study that demonstrates that patients in long-term remission of CS have a lower physical 
fitness level when compared to a well-matched healthy control group. In addition, chapter 
7 shows that this finding is independent of current daily activity levels. Chapter 7 is the first 
study to generate evidence that there are no differences between patients and matched 
controls in the cross-sectional area of muscle fiber types, any of the capillary measures, and 
mitochondrial content. There were also no significant differences in the protein content of 
eNOS, eNOS-P-ser1177, NOX2, p47phox and p67phox.
The findings in chapter 7 could be an explanation for the persisting complaints of fatigue 
and lack of energy in these patients and confirm that biochemical cure does not lead to 
complete functional recovery in CS patients. These findings may also have implications for 
patients on chronic GC therapy. Further research is needed to elucidate the exact cause of 
the impaired physical fitness and whether a standardized comprehensive physical recovery 
program could restore physical fitness after long-term remission of CS. The finding of a 
decreased oxygen pulse in patients during exercise testing warrants further investigation 
into cardiac function in future research.
As previously mentioned, CS is associated with centripetal obesity. Little is known about 
the effects of chronic hypercortisolism on adipose tissue morphology and physiology. This 
is highly relevant because changes in the function of adipose tissue have been associated 
with the development of cardiovascular and metabolic adverse effects [64-68].  The aim of 
chapter 8 was to analyze changes in fat cell size, macrophage infiltration and local adipose 
tissue adipokine profiles in perirenal and subcutaneous fat depots in patients with active CS. 
Subcutaneous (SC), and perirenal (PR) adipose tissue of 10 patients with active CS were 
compared to adipose tissue of 10 gender-, age- and BMI-matched controls with regard to 
adipocyte size, macrophage infiltration and adipose tissue leptin and adiponectin levels in 
adipose tissue lysates and conditioned supernatants. In the patients with CS, adipose tissue 
was collected during adrenal surgery and in the controls during a kidney donation procedure 
or during bariatric surgery.  Compared to controls, adipocyte size was significantly larger in 
PR adipose tissue in patients with active CS. There was no difference in adipocyte size in SC 
adipose tissue between patients and controls. The percentage of macrophage infiltration of 
the PR adipose tissue and PR adipose tissue lysate leptin levels were higher and adiponectin 
levels were lower in SC and PR adipose tissue lysates in patients with CS compared to 
controls. The adiponectin levels were also lower in the SC adipose tissue supernatants of 
patients with CS compared to controls. 
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Chapter 8 is the first study to show that PR adipocyte size is larger in patients with 
active CS. One previous study described a larger visceral adipocyte size during active CS 
[69]. We did not find a larger adipocyte size in SC adipose tissue of active CS. This can 
possibly be explained by the fact that most effects of GC on adipose tissue activity and 
lipid accumulation in humans are seen in visceral rather than in SC fat [70]. Macrophage 
infiltration into different adipose tissue compartments has not been studied before in active 
CS. Chapter 8 shows a higher percentage of macrophage infiltration in PR adipose tissue 
in active CS compared to matched controls. These results are in concordance with the 
findings in generalized obesity where adipocyte hypertrophy is accompanied by death of 
adipocytes and macrophage recruitment [71]. It is suggested that, at least in part, this is 
caused by hypoperfusion leading to an inadequate oxygen supply in the face of expanding 
adipose tissue [72]. Infiltrated macrophages interact with adipocytes in a paracrine manner 
increasing the production of proinflammatory adipokines and reducing the production of 
anti-inflammatory adiponectin [73] as found in chapter 8. Similar to the other parameters, 
these differences were not found in SC adipose tissue. Local adipokine concentrations 
in different adipose tissue compartments have not been studied before in active CS. 
Increased serum leptin levels in obesity and CS are associated with insulin resistance, 
atherogenesis and cardiovascular disease [74, 75]. In chapter 8, the higher PR leptin 
levels in active CS adipose tissue lysates could be explained by the higher adipocyte size in 
this compartment, which is supported by the statistically significant correlation between 
adipocyte size and leptin levels. Our results are in accordance with previous findings of 
increased serum leptin levels during active CS [75-77]. In chapter 8 no differences in 
local adipokine concentrations were found in the SC compartments between patients and 
controls, which is in accordance with the preferential effect of glucocorticoids on visceral 
adipose tissue. Furthermore, this finding suggests that the increase in serum leptin levels 
previously found in CS in remission [31] is probably caused by increased leptin production 
by the PR adipose tissue compartment. Serum adiponectin levels are markedly decreased 
in obesity and are associated with insulin resistance [74]. In chapter 8, we found lower 
adiponectin levels in SC supernatants and lower adiponectin levels of SC and PR fat lysates 
in patients with active CS. As with leptin levels, an association was found with adipocyte 
size. Adipocyte size was inversely correlated with PR fat lysate adiponectin levels. Multiple 
studies have investigated serum adiponectin levels in active CS. However, these studies 
have reported conflicting data [56, 78, 79]. The findings in chapter 8 suggest that the 
lower serum adiponectin level in patients with cured CS as recently described by our group 
[31] could be the result of decreased adiponectin production in SC and PR adipose tissue. 
In conclusion, the central adipose tissue distribution in active CS appears primarily to be 
caused by adipocyte hypertrophy. This is accompanied by and associated with an adverse 
local adipokine profile in these adipose tissue compartments. Furthermore, the number of 
macrophages in PR adipose tissue in active CS is increased.
Future research should be performed to further elucidate the role of adipose tissue 
parameters as assessed in chapter 8, both during active CS and after remission, as these 
mechanisms might also play a role in patients on chronic glucocorticoid treatment.
General conclusion and future perspectives
The general conclusion of this thesis is that the consequences of endocrine tumors, 
specifically thyroid carcinoma,  CS and acromegaly sustain after biochemical/oncological 
cure. This thesis has shown that there is an aftermath of treatment with long-term adverse 
effects on QoL and long-term physical consequences. These long-term effects deserve the 
attention of physicians and other healthcare providers and should be incorporated into the 
information provided to patients, insurance companies, employers etc.  The goal of future 
research in this field should be to improve patient care after “cure”. Important for future 
research in the field of rare endocrine diseases, such as thyroid carcinoma, acromegaly and 
CS, is to join efforts and to perform more multicenter research in an international context, 
as this would significantly strengthen and increase the impact of the research. Prospective 
interventional studies towards improving the recovery of patients with endocrine diseases 
are also badly needed. The European Reference Network Rare Endocrine Diseases provides 
a promising opportunity to extend our collaboration internationally and to facilitate 
dissemination and implementation of the results. 
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Het menselijke hormonale systeem bestaat uit meerdere hormoonklieren. Hormonen 
reguleren een groot aantal functies van ons lichaam. Normaal gesproken hebben deze 
hormoonklieren een vast formaat en wordt de hoeveelheid hormonen die zij uitscheiden 
strikt gereguleerd. Soms echter, ontstaat er overmatige of onvoldoende productie van een 
bepaald hormoon of ontstaat er groei van een hormoonklier door goed- of zelfs kwaadaardige 
tumorgroei. Dit kan leiden tot ziekte. In dit proefschrift worden een drietal van deze ziekten 
onderzocht; schildklierkanker, acromegalie en het syndroom van Cushing. 
Schildklierkanker is een ziekte van de schildklier welke is gelegen aan de voorzijde van de hals 
(zie figuur 4 van hoofdstuk 1). Schildklierhormoon is verantwoordelijk voor het reguleren 
van meerder processen in het lichaam. Schildklierkanker kan ontstaan vanuit verschillende 
celtypen in de schildklier. Het eerste symptoom van schildklierkanker is vaak het voelen van 
een zwelling in de hals/schildklierregio. Soms kan ook een opgezette lymfeklier een eerste 
teken van de ziekte zijn. De meeste zwellingen in de hals zijn echter goedaardig en slechts 
5% van deze zwellingen zijn kanker. Latere symptomen kunnen pijnklachten zijn en soms 
heesheid door ingroei van de kanker in de zenuwen van de stembanden. Schildklierkanker 
leidde in 2010 tot 36,000 doden wereldwijd. Behandeling van schildklierkanker bestaat over 
het algemeen uit het operatief verwijderen van de tumor, gevolgd door een nabehandeling 
met radioactief jodium. 
Acromegalie is een ziekte die meestal wordt veroorzaakt door een verhoogde aanmaak 
van groeihormoon in de hypofyse. Soms kan de verhoogde aanmaak ook voortkomen uit 
tumoren elders in het lichaam. De hypofyse is een hormoonklier, ter grootte van een 
erwt, die onder aan het brein hangt. Door een overschot aan groeihormoon kan reusgroei 
ontstaan indien iemand nog niet voorbij de puberteit is. Bij volwassenen ontstaat ook groei, 
echter niet meer in de lengte. Kenmerkende symptomen van acromegalie zijn groei van het 
voorhoofd, neus, kaak, handen en voeten (zie figuur 6 van hoofdstuk 1). Tevens kunnen er 
klachten ontstaan zoals gewrichtspijnen, dikker worden van de huid, verlaging van de stem, 
hoofdpijn, snurken en problemen met het zien. Complicaties van de ziekte kunnen verder 
suikerziekte en een hoge bloeddruk zijn. De ziekte komt het meest voor op middelbare 
leeftijd. Mannen en vrouwen krijgen de ziekte even vaak. De behandeling van de ziekte 
bestaat over het algemeen uit medicatie en operatief verwijderen van de tumor.
Het syndroom van Cushing wordt veroorzaakt door een verhoogde aanmaak van het hormoon 
cortisol (stresshormoon) aangestuurd vanuit de eerder genoemde hypofyse of de bijnieren. 
Vaak wordt het echter ook veroorzaakt door medicamenteus toedienen van cortisol in de 
vorm van medicijnen zoals prednison. De bijnieren zijn gelegen boven de nieren. Cortisol 
is van groot belang bij het reguleren van meerdere metabole processen in het lichaam, 
maar ook bij het functioneren van het immuunsysteem. Symptomen van het syndroom van 
Cushing bestaan uit een hoge bloeddruk, dikker worden van de buik, striae (huidstriemen), 
vetophoping in de nek, een rood bol gelaat, spierzwakte en een kwetsbare, slecht genezende 
huid met veel blauwe plekken (zie figuur 5 van hoofdstuk 1). Bij vrouwen kan er ook een 
overmatige haargroei en onregelmatige menstruatie optreden. Twee tot  drie per miljoen 
mensen per jaar krijgen deze ziekte. Meest aangedaan zijn mensen tussen de 20 en 50 jaar 
oud. Vrouwen krijgen de ziekte 3 keer vaker dan mannen. De behandeling van de ziekte 
bestaat over het algemeen uit medicatie en operatieve verwijdering van de tumor.
Voor alle bovengenoemde ziekten geldt dat we inmiddels goed weten hoe we ze moeten 
behandelen. Veel van deze patiënten kunnen we genezen, waardoor de overleving bij deze 
ziekten over het algemeen goed is. Uit wetenschappelijk onderzoek wordt steeds meer 
duidelijk dat deze ziekten, op de lange termijn na genezing, forse lichamelijke gevolgen 
kunnen hebben en ook de kwaliteit van leven sterk kunnen beïnvloeden. Daarom was het 
doel van de onderzoeken in dit proefschrift om te bekijken wat de lange termijn effecten zijn 
op fysiek- en psychosociaal vlak van de eerder genoemde ziekten, waardoor deze effecten 
beïnvloed worden en hoe we hier iets aan kunnen doen. 
Hoofdstuk 1, de introductie, geeft een overzicht van de eerder beschreven hormoonklieren 
en de daarbij behorende ziektebeelden. Tevens wordt er een overzicht gegeven van de 
wetenschappelijke literatuur die reeds bestaat omtrent de lange termijn gevolgen van 
bovengenoemde ziekten. Dit als opmaat voor de introductie van de studies die in dit 
proefschrift beschreven staan. In deze introductie worden de redenen gegeven waarom 
we de verschillende studies hebben uitgevoerd en worden de doelen van de verschillende 
studies beschreven.
Deel 1 Gezondheid gerelateerde kwaliteit van leven na 
behandeling voor schildklierkanker en acromegalie
Patiënten die schildklierkanker hebben gehad blijken zelfs na jarenlange genezing nog een 
verminderde kwaliteit van leven te ervaren. Dit wordt onder andere veroorzaakt door 
“distress” die zij ervaren op emotioneel, psychisch of sociaal vlak zich uitend als gevoelens 
van kwetsbaarheid, verdriet, angst, depressie, paniek en een sociaal isolement. De mate 
van “distress” bij patiënten van schildklierkanker was nooit eerder objectief gemeten en er 
was geen eerder onderzoek beschikbaar naar de oorzaken van deze “distress”. In hoofdstuk 
2 onderzochten wij daarom de mate van “distress” bij deze patiënten door middel van de 
“distress” thermometer en de “probleemlijst” (een tweetal vragenlijsten). Hieruit bleek dat 
er bij 34.3% van de 145 deelnemers sprake was van significante “distress” meest veroorzaakt 
door lichamelijke (86%) en emotionele (76%) problemen. Tevens bleek bij deze patiënten 
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de kwaliteit van leven sterk verminderd te zijn. Op basis van de verzamelde data is niet 
duidelijk te voorspellen welke mensen last krijgen van meer “distress”. Wel bleek er een 
duidelijke relatie te bestaan tussen “distress” en werkloosheid. Uit hoofdstuk 2 blijkt dat 
de gebruikte vragenlijsten nuttige screeningsinstrumenten zijn om “distress” te detecteren. 
Het gebruik van de vragenlijsten is een goede eerste stap om het gesprek met de patiënt 
aan te gaan over de problemen die nog spelen. Dit gesprek is weer een eerste stap naar een 
eventuele oplossing van het probleem. Gebruik van de vragenlijsten is inmiddels standaard 
onderdeel van de landelijke schildklierkanker zorg. Toekomstig onderzoek moet uitwijzen of 
dit ook leidt tot voordelen voor de patiënt. 
Schildklierkanker wordt vaak operatief behandeld. We weten van hoofd-, halschirurgie bij 
andere ziekten en van verhalen van schildklierkanker patiënten uit de spreekkamer dat er 
na de ingreep vaak sprake blijft van schouderklachten. Bij deze groep patiënten was echter 
nooit eerder onderzocht hoe vaak dit precies voorkomt en wat de mogelijke oorzaken hiervan 
zijn. In hoofdstuk 3 hebben we dit onderzocht met een set vragenlijsten (DASH, EORTC 
QLQ-C30).  Maar liefst 58.7% van de patiënten die gemiddeld meer dan 10 jaar geleden 
geopereerd waren aan schildklierkanker rapporteerden schouderklachten in vergelijking 
met maar 13.6% van de gezonde controlepersonen met vergelijkbare leeftijd en geslacht. 
Hoofdstuk 3 liet tevens zien dat er een relatie lijkt te bestaan tussen het verwijderen van 
de lymfeklieren in een bepaald deel van de hals (regio 5), het beschadigen van een zenuw 
in dit gebied (nervus accessorius) en schouderklachten. Tevens bleek er een relatie te 
bestaan tussen schouderklachten en werkloosheid. Ook bleken de schouderklachten een 
duidelijk verband te hebben met een verminderde kwaliteit van leven. Wij concluderen uit 
deze bevindingen dat patiënten die deze operaties ondergaan vooraf geïnformeerd dienen 
te worden over deze mogelijke gevolgen. Na de operatie is het noodzakelijk om naar deze 
klachten te vragen en om zo nodig de schouder verder te onderzoeken. Indien noodzakelijk 
dient in een vroeg stadium gestart te worden met fysiotherapie om verdere problemen in de 
toekomst te voorkomen. Toekomstig onderzoek dient uit te wijzen of deze aanpak inderdaad 
de klachten verminderd, of er meer duidelijke oorzaken van de klachten geïdentificeerd 
kunnen worden en wat de hierbij behorende behandelingen dienen te zijn.
Bij patiënten genezen van acromegalie is gebleken dat meerdere factoren een negatieve 
invloed kunnen hebben op de kwaliteit van leven, waaronder de manier van behandelen met 
medicijnen, blijvende gewrichtsklachten en een groeihormoon gebrek na de behandeling. 
Tevens weten we uit eerder onderzoek van onze groep dat het uiterlijk van deze patiënten 
nooit meer wordt zoals het vroeger was. Uit wetenschappelijk onderzoek blijkt dat het 
uiterlijk een factor is met een sterke invloed op de kwaliteit van leven bij deze patiënten 
tijdens de ziekte. Er is echter nooit onderzocht of dit nog steeds het geval is geruime tijd na 
genezing. In hoofdstuk 4 onderzochten we daarom door middel van vragenlijsten (DAS59, 
RAND36, AcroQoL) in welke mate  er sprake is van zelfbewustzijn van het uiterlijk en in 
welke mate dit negatieve invloed heeft op de kwaliteit van leven. Hieruit bleek dat bij 73 
patiënten die gemiddeld meer dan 10 jaar genezen waren er bij 46.6% van de patiënten 
sprake was van een verhoogd zelfbewustzijn van het uiterlijk in vergelijking met 22.8% in 
de algemene populatie. Van deze mensen gaf 85.3% aan dat het gezicht de bron van het 
verhoogde zelfbewustzijn was. Tevens werd er een duidelijk verband gevonden tussen het 
verhoogde zelfbewustzijn van het uiterlijk en een verminderde kwaliteit van leven. Deze 
bevindingen maken duidelijk dat artsen zich bewust dienen te zijn van dit probleem. Dit 
probleem dient bespreekbaar gemaakt te worden en er dient met individuele patiënten 
nagedacht te worden over eventuele behandelingen in de vorm van psychologische 
begeleiding danwel plastische of reconstructieve chirurgie. Toekomstig onderzoek moet 
uitwijzen of aandacht voor dit probleem ook daadwerkelijk leidt tot vermindering van de 
klachten hieromtrent bij patiënten. Tevens dient bekeken te worden wanneer het optimale 
moment voor chirurgisch corrigeren van het afwijkende gelaat zou zijn, omdat we nog niet 
precies weten wanneer een patiënt na genezing stopt met vergroeien.   
Deel 2 Lichamelijke effecten op lange termijn na genezing 
van het syndroom van Cushing
De lange termijn effecten op het lichaam van het syndroom van Cushing zijn de laatste 
jaren in toenemende mate een onderwerp van wetenschappelijk onderzoek. Onze groep 
en anderen hebben aangetoond dat er vele metabole veranderingen en veranderingen 
van het hartvaatstelsel kunnen blijven bestaan na “genezing” van de ziekte. Tevens blijken 
deze patiënten, op lange termijn, een dikkere buik te houden en blijkt de uitscheiding van 
vethormonen (leptine, resistine en adiponectine) door het vetweefsel gestoord te blijven. 
De mate waarin patiënten klachten houden verschilt echter sterk tussen de verschillende 
patiënten. We weten dat mensen verschillend kunnen reageren op een verhoogd cortisol 
gehalte in het bloed, doordat zij verminderd of juist meer gevoelig kunnen zijn voor dit 
hormoon, door genetische veranderingen van de receptor voor dit hormoon. Nooit 
eerder was onderzocht of deze genetische veranderingen de lange termijn effecten van 
het syndroom van Cushing beïnvloeden. Daarom hebben we in hoofdstuk 5 gekeken naar 
de aanwezigheid van deze genetische veranderingen in cortisol gevoeligheid bij patiënten 
genezen van het syndroom van Cushing.  Hieruit bleek dat dragers van de zogenaamde 9β 
mutatie van de cortisol receptor na genezing een hogere bloeddruk hebben dan de niet-
dragers van deze mutatie. Dragerschap van de zogenaamde BclI mutatie bleek  geassocieerd 
te zijn met een verhoogd vetpercentage in de armen en benen. Tevens bleek er bij dragers 
van deze mutatie sprake te zijn van een verhoogde leptine waarde in het bloed. Dit is een 
stof die vooral wordt geproduceerd in het onderhuidse vetweefsel en die geassocieerd is 
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met een verhoogde kans op ziekten van het hart en de bloedvaten en met verminderde 
gevoeligheid voor insuline en daardoor suikerziekte. Als laatste bleek dragerschap van deze 
mutatie geassocieerd te zijn met een verhoogde waarde in het bloed van de stof E-selectine. 
Dit is een stof die verband houdt met de vorming van aderverkalking. Dit blijkt ook uit het 
feit dat dragerschap van de BclI mutatie in hoofdstuk 5 samenhing met een verhoogde” 
intima media dikte” van de bloedvaten. Dit betekend dat er bij deze patiënten meer sprake 
was van beginnende aderverkalking dan bij niet-dragers van de mutatie.  Hoofdstuk 5 toont 
dus aan dat de lange termijn effecten van het syndroom van Cushing beïnvloed worden door 
mutaties van de cortisol receptor. Dit betekend dat dragers van deze mutaties mogelijk 
intensiever gevolgd moeten worden na genezing van het syndroom van Cushing met meer 
aandacht voor hartvaatziekten en suikerziekte. Behalve voor patiënten met het syndroom 
van Cushing kunnen de bevindingen in hoofdstuk 5 ook van belang zijn voor mensen die 
langere tijd cortisol in medicamenteuze vorm gebruikt hebben zoals prednison. Toekomstig 
onderzoek dient gericht te zijn op het reproduceren van onze bevindingen in een grotere 
groep patiënten. Tevens dient onderzocht te worden in welke mate deze mutaties bijdragen 
aan de lange termijn effecten van cortisol in medicamenteuze vorm. 
In de afgelopen jaren hebben meerdere wetenschappelijke onderzoeken bekeken wat 
de lange termijn effecten van het syndroom van Cushing zijn voor de gezondheid van de 
bloedvaten. Resultaten van deze onderzoeken waren tegenstrijdig en uitgevoerd met 
beperkte middelen in kleine groepen patiënten. Daarom hebben wij in hoofdstuk 6 getracht 
de gezondheid van de kleine en grote bloedvaten van patiënten genezen van het syndroom 
van Cushing in kaart te brengen. We deden metingen van stoffen in het bloed geassocieerd 
met vaatschade, deden metingen die een inschatting geven van de gezondheid van de 
binnenbekleding van de bloedvaten, ofwel het endotheel,  en maten of er sprake was van 
aderverkalking bij deze (ex)patiënten. Uit de resultaten van hoofdstuk 6 bleek dat er geen 
verschillen zijn in gezondheid van de bloedvaten tussen patiënten die langer dan 4 jaar 
genezen zijn van het syndroom van Cushing en gezonde controlepersonen die vergelijkbaar 
waren met de patiënten op het gebied van leeftijd, geslacht en body mass index (BMI).  In 
vergelijking met eerdere studies die wel verschillen lieten zien bleek dat de groep patiënten 
in hoofdstuk 6 veel beter behandeld waren voor bijkomende ziekten zoals hoge bloeddruk 
en suikerziekte. Dit toont aan dat het goed controleren op deze bijkomende ziekten en op 
tijd behandelen hiervan waarschijnlijk maken dat de gezondheid van de vaten vergelijkbaar 
blijft met die van gezonde personen. We weten immers dat hoge bloeddruk en suikerziekte 
de bloedvaten kunnen beschadigen. Deze beschadigingen brengen uiteindelijk een grote 
kans op bijvoorbeeld hartinfarcten en herseninfarcten met zich mee. 
Na genezing van het syndroom van Cushing blijft er vaak sprake van een verminderde kwaliteit 
van leven, welke onder andere wordt veroorzaakt door vermoeidheid en een verminderd 
vermogen zich in te spannen. Het was echter onbekend of er na genezing van de ziekte 
sprake is van verminderde fysieke fitheid die deze vermoeidheid kan verklaren. Daarom 
hebben we dit onderzocht in hoofdstuk 7 van dit proefschrift. Dit hebben we gedaan door 
middel van een maximale inspanningstest op een speciaal geprepareerde fiets en metingen 
van de dagelijkse activiteiten van de patiënten door middel van een bewegingsmonitor. 
Tevens hebben we gekeken naar de bloedvoorziening en energiehuishouding in de spieren 
door middel van een biopt uit het bovenbeen. Hoofdstuk 7 laat zien dat er bij patiënten 
>4 jaar genezen van het syndroom van Cushing nog steeds sprake blijkt te zijn van een 
verminderde fysieke fitheid en dat dit onafhankelijk is van hun dagelijkse activiteiten 
niveau. Op het gebied van de spiervezels werden geen verschillen tussen ex-patienten en 
gezonde personen gevonden die dit verschil in fysieke fitheid kunnen verklaren. Wel werden 
tijdens de inspanningstest aanwijzingen gevonden voor een verminderde pompfunctie van 
de hartspier. Het is belangrijk in de toekomst verder onderzoek te verrichten naar dit 
onderwerp aangezien de oorzaak van de verminderde fitheid uit ons onderzoek nog niet 
geheel duidelijk is geworden. De bevindingen in hoofdstuk 7 kunnen wel een verklaring zijn 
voor de blijvende vermoeidheidsklachten die regelmatig ervaren worden door patiënten 
na genezing van het syndroom van Cushing. Onze bevindingen reiken wellicht verder dan 
alleen deze patiënten, omdat ditzelfde fenomeen mogelijk ook op zou kunnen treden na 
langdurig gebruik van geneesmiddelen die cortisol bevatten zoals het eerder genoemde 
prednison. Tevens zou het interessant zijn om in de toekomst te bekijken of deze klachten 
te verhelpen zijn middels een revalidatieprogramma. 
Zoals eerder genoemd is het syndroom van Cushing sterk geassocieerd met een centrale 
vetverdeling, ofwel een ophoping van vet in de buikregio. De precieze effecten die een 
overmaat aan bijnierhormoon op lokaal buikvet heeft waren nog niet goed bekend. Daarom 
hebben we in hoofdstuk 8 gekeken of de toename in buikvet tijdens het syndroom van 
Cushing vooral wordt veroorzaakt door opzwellen van de reeds aanwezige vetcellen of door 
een toename van het aantal vetcellen. Tevens hebben we gekeken of deze veranderingen 
gepaard gingen met een toename van het aantal ontstekingscellen in het vetweefsel en 
veranderingen in de uitscheiding van een aantal vethormonen; leptine en adiponectine. 
Dit hebben we gedaan door tijdens verschillende operaties die al gepland stonden voor 
het verwijderen van een bijnier (dit is een behandeling voor het syndroom van Cushing) 
ook een beetje onderhuids vet en vet uit de buikholte te verwijderen. Dit onderzoek is 
van belang, omdat onwenselijke veranderingen in deze parameters verband houden met 
verhoging van het risico op hart- en vaatziekten en suikerziekte. Uit hoofdstuk 8 bleek 
dat er bij patiënten met het syndroom van Cushing vooral sprake is van opzwellen van de 
reeds aanwezige vetcellen, dat het aantal ontstekingscellen in het vet inderdaad toeneemt 
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en dat dit gepaard gaat met een onwenselijke verstoring van de uitscheiding van de eerder 
genoemde vethormonen. Opvallend hierbij was dat deze veranderingen vrijwel alleen 
optreden in het vetweefsel uit de buikholte en dat het onderhuidse vet vrijwel niet wordt 
beïnvloed. 
Hoofdstuk 9 van dit proefschrift is een samenvatting van alle bevindingen en een 
algemene discussie met betrekking tot de gevonden resultaten. Tevens worden er in dit 
hoofdstuk aanbevelingen gedaan over de richting van het toekomstige onderzoek. De 
algemene conclusie van dit proefschrift is dat hormonale ziekten vaak niet eindigen na de 
normalisering van de waarden in het bloed. We hebben aangetoond dat er een lange nasleep 
kan zijn zowel op het gebied van kwaliteit van leven als op het vlak van lichamelijk klachten/
effecten. Deze lange termijn effecten verdienen de aandacht van de behandeld artsen 
en andere hulpverleners. Tevens zouden onze bevindingen opgenomen moeten worden 
in de voorlichting die de patiënt krijgt over zijn of haar ziekte en in de informatie aan 
bijvoorbeeld werkgevers en verzekeraars. Het algemene doel van toekomstig onderzoek 
dient het optimaliseren van de zorg na genezing van deze patiënten te zijn. 
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Dankwoord
Dit proefschrift is mede mogelijk gemaakt door velen. Iedereen die in meer of mindere 
mate betrokken is geweest wil ik hartelijk bedanken. Een aantal groepen en personen wil ik 
expliciet noemen.
Alle proefpersonen/patiënten die hebben deelgenomen aan de studies genoemd in dit 
proefschrift waren van cruciaal belang. Zonder jullie waren deze studies niet mogelijk 
geweest. Als verlengde arm van de individuele patiënten zijn ook de bijniervereniging 
NVACP en het Bijnierfonds van groot belang geweest voor het tot stand komen van dit 
proefschrift. Specifiek dienen hierbij genoemd te worden Alida Noordzij en Johan Beun. 
Hun ondersteuning heeft bestaan uit het financieel mogelijk maken van een deel van de 
studies in dit proefschrift. Tevens zijn zij van groot belang geweest in het inventariseren van 
de vragen en hulpbehoeften die leven bij de patiënt. Alida, Johan, mijn bewondering voor de 
inzet die jullie altijd hebben gehad voor de NVACP/Bijnierfonds is groot. 
prof. dr. Hermus, beste Ad, als student geneeskunde begon ik al met onderzoek doen op de 
afdeling endocrinologie. Hierna nam je me aan als full-time arts onderzoeker hetgeen mij de 
mogelijkheid bood me enkele jaren bezig te houden met de wetenschap. De rust waarmee 
je begeleiding biedt en de tijd voor overleg die je altijd weet vrij te maken maakt dat je je 
als jonge onderzoeker in volledige vrijheid kan ontwikkelen.  Deze jaren hebben mij sterk 
gevormd in mijn carrière als arts waarvoor ik je zeer dankbaar ben. Tevens wil ik je bedanken 
voor het vertrouwen dat je in die jaren in me gesteld hebt. 
dr. Netea-Maier, beste Romana, jaren geleden leerde ik je kennen toen ik als student nog 
onderzoek deed bij de chirurgie. We waren toen bezig een database van schildkliercarcinoom 
patiënten op te zetten. Toen ik tijdens mijn co-schappen tot de conclusie kwam dat ik 
internist wilde worden was jij de eerste persoon waarmee ik contact opnam. Je had meteen 
een project voor me voor verder onderzoek. Hieruit resulteerde onze eerste publicatie 
samen, tevens hoofdstuk 2 van dit proefschrift. Hierna raakte ik langzaam bevangen door de 
endocrinologie. Bij start van mijn promotietraject ben je co-promotor geworden en vooral 
tijdens het opzetten van de acromegalie- en schildkliercarcinoom studies heb ik veel gehad 
aan de overlegmomenten op jouw kamer. Ik wil je bedanken voor de ondersteuning in de 
afgelopen jaren en kijk uit naar eventuele verdere samenwerking in de toekomst. 
prof. dr. Smit, beste Jan, halverwege dit promotietraject kwam je in Nijmegen werken 
en raakte betrokken als promotor. Ondanks jouw drukke baan als afdelingshoofd en 
plaatsvervangend opleider maakte je wekelijks tijd vrij voor overleg en wekte je, door je rust, 
altijd de indruk alle tijd voor mij te hebben. Hiervoor wil ik je hartelijk bedanken.
dr. Plantinga, beste Theo, zonder jou was het niet mogelijk geweest om de meer basale 
noten te raken in ons onderzoek.  Altijd was je bereid om mee te denken en in het lab heb 
je me veel nieuwe dingen geleerd. Daarnaast wil ik je bedanken voor de gezellige tijd die we 
samen gedeeld hebben in “de buitenhoek”. 
Ex-kamergenoten Margreet Wagenmakers en Anouk van Berkel. Margreet, onze jarenlange 
samenwerking heeft inmiddels al meerdere mooie vruchten afgeworpen, zowel in de vorm 
van mooie publicaties als een vriendschap. Het werk dat jij al had verricht op het gebied 
van het Cushing onderzoek is een onmisbaar fundament gebleken voor het bouwen van dit 
proefschrift. Onze eindeloze gesprekken en discussies op ons kantoor zijn de bouwstenen 
geweest waarmee de verschillende studies zijn opgebouwd. Anouk, halverwege mijn traject 
kwam je bij ons op de kamer. Het prettige sociale klimaat dat daar al heerste werd er daarmee 
alleen maar beter op. Ik wil jullie bedanken voor het vele lachen, het fijne werkklimaat, de 
hulp en de ondersteuning in de afgelopen jaren.  
Thalijn Wolters, met jou als mijn opvolgster heb ik er alle vertrouwen in dat de lopende 
acromegalie studies in goede handen zijn. Dit blijkt ook uit de drie mooie artikelen die we 
inmiddels hebben kunnen schrijven in de afgelopen maanden. 
Duby Ballak, bedankt voor je hulp bij onze “vet” studie. Zonder jouw ondersteuning was dit 
niet gelukt. 
Mischa de Ridder, samen begonnen we aan ons wetenschappelijk avontuur bij de chirurgie. 
Jij zwaaide af naar de radiotherapie en ik naar de endocrinologie. Gelukkig hebben we samen 
nog een mooie publicatie kunnen schrijven (hoofdstuk 2 van dit proefschrift).
prof. dr. Wagenmakers, beste Ton, samen met Margreet heb jij meegedacht over de 
ontwerpen van onze Cushing studies. Jouw kennis van de fysiologie is hierbij van onschatbare 
waarde geweest. Tevens heb je de medewerkers en faciliteiten van jouw laboratorium in 
Liverpool (John Moores University) ingezet voor ons onderzoek. Hiervoor ben ik jullie 
ontzettend dankbaar. 
prof. dr. Pereira, beste Alberto, ik wil je bedanken voor de welwillendheid mee te werken 
aan onze studies en het prettige contact de afgelopen jaren.  
prof. dr. de Wilt, beste Hans, samen met Mischa begon ik als student met het opzetten van 
de schildkliercarcinoom database. Nadat ik het licht had gezien en besloot endocrinoloog 
te willen worden hebben we nog erg prettig samen kunnen werken aan hoofdstukken 2 en 3 
van dit proefschrift. Bedankt daarvoor.
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prof. dr. van Rossum, beste Liesbeth,  graag wil ik je bedanken voor de rol die je hebt 
gespeeld bij onze publicatie over glucocorticoïd receptor polymorfismen, hoofdstuk 6 van 
dit proefschrift. Jouw uitgebreide kennis op dit gebied is van groot belang geweest bij de 
afronding van dit onderzoek.
dr. Thijssen en prof. dr. Hopman, beste Dick en Maria, bedankt voor de fijne samenwerking 
tijdens onze Cushing onderzoeken en bedankt voor de faciliteiten die de afdeling fysiologie 
ons heeft geboden voor het uitvoeren van ons onderzoek. Tevens wil ik jullie bedanken voor 
de verdere samenwerkingen die er ontstaan zijn tussen de afdeling endocriene ziekten en 
de afdeling fysiologie. Tim Schreuder, bedankt voor de metingen die je hebt gedaan in onze 
vaatstudie.
Suzanne Holewijn, bedankt voor de vaatmetingen die je voor ons gedaan hebt. 
dr. Langenhuijsen, dr. D’Ancona en dr. van Dielen, beste Hans, Frank en Francois, bedankt 
voor het aanwenden van jullie chirurgische vaardigheden voor het verkrijgen van het 
vetweefsel noodzakelijk voor onze “vet”studie.
prof. dr. Rongen, beste Gerard, bedankt voor het meedenken over onze vasculaire studie en 
de praktische ondersteuning bij het prikken van de arterielijnen. 
Alle Studenten die ik heb mogen begeleiden tijdens hun wetenschappelijke stage (Bart 
Cornelissen, Karen Massop, Karen Sleddens, Renske Pauwels, Roel Pelleboer, Lisanne 
Janssen, Marika Tesselaar wil ik bedanken voor de bijdrage die zij geleverd hebben aan 
dit proefschrift. Speciale vermeldingen zijn op de plaats voor Femke Wessels, Hanne 
Rooijackers, Lien Coolen en Rosalie Sterenborg, voor hun uitzonderlijk grote bijdragen die 
tevens geleid hebben tot co-auteurschap in dit proefschrift. 
Alle mensen van de afdelingen endocriene ziekten en het lab experimentele interne 
geneeskunde wil ik bedanken voor de prettige samenwerking in de afgelopen jaren. Speciaal 
wil ik daarbij noemen de harde kern van het secretariaat endocriene ziekten; Maria, Masja 
en Mieke. Bedankt dat ik voor alle praktische zaken altijd bij jullie terecht kon. 
Alle co-auteurs van dit proefschrift die niet expliciet genoemd zijn wil ik hartelijk danken 
voor hun bijdrage aan het tot stand komen van dit werk.
Chema, Sander, Jens en Martijn, tijdens onze studie geneeskunde heb ik genoten van 
jullie kwaliteiten in de studiebanken, maar vooral van die aan de bar. Hierna zijn we allen 
gaan promoveren en zagen we elkaar nog veel in de wandelgangen van het Radboud, 
aesculaaf, tijdens de ronde van Vlaanderen etc. etc. Ik wil jullie bedanken voor jullie prettige 
vriendschap en hoop dat deze nog lang mag voortduren.  
Mannen van W.A.L.E.W.Y.N., odi profanum vulgus et arceo.
Lieve pa en ma, jullie hebben me gemaakt tot wie ik ben. Pa aan het werk voor het gezin 
en de stabiele factor bij de voetbal in het weekend. Ma de stabiele factor thuis. Zonder 
jullie was dit proefschrift niet mogelijk geweest. Ik wil jullie vanuit het diepst van mijn hart 
bedanken voor alles dat jullie voor mij gedaan hebben. 
Lieve Megan, kleine zusjes worden groot. Al jaren achtervolgen we elkaar, dezelfde 
basisschool, middelbare school, studie, specialisatie en nu mogelijk ook dezelfde differen-
tiatie. Met veel plezier praat ik al jaren met je over de patiëntenzorg en het onderzoek. Een 
deel van ons beider promotie hebben we zelfs uitgevoerd op dezelfde gang in het ziekenhuis en 
de laatste 4 maanden van mijn promotie zelfs bij elkaar op de kamer! Ik heb bewondering voor 
de manier waarop je jouw werk uitoefent en ik waardeer je om de fijne persoon die je bent. Een 
fijnere zus had ik me niet kunnen wensen.
Lieve Bernadette, bedankt voor het feit dat je in mijn leven bent. Door jou heb ik het erg 
fijn thuis en is er voldoende ruimte voor ontspanning naast het harde werken. Aangezien je 
zelf ook gepromoveerd bent heb je (bijna) altijd begrip gehad voor het doen van onderzoek 
in de weekenden en vrije avonduurtjes. Ik heb erg genoten van de momenten waarop we 
samen over onderzoek spraken en van de bruggen die we inmiddels gemaakt hebben tussen 
ons acromegalie onderzoek en jouw onderzoek naar gebitsslijtage. Je bent wijs, mooi, lief, 
zacht. ‘k hou van jou.
Lieve Sebastiaan en Floris, mijn kleine mannen, jullie zijn het mooiste dat mij ooit is 
overkomen. Kooooo!
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Naam promovendus: S.H.P.P. Roerink PhD periode: 01-01-2012 t/m 28-10-2019
Promotor(en): prof. dr. A.R.M.M. Hermus 
prof. dr. J.W.A. Smit
Graduate school: Radboud 
Institute for 
Health Sciences
Copromotor(en): dr. R.T. Netea-Maier 
dr. T.S. Plantinga
Courses Jaar 
afgerond
ECTS
Postgraduate course on growth hormone, growth factors and metabolic 
disorders (Pfizer, Marstrand Gothenburg)
2012 1
Postgraduate course biometrics (Radboudumc, Nijmegen) 2013 1,9
Postgraduate course on pituitary disease (Ipsen, Annecy) 2015 1
Fundamental Critical Care Support (FCCS, Houten) 2016 0,8
Interactive communication course (CIC) (Radboudumc, Nijmegen) 2017 0,6
Endocrinology Knowledge Exchange Program (EKEP) (ErasmusMC/
Kremlin Bicetre, Paris)
2013 0,8
Basic course in endocrinology (Dutch university hospitals, Bunnik) 2018 0,8
Reviewing scientific publications (Journals) 2019 1
BROK Course (Maastricht University, Nijmegen) 2012 1,5
BROK course re-registration (Radboudumc, Nijmegen) 2016 0,1
Diabetes Education Study Group Course (2x) (DESG, Hoevelaken) 2017 1
Lecturing & supervision of internships Jaar 
afgerond
ECTS
Radboud Adrenal Masterclass (Radboudumc, Amsterdam) 2019 0,1
Patient lecture pituitary patient society (Hypofysestichting, Nijmegen) 2013 0,1
Patient lecture Dutch Adrenal Fund 2018 (NVACP, Soestduinen) 2018 0,1
Patient lecture Dutch Adrenal Fund 2014 (NVACP, Soestduinen) 2014 0,1
Patient lecture Dutch Adrenal Fund 2013 (NVACP, Soestduinen) 2013 0,1
Student internship coaching; Bart Cornelissen (bachelor technical 
medicine University of Twente) (Radboudumc, Nijmegen)
2013 1
Student internship coaching; Femke Wessels (master medicine)  
(Radboudumc, Nijmegen)
2013 1
Student internship coaching; Hanne Rooijackers (master medicine)   
(Radboudumc, Nijmegen)
2014 1
Student internship coaching; Karen Massop (master medicine)   
(Radboudumc, Nijmegen)
2014 1
Student internship coaching; Karen Sleddens (master medicine)   
(Radboudumc, Nijmegen)
2012 1
Student internship coaching; Lien Coolen (master medicine)   
(Radboudumc, Nijmegen)
2014 1
Student internship coaching; Lisanne Janssen (master medicine)   
(Radboudumc, Nijmegen)
2012 1
Student internship coaching; Renske Pauwels (master medicine)   
(Radboudumc, Nijmegen)
2013 1
Student internship coaching; Roel Pelleboer (master medicine)   
(Radboudumc, Nijmegen)
2012 1
Student internship coaching; Thalijn Wolters (master medicine)   
(Radboudumc, Nijmegen)
2014 1
Congresses Jaar 
afgerond
ECTS
Dutch endocrine meeting 2012 (oral presentation) (NVE, 
Noordwijkerhout)
2012 0,25
Dutch endocrine meeting 2013 (oral presentation) (NVE, 
Noordwijkerhout)
2013 0,25
Dutch endocrine meeting 2014 (oral presentation) (NVE, 
Noordwijkerhout)
2014 0,25
Dutch endocrine meeting 2017 (oral presentation) (NVE, 
Noordwijkerhout)
2017 0,25
Northern European Neuro-Endocrine Group (NENEG) Meeting (oral 
presentation) (NENEG, Oslo)
2013 0,4
Dutch endocrine meeting 2015 (oral presentations) (NVE, 
Noordwijkerhout)
2015 0,5
Endocrine Society Annual Meeting 2013 (poster presentation) 
(Endocrine Society, San Francisco)
2013 1
Totaal EC punten: 23,9 waarvan 23,9 afgerond
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Data management page according to FAIR principles
This thesis is based on the results of human studies, which were conducted in accordance 
with the principles of the Declaration of Helsinki. The medical and ethical review board 
Committee on Research Involving Human Subjects Region Arnhem Nijmegen, Nijmegen, 
the Netherlands has given approval to conduct these studies.
This project is stored on the Radboudumc, department server: (H:)AIGdata$(\\umcfs073) 
under Research. The study in chapter 4 was funded by IPSEN. The studies in chapters 5, 
6, 7 and 8 was funded by the Dutch Adrenal Patient Society (NVACP) and the Dutch 
Adrenal Fund. 
In our studies patients received questionnaire booklets containing the written informed 
consent. The participating physicians filled in the research form on paper. Furthermore, 
hard copy case record forms were used in some of the studies. The paper data were stored in 
the department archive (Radboudumc, room M379.03.125). The privacy of the participants 
in our studies is warranted by use of encrypted and unique individual subject codes. This 
code correspondents with the code on the patient- and physicians booklets. The code was 
stored separately from the study data. 
The data will be saved for 15 years after termination of the study. Using these patient data 
in future research is only possible after a renewed permission by the patient as recorded 
in the informed consent. The datasets analyzed during these studies are available from the 
corresponding author on reasonable request.
